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Abstract 
 
Introduction 
Prognostication in Acute pancreatitis (AP) remains a challenging issue. This study aimed to 
measure gene expression of the peripheral blood in patients with acute pancreatitis and 
identify an expression signature that would accurately stratify patients into either mild or 
severe disease groups. MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene 
expression and play important roles in a variety of cellular functions. These have emerged as 
major potential biomarkers in a variety of sepsis related disorders and cancers. Alongside, 
gene expression profiling, the prognostic potential of micro RNA at the time of admission in 
context of acute pancreatitis was also explored. 
Methods 
This observational study was conducted at Royal Liverpool University Hospital, NHS 
Foundation Trust, in collaboration with University Hospital Aintree, NHS Foundation Trust. 
For gene expression profiling, Affymetrix HGU133 Plus 2.0 microarrays were utilised. Total 
RNA extracted from whole blood samples of patients collected at the time of admission was 
included. A pilot study was conducted in the first instance to enable sample size calculations. 
Analysis was performed using Partek Genomics Suite software. Expression level data were 
quantile normalised and ANOVA was used with batch hybridization effects. 
For microRNA analysis, a similar pilot study was undertaken to estimate sample size. Total 
RNA was extracted from plasma samples of patients obtained at the time of admission. RNA 
were hybridised to GeneChipTM miRNA 2.0 arrays. Analysis was performed using 
appropriate packages in R/Bioconductor and using Partek Genomics Suite software. 
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Expression level data were invariant set normalized. Differential expression of miRNAs in 
severe compared to mild pancreatitis was detected using ANOVA with batch hybridization 
effects removed. Severity was defined in line with Atlanta criteria for both the parts of the 
study. 
Results 
58 patients were included (23 severe, 35 mild). After adjusting for batch effects, setting 
power at 80%, fold change at 1.5 and significance at 0.05, 98 genes were identified that were 
differentially expressed between mild and severe disease. More specifically, 49 genes were 
up-regulated in severe form and 49 were down-regulated when compared to the mild disease. 
Canonical pathway analysis revealed signalling in T cells and lymphocytes to be the most 
significant pathway involved in the process. These were specifically down-regulated in 
severe form of the disease. While a lot of processes associated with the cellular immune 
response were down-regulated in severe pancreatitis, the innate response didn’t change and 
the humoral response might be stimulated. Nuclear Factor of Activated T cells (NFAT) was 
noted to be the most significantly implicated gene in the dataset, being a key molecule 
implicated in at least 12 different pathways. 
Nineteen patients were included (severe 9, mild 10) for the miRNA profiling. Keeping the 
FDR p <0.05, 45 micro RNA were found to be differentially expressed between mild and 
severe pancreatitis. Out of these, only 23 were annotated in IPA – 22 were novel discoveries. 
Interestingly, 19 small nucleolar RNA (snoRNAs) were identified to be differentially 
expressed between the two groups.  
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Conclusions 
Understanding more about the pathophysiology and genomic regulation in acute pancreatitis 
will provide us with potential prognostic biomarkers and targets for therapy. This study has 
selected a series of gene expression features which could act as biomarkers to accurately 
stratify patients into mild and severe groups. Appropriate therapy can then be chosen earlier 
to improve outcomes in the disease. MiRNA and snoRNA can predict severity of acute 
pancreatitis at the time of admission. These can also be developed to predict specific 
complications of the disease, including organ failure and pancreatic necrosis, as early as, at 
the time of admission. Once developed, this could fill in the gap that currently exists in 
prognostication arena in acute pancreatitis.    
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1.1 Pancreas as a gland 
 
Pancreas is a retroperitoneal lobulated organ which serves, both, as an endocrine and 
exocrine gland. Various types of endocrine cells (α, β, δ, and PP), arranged as islets of 
Langerhans, produce different peptides, including glucagon, insulin, somatostatin, pancreatic 
polypeptide, which are invariably delivered to other parts of the body via the blood stream. 
Acinar exocrine cells are essentially of one type, although each one contains a myriad of 
different substances, helping to secrete a potent mixture of digestive enzymes in response to 
food intake. These enzymes are synthesised and secreted by the acinar cells, whereas, 
columnar epithelial cells lining the ductal system secrete bicarbonate. However, the acinar 
cell itself is not the functional unit in the exocrine pancreatic tissue because acinar cells are 
organized into acini which are made up of many acinar cells and are linked by numerous gap-
junctional channels that help to allow direct chemical and electrical intercellular 
communication.  
 
Morphological and functional disorders affecting pancreatic tissue, both exocrine and 
endocrine, lead to a whole spectrum of clinical conditions (figure 1.1). Benign diseases of the 
pancreas are often complex and can prove to be challenging, both diagnostically and 
therapeutically. Despite advances, cancer of the pancreas still carries a dismal prognosis.  
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Pancreas
Benign Malignant
•Acute Pancreatitis
•Chronic Pancreatitis
•Autoimmune 
Pancreatitis
•Cystic Fibrosis
•Haemochromatosis
•PDAC*
•Acinar cell tumours
•Sarcomas
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Figure 1.6 – Pathological conditions affecting pancreas 
 
1.2 Acute pancreatitis – an overview 
 
“Most terrible of all calamities that occur in connection with the abdominal viscera. The 
suddenness of its onset, the illimitable agony which accompanies it, and the mortality 
attendant upon it render it all the most formidable of catastrophes”. 
 
- Moynihan 1925 [1]. 
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The incidence of acute pancreatitis is increasing in Europe, with significant medical, surgical 
and financial implications. The overall incidence of acute pancreatitis is 150 to 420 cases per 
million population in UK with a hospital admission rate of 9.6 per year per 100,000 
population in the United Kingdom [2, 3].  
 
1.2.1 Classification 
 
Acute pancreatitis may be classified based on pathology, aetiology, severity of disease or the 
presence of necrosis. 
 
Clinically, acute pancreatitis can be classified as mild or severe. 
 
Mild oedematous pancreatitis (MAP) usually presents with minimal organ dysfunction and 
leads to uneventful recovery. In this state, the pancreas shows oedematous swelling and 
multiple tiny spots of fatty tissue necrosis, mainly on the surface of the gland but also to some 
extent in the interlobular fatty tissue that infiltrates the pancreas [4]. The mild form only 
rarely progresses to severe pancreatitis [5], since the interstitial oedema, which is rich in 
pancreatic enzymes, is usually resolved by macrophages within a few days and does not lead 
to secondary changes. The fate of fat necrosis depends on its size. A small focus of fat 
necrosis (<1 cm) on the surface of the pancreas, as seen in mild pancreatitis, resolves entirely. 
The necrotic material, rich in lipids, is phagocytised by macrophages, which are transformed 
to foam cells. Later such an area may show a small focus of fibrotic tissue. 
 
Severe acute pancreatitis (SAP) is associated with organ failure and/or local complications 
such as necrosis, abscess, or pseudocyst. The peri-pancreatic tissue shows numerous large 
and often confluent areas of fat necrosis. In addition, there are also necrotic foci within the 
pancreas, although these are usually small compared with the extra-pancreatic alterations. 
Intra-pancreatic necrosis also develops in the interlobular fatty tissue, where it is dependent 
on the amount of fat in the pancreas. Where fat necrosis comes into contact with a blood 
vessel, it damages the vessel wall, leading to thrombosis and eventually, vessel necrosis, 
rupture, and haemorrhage. Focal destruction of single interlobular ducts and peripheral acinar 
cells are further sequelae of expanding fat necrosis. Fat necrosis can become infected, usually 
with the gut derived gram negative bacteria, adding to the mortality of the disease. Infection 
of the peritoneal cavity leads to purulent peritonitis. Necrotic areas within the pancreas 
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resolve slowly and may induce interlobular fibrosis [6, 7]. If this process, termed the 
“necrosis–fibrosis sequence” [8], takes place repeatedly because of recurrent attacks of severe 
acute pancreatitis and also involves the large interlobular ducts or the main duct, acute 
pancreatitis may evolve into chronic pancreatitis (CP) [7, 9-11]. 
 
1.2.2 Aetiology  
 
Gallstones and alcohol excess continue to be the main causative agents (figure 1.2). In 
approximately 10–20% of patients, no aetiology is identified. Some of these patients may 
have microlithiasis as the aetiology of AP. With the increasing knowledge and understanding 
of the role of genetic abnormalities in hereditary and idiopathic chronic pancreatitis (CP), it is 
possible that these abnormalities will be implicated in idiopathic AP. Furthermore, 
polymorphisms in inflammatory mediators may influence disease severity [12] . 
 
Acute Pancreatitis
Mechanical
•Gallstones
•Ampullary obstruction
•Pancreatic duct obstruction
•Iatrogenic – ERCP*
•Congenital malformation
•Trauma
Toxic-Metabolic
•Alcohol 
•Hypertriglyceridemia
•Hypercalcemia
•Medications
•Organophosphates
•Scorpion toxin
•Methylene chloride
Vascular
•Hypotension
•Vasculitis
•Hypercoagulable state
•Embolism
Miscelleneous
•Tropical pancreatitis
•Cystic fibrosis
•Autoimmune
Infection
•Cytomegalovirus
•Tuberculosis
•HIV
•Coxsakie virus
•Mumps virus
•parasites
*Endoscopic Retrograde Cholangio-Pancreatography 
Human Immunodeficiency Virus 
Figure1. 7 - Conditions leading to acute pancreatitis 
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Gallstone (Biliary) pancreatitis – Gallstones are implicated in approximately 80% of all 
cases of acute pancreatitis [13, 14]. Although gallstones are common, they rarely cause 
pancreatitis. It is estimated that over a 20- to 30-year period, the risk of developing biliary 
pancreatitis in patients with asymptomatic gallstones is approximately 2%. Various theories 
have been proposed about the possible mechanism of development of pancreatitis secondary 
to gallstones, most of these arising out of works of Opie [15]. 
 
Detailed studies of patients with “idiopathic” acute pancreatitis suggest that a high proportion 
of these cases are due to microlithiasis, which may be detected by endoluminal ultrasound 
(EUS) if performed early enough after the onset of disease. Such studies suggest that up to 
80% of “idiopathic” cases are actually due to gallstones [16-18]. 
 
Alcoholic pancreatitis - Alcoholic pancreatitis can present as acute pancreatitis, although in 
most patients, it occurs in the presence of already established chronic pancreatitis. It is the 
most common cause of recurrent pancreatitis. In UK, approximately 20-30% cases of acute 
pancreatitis are thought to be due to alcohol abuse [19]. It is of interest to note that the 
incidence of alcohol-induced acute pancreatitis may have been increasing over the past 
decade. A study in the UK has reported an increase in the crude incidence rate of alcohol-
induced acute pancreatitis from 14.5 cases per 100 000 population in 1989–90 to 20.7 per 
1,00,000 in 1999–2002 [19]. The incidence of alcoholic pancreatitis is low (about 5%) in 
alcohol abusers [20, 21]. As reported by Dreiling and Koller [20], given 100 alcoholics, five 
will develop clinical acute pancreatitis, 15 will develop alcoholic cirrhosis, while only one 
will develop clinical evidence of both diseases. This estimate suggests that in addition to 
alcohol ingestion, other factors, such as genetic background or environmental influences, may 
affect patient susceptibility. Several major physiological mechanisms may contribute to the 
development of alcoholic pancreatitis, including abnormal sphincter of Oddi spasm, 
obstruction of the small ducts by proteinaceous material, and direct toxic effect of alcohol 
and its metabolites. Despite the fact that alcoholic pancreatitis can be complicated by severe 
disease, it is a less common cause of fatal pancreatitis. 
 
Other aetiologies - Other potential causes identified include pancreatic cancer in 1% of 
cases, post-ERCP in 2–3%, medications in 1%, miscellaneous causes in 2%, and unknown 
causes in 15–23% of first attacks of acute pancreatitis. 
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Recurrent Acute Pancreatitis - Bouts of recurrent acute pancreatitis are most commonly 
alcohol-related (60%); other aetiologies include unknown causes (17%) and untreated 
gallstones (19%). Recurrent acute pancreatitis appears to be relatively benign and is 
associated with a low mortality rate. 
 
1.2.3 Clinical course  
 
The majority of patients with mild pancreatitis recover uneventfully and once the etiological 
factor is identified and removed, there are no long-term complications or recurrences. 
Approximately 10–20% of patients with acute pancreatitis develop severe disease and have a 
complicated hospital course. 
 
In general, severe pancreatitis develops in two phases (Figure 1.3). 
 
Acute Pancreatitis
Mild edematous pancreatitis SIRS
Organ failure
Acute necrotising pancreatitis
Sterile Infected
Sepsis Systemic failure
Death
Pseudocyst
Complete resolution
Death
 
□early phase 
□late phase 
Figure 1.8 - Clinical course of Acute Pancreatitis 
 
The first two weeks after onset of symptoms are characterised by the systemic inflammatory 
response syndrome (SIRS) (Figure 1.4). Release of pro-inflammatory mediators is thought to 
contribute to the pathogenesis of SIRS associated pulmonary, cardiovascular, and renal 
insufficiency [22, 23]. Similarly, pancreatic necrosis develops within the first four days after 
the onset of symptoms to its full extent in most of the cases [24], although late onset 
pancreatic necrosis has also been reported in literature [25]. Although SIRS in the early phase 
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of severe pancreatitis may be found in the absence of significant pancreatic necrosis, the 
majority of patients with severe early organ dysfunction will have pancreatic necrosis on 
computed tomography (CT) scan [26]. Late deterioration of organ dysfunction occurs most 
commonly in the second to third week after admission [24], and is usually the result of 
secondary infection of pancreatic or peripancreatic necrosis.  
 
 
 
 
 
 
Figure 1.9 - Course of severe acute pancreatitis – (adapted with permission) 
 
1.2.4 Complications associated with the severe disease 
 
Since acute severe pancreatitis is a systemic disease, it not only results in local complications, 
but can also lead to organ failure (figure 1.5). 
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EPR necrosis – Extra-pancreatic retroperitoneal necrosis, ARDS – Acute Respiratory Distress Syndrome, DIC – Disseminated Intra-vascular 
Coagulopathy, TTP – Thrombotic Thrombocytopenic Purpura, HUS – Haemolytic Uraemic Syndrome 
Figure 1.10 – Complications of Acute Pancreatitis 
 
 
Respiratory dysfunction is the most critical of all extra-pancreatic manifestations. It occurs 
in almost 75% of cases and ranges from hypoxemia to Acute Respiratory Distress Syndrome 
(ARDS).  Course of pulmonary dysfunction and subsequent failure happens in three stages; 
Stage 1 deals with pulmonary manifestations in the form of tachypnoea, mild respiratory 
alkalosis and hypoxemia without any noticeable changes radiologically; stage 2 emphasises 
radiologic changes observed in the form of pulmonary infiltrates or atelectasis, pleural 
effusions, and pulmonary oedema and stage 3 is hallmarked by ARDS, characterised by 
severe dyspnoea and extreme hypoxemia refractory to a high inspired oxygen concentration. 
 
Vascular complications in pancreatitis are well recognized and occur in approximately one 
fourth of the patients [27]. The most common complications are haemorrhage into a 
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pseudocyst, erosions of the upper gastrointestinal arteries, thromboses of the portal venous 
system, formation of varices or pseudoaneurysms and rupture of a pseudoaneurysm. 
Pancreatitis in combination with vascular complications is dangerous and potentially lethal. 
The survival of patients with pancreatitis and vascular complications depends on the early 
diagnosis of these complications. 
 
Acute renal failure is one of the most common complications in patients with severe acute 
pancreatitis. Its incidence rate ranges from 14% to 42% in the literature [28, 29]. The history 
of renal disease, acute coronary syndrome (ACS), and hypoxemia are the significant risk 
factors for it [30]. 
 
Pancreatic pseudocysts are well known sequelae of acute pancreatitis with a prevalence rate 
ranging from 6% to 18.5% [5, 31]. Complications arising out of pseudocysts, influencing 
patient morbidity and mortality include rupture into gastro-intestinal tract tract, peritoneal 
cavity or vascular system [32], haemorrhage due to erosion into a major vessel [33], infection 
[34] and obstructive jaundice arising from pressure on the common bile duct [35, 36]. 
 
Pancreatic and gastrointestinal tract fistulas (gastric, enteric, duodenal, and colonic) are 
common complications of severe necrotizing pancreatitis. Mortality in these patients parallels 
the mortality for severe necrotizing pancreatitis [37, 38]. 
 
Pancreatic endocrine and exocrine insufficiencies are well reported follow-up 
complications of acute necrotizing pancreatitis. Pancreatic endocrine insufficiency is 
diagnosed on the basis of abnormal oral glucose tolerance test, after recovery from acute 
illness. Pancreatic exocrine insufficiency is diagnosed on the basis of clinical symptoms of 
steatorrhea [39-41].  
 
In contemporary pancreatic practice, the diagnosis and management of colonic 
complications of pancreatitis remains a relatively difficult management problem. These 
roughly include colonic necrosis [42-44], colonic fistula [42], colonic stricture/stenosis [45], 
colonic obstruction and colonic haemorrhage [44]. In 1989, Aldridge and colleagues reported 
36 cases of large bowel involvement in acute necrotising pancreatitis and discovered a 
spectrum of changes in the resected colons ranging from pericolitis through to ischaemic 
necrosis, suggesting at least two possible mechanisms [43]. Kriwanek et al found colonic 
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necrosis to be an independent prognostic factor for death in his patient cohort with an 
associated mortality of 53% [46]. Hence, colonic necrosis is a potentially lethal complication 
of acute pancreatitis with a mortality of 54% and an overall mortality of 35% for patients 
with colonic complications of pancreatitis [44]. 
 
1.2.5 Mortality in acute pancreatitis 
 
The mortality of acute pancreatitis is reported in the literature as being between 1.3 and 10%. 
A range of 2–5% likely represents a true mortality because the higher rates are indicated in 
studies from referral centres and probably do not include patients with mild disease. Overall, 
studies suggest a reduction in mortality in the last decade. The mortality rate takes a big leap 
in severe acute pancreatitis, where the reported figures are between 14 and 30%. 
Approximately half of this mortality is seen in the first two weeks [47-49]. Mortality appears 
to be influenced by age, aetiology (higher in patients with idiopathic, post-ERCP pancreatitis, 
and gallstone), presence of organ failure on admission and the presence of pancreatic 
necrosis. Additionally, patients with severe pancreatitis transferred to tertiary care facilities 
for management have higher mortalities [50]. Most studies suggest that approximately 10–
20% of fatal pancreatitis is missed with the diagnosis only being made at autopsy. The missed 
diagnosis appears in patients who present without abdominal pain, with acute respiratory 
failure or neurological changes, and/or normal serum enzymes or pancreatic imaging. 
 
1.2.6 Available treatment modalities 
 
For a disease of this magnitude, it is unfortunate that there is no pancreatitis specific 
pharmacotherapy available to treat acute pancreatitis. Therefore, the management of the 
disease largely remains supportive. The primary objective in the initial treatment of acute 
pancreatitis is to provide supportive therapy and to treat specific complications as these arise. 
It is also of paramount importance to make efforts to limit both the pancreatic inflammation 
and invariably, pancreatic necrosis and the systemic inflammatory response by specifically 
interrupting their pathogenesis. 
 
Fluid resuscitation and rehydration - Maintaining an adequate intravascular volume is 
probably the most essential therapeutic measure in the treatment of acute pancreatitis. If not 
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achieved, it is also the most consequential mistake. Patients with acute pancreatitis can 
sequester large amounts of fluid into the retroperitoneal space, intraperitoneal cavity 
(pancreatic ascites), gut and the pleural space. Haemodilution to a haematocrit of around 30% 
with dextran 60 has been shown to improve pancreatic microcirculation and oxygenation in 
experimental acute pancreatitis [51]. There is also increasing evidence that oxygen 
supplementation to maintain an arterial saturation of 95% is associated with the resolution of 
organ failure, since it ensure optimal oxygen transport [52]. 
 
Nutritional supplementation – Severe acute pancreatitis creates a catabolic stress state, 
exacerbating the pathological progression by promoting systemic inflammatory response and 
nutritional deterioration [53]. This, combined with absence of oral intake, promotes persistent 
negative nitrogen balance that appears to be associated with a higher mortality rate as a result 
of loss of function and structural integrity of vital organs [5, 54, 55] Increasing evidence 
suggests that enteral feeding is not only safe but can also reduce complications by helping to 
maintain the intestinal barrier function and intestinal blood flow, and by preventing or 
reducing bacterial translocation from the gut. Furthermore, enteral nutrition eliminates some 
of the complications of parenteral nutrition, such as catheter sepsis, as well as other less 
common complications. 
Recent meta-analyses have supported use of enteral nutrition in patients with severe 
pancreatitis requiring nutritional support over total parenteral nutrition. It has also been found 
that patients receiving enteral nutrition are less likely to suffer from multiple organ failure, 
systemic infections, operative interventions and more importantly, death [56-58]. 
 
Treatment of pain – Inflammatory mediators released as a result of pancreatic inflammation 
and necrosis can have a direct effect on sensory nerve fibres in the celiac plexus (spinal cord 
level T5–T9) and therefore mediate visceral pain, which is often excruciating. Adequate pain 
relief is therefore one of the most important and urgent treatment goals. The systemic 
administration of intravenous procaine hydrochloride has long been advocated as an 
alternative to opiates, but has now been shown to be completely ineffective for the treatment 
of pain in patients with acute pancreatitis [59, 60]. Concerns that morphine analogues might 
negatively affect the course of pancreatitis because of their inhibitory effect on the sphincter 
of Oddi are unwarranted [61]. Some centres have begun to use thoracic epidural analgesia to 
treat pain in acute pancreatitis patients [62] . This medication not only leads to rapid pain 
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relief [63] but often abolishes the need for opiates. Although shown to be effective in a few 
studies, well designed randomised multicentre trials are required to establish its efficacy. 
 
Role of antibiotics in acute pancreatitis – Infected pancreatic necrosis increases mortality 
risk to more than 40% and requires surgical debridement to improve clinical outcome [24, 64, 
65] . The infecting agents, usually gut-derived bacteria [66], and organisms are thought to 
migrate from nearby bowel via intervening lymphatics. Gut mucosal defences against 
bacterial translocation become impaired in severe acute pancreatitis [67, 68]. Infected 
pancreatic necrosis worsens pre-existing multi-organ failure and may lead to development of 
new organ failure or other signs of systemic sepsis [5]. There appears to be a window of 
opportunity of around 1-2 weeks during which infection may be prevented by administering 
antibacterial therapy with agents active against enteric organisms [24, 69]. Recent meta-
analyses have reported conflicting results with regards to efficacy of prophylactic antibiotic 
therapy in acute pancreatitis. While some of them have not shown any reduction in mortality 
or protection against infected necrosis or frequency of surgical intervention [70, 71], others 
have strongly advocated prophylactic use of antibiotics in settings of acute necrotising 
pancreatitis [72, 73][74].  
 
1.2.6.1 Interventional management 
 
Endoscopic sphincterotomy - There has been much interest and debate on the early 
endoscopic removal of gallstones retained in the common bile duct in patients with acute 
biliary pancreatitis. Although ERCP has no role in the initial diagnosis of acute pancreatitis, 
there is good evidence that early endoscopic sphincterotomy with the aim of removing 
obstructing gallstones is the procedure of choice in patients with cholangitis or with impacted 
stones [75]. In cases of mild acute biliary pancreatitis without signs of cholestasis, cholangitis 
or clinical deterioration, monitoring of the clinical progress alone suffices, without requiring 
any interventional modality. A randomised controlled trial has shown that patients with 
predicted severe pancreatitis, but without biliary obstruction, do not benefit from endoscopic 
sphincterotomy [76].  
 
Surgical procedures – Management of pancreatic necrosis has taken a shift from very 
aggressive open surgery to more conservative intensive care approach in the recent years. 
Surgery is now indicated in acute necrotising pancreatitis only for infected pancreatic tissue, 
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diagnosis of which is made on the evidence of bacterial or fungal growth on the fine needle 
aspiration or presence of gas in the retroperitoneum on CT scan. Aim of a standard surgical 
treatment is to control the focus so that further complications are avoided by restricting the 
progression of infection and release of pro-inflammatory mediators. Although a generally 
accepted principle of organ preserving surgical approach is the gold standard, four principle 
methods have been advocated. 
 
 Necrosectomy combined with open packing [77] 
 Planned staged re-laparotomies with repeated lavage [78] 
 Closed continuous lavage of the lesser sac and retroperitoneum [79] 
 Closed packing [80] 
 
Open necrosectomy has been associated with high rates of morbidity (34-95%) and mortality 
(11-39%), along with the risk of long term pancreatic insufficiency [39, 81-83], morbidity is 
low in techniques which provide postoperative exit channels for further slough and infected 
debris [84].   
 
Advent of minimally invasive interventional procedures has revolutionised the surgical 
management of acute necrotising pancreatitis. The rationale is to minimise peri- and 
postoperative stress in critically ill septic patients, suffering from multi-organ failure. These 
procedures, including percutaneous drainage, endoscopic drainage, or minimally invasive 
surgery play a role as a temporary measure to bridge the critical early time after onset of 
acute pancreatitis to a later optimal time point for definitive intervention. The Dutch 
multicentre randomised controlled trial demonstrated that a minimally invasive step-up 
approach, which consisted of percutaneous/endoscopic drainage of infected fluid collection 
as the first step and minimally invasive retroperitoneal necrosectomy as the next step if 
required, reduced the rate of the major complications and death among patients with 
necrotising pancreatitis and infected necrotic tissue, as compared with open necrosectomy 
[85]. 
The pancreatic unit at the Royal Liverpool University Hospital has been performing Minimal 
Access Retroperitoneal Pancreatic Necrosectomy (MARPN) since 1998. 
The technique involves using a nephroscope over a guidewire that is placed under CT 
guidance into the necrotic tissue and can be performed under local anaesthetic as well. 
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Various publications outlining the unit’s experience with the technique and comparing it with 
the traditional open necrosectomy (ON) have shown superiority of MARPN over the former. 
ON was found to be associated with increased post-operative multi-organ failure and 
mortality when compared with MARPN [39, 86-89].  
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Acute pancreatitis is a disorder that has numerous causes and an obscure pathogenesis. The 
spectrum of the disease can range from mild and self-limiting to severe and fatal. Several 
aspects of the condition remain poorly understood or controversial, although recent advances 
have improved our understanding in many areas, such as predisposing risk factors, pathology, 
and biochemical events within the pancreas, through a large number of clinical and 
experimental studies. However, the earliest changes in the pancreas, the so-called initiator or 
trigger mechanisms, await discovery. The clinical disease varies in severity, but the basic 
response of the pancreas to the injurious stimulus appears to be limited to one or two 
sequences of events, giving credence to the idea of a "common pathway" for the initiation of 
pancreatitis, despite the disparate predisposing factors. The latter must lead to similar cellular 
alterations, which manifest as clinically similar forms of pancreatitis. Any encompassing 
theory of the pathogenesis of pancreatitis must explain the diversity of the initiating stimuli, 
the varying clinical and pathologic pictures and the systemic manifestations of the disease. 
2.1 The Trypsin Centred Theory 
 
This widely popular theory rests on the common knowledge that most experimental models 
of AP have shown pathological activation of trypsinogen to trypsin [90-92]. This invariably 
establishes a cause-effect relationship [91, 93]. However, new emerging evidence questions 
this very notion [91].  
 the detectable premature trypsinogen activation – may not be pathologically significant 
quantitatively 
 Protective responses within the acinar cell may be adequate to clear the response 
efficiently 
 It may lead to some pathologic acinar cell inflammatory signalling without incurring any   
direct cell damage 
 Alternatively, it may cause some direct cell damage, consequently, triggering protective 
and pathologic cellular pathways such as autophagy and endoplasmic reticulum (ER) 
stress, and activate pathological inflammatory signalling 
 Premature activation may act as a protective response leading to rapid cell death [94, 95] 
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 Trypsinogen knock out mice experiments have successfully shown development of local 
and systemic inflammation comparable to that seen in wild type mice in the absence of 
significant pathological trypsinogen activation [96, 97].  
 Other, alternative, trypsin-independent pathological events may be present in sufficient 
degree to cause pancreatitis independently of or in conjunction with trypsin-related injury 
[96].  
 
Thus, premature trypsinogen activation seems to contribute to a component of local injury but 
inflammation, both local and systemic, progresses independently of trypsinogen activation 
during acute pancreatitis and therefore, this does not necessarily translate into pathogenicity 
[96-98]. Although some recent work into hereditary pancreatitis with identification of mutant 
genes (PRSS1, CFTR, SPINK1, CTRC and CASR) [99-102] has supported the trypsin 
centred theory, it is not without its flaws [103-109] and this remains open to speculations. 
 
 
Regardless of the exact mechanisms leading to the development of pancreatitis, once the 
inciting agent/pathway activates the inflammatory cascade, the pancreatic inflammation is 
driven by release of active pancreatic enzymes and inflammatory mediators into the blood 
stream [110, 111]. TNF-α, IL-1, IL-6, IL-8, IL-10, PGE2, C reactive protein and PAF 
especially are crucial in this process [112-118]. The release of these interleukins and TNF-α 
from macrophages triggers an inflammatory cascade, resulting in necrosis of the acini and 
pancreatic islets, interstitial fat necrosis, necrotising vasculitis and systemic inflammatory 
response syndrome (SIRS) [23]. SIRS may develop into ARDS and multi-organ dysfunction 
syndrome (MODS). TNF-α induced response also damages the intestinal barrier leading to 
bacterial translocation (from small bowel or colon) and pancreatic infection. It is an important 
factor for complications, increases mortality by several folds [119-121] and may be a feature 
of early phase of the disease [122]. 
 
2.2 Inflammatory versus anti-inflammatory response in 
Acute Pancreatitis 
 
The initial events in acute pancreatitis lead to disruption of the acinar cells, following on from 
intracellular co-localisation of digestive and lysosomal enzymes [123-125]. When the natural 
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defence mechanisms fail to contain the inflammatory process to the local site, uncontrolled 
activation of inflammatory cells and mediators leads to an inflammatory rampage that leads 
to SIRS [126]. Cytokines are poured out into the circulation [127], leading to activation of 
other pro-inflammatory signals, synthesis of acute phase proteins and activation of vascular 
endothelium. This leads to increased permeability, copious leakage from the capillaries and 
migration of leukocytes into the tissues. Coagulation cascade is activated consequently. 
Vascular endothelium in addition to being activated, also suffers damage from the proteolytic 
enzymes and oxygen radicals released from circulating activated neutrophils and monocytes 
[128]. This dysfunction of endothelium results in impairment of microcirculation, lack of 
oxygen to organs and subsequently leads to organ dysfunction and failure [129, 130].  
 
The emerging concept of compensatory anti-inflammatory response syndrome (CARS) has 
provided useful explanations for some of the aspects of the pathophysiology of the disease 
[131, 132]. Although, a lot of it still hides in the shrouds of mystery, it is widely agreed upon 
that in acute pancreatitis, it is observed and leads to effects in the later part of the disease – 
secondary infections due to excessive immunosuppression [24]. Some studies have provided 
useful data and hence, established evidence that in AP decreased HLA-DR expression of 
monocytes, resultant from impaired antigen presentation capacity [133], is positively 
associated with development of secondary infections [132], organ failure [134] and mortality 
[135]. Another important contributor to CARS is IL-10. It not only decreases monocyte 
HLA-DR expression but has also been found to predict development of organ failure in the 
early part of the disease [136]. IL-6 and IL-1ra are also important as IL-6 prevents synthesis 
of TNF α and IL 1β.  
 
2.3 Inflammatory Role of Acinar Cells 
 
 
It has only transpired recently that pancreatic acinar cells act as inflammatory cells, releasing 
inflammatory signals and provoking immune responses when noxious stimuli incite injury 
within them. These are also capable of activating signalling pathways, giving way to 
expression of various inflammatory mediators [137, 138].  
 
Cytokine production by acinar cells in the context of AP has been well established by various 
studies which have shown production, release and response to TNF α, IL-6, IL-10 and IL-1β 
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in in vivo and in vitro models [139-144].  These cytokines not only accelerate pancreatic 
inflammation, through induction of regulatory genes in acinar cells, but also play a pivotal 
role in determining severity of acute pancreatitis by inducing apoptosis in acinar cells [139, 
145].  
 
Chemokines have also been laid out to be involved in the early inflammatory response 
mounted by acinar cells. Monocyte chemo-attractant protein-1 (MCP-1), macrophage 
inflammatory protein (MIP)-1α, regulated upon activation, normal T expressed and secreted 
(RANTES), IL-8, cytokine induced neutrophil chemo-attractant (CINC), Mob-1 (the 
homologue of human IP-10) and MIP-2 have all been identified as being secreted by acinar 
cells during AP in animal models [140, 146-151]. 
 
Acinar cells regulate the pathological functioning of cytokines and chemokines, in the 
context of acute pancreatitis, through four major inflammatory pathways - Nuclear Factor-κβ 
(NF-κβ), Signal Transducers and Activators of Transcription (STAT), Mitogen Activated 
Protein Kinase (MAPK) and Activating Factor 1 (AP-1). These pathways accentuate the 
inflammatory process, through induction of genes responsible for expression of cytokines and 
chemokines, leading to overproduction [137-139, 142, 143, 150-157]. 
 
2.4 Calcium Signalling  
 
Works from Liverpool NIHR Pancreas Biomedical Research unit have clearly demonstrated 
prolonged elevations in cytosolic calcium to be the trigger of AP [158], which leads to store-
operated calcium entry dependent (SOCE) pancreatic acinar cell injury and necrosis [159-
164]. The concept is undoubtedly old but there has been increasing evidence in the recent 
times. The abnormal elevations of calcium lead to molecular events that play a crucial role in 
the pathogenesis of AP. These include premature intracellular enzyme activation, 
mitochondrial dysfunction, impaired autophagy and vacuolization, to name a few [165]. 
Mitochondrial dysfunction, likely due to intracellular calcium overload, is now recognised to 
be at the heart of the pathogenesis of AP, being the principle mechanism of injury [159, 166-
171]. Mitochondrial matrix calcium overload drives opening of the Mitochondrial 
Permeability Transition Pore (MPTP) – a non-specific channel that forms in the inner 
mitochondrial membrane that has already been demonstrated to be crucial to AP by 
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mediating impaired ATP production, defective autophagy, zymogen activation, inflammatory 
responses and necrosis. Cell death occurs when the ability to produce ATP has been critically 
affected due to significant damage to the mitochondria consequent to the cytosolic calcium 
overload [172]. Additionally, many studies have indicated the importance of inositol 
triphosphate (IP3) [173-175] and ryanodine [161, 176] stimulated calcium release channels on 
internal stores to pancreatic injury induced by AP precipitants. Concurrently, recent evidence 
has demonstrated a role for the STIM1-Orai complex as the principal calcium entry channel 
in pancreatic acinar cells [160, 164, 177]. Indeed, inhibition of Orai1 channels has been 
shown to cause reduced pathological calcium entry into murine pancreatic acinar cells, 
necrotic cell death and trypsin activation, suggesting therapeutic potential of calcium release 
activated calcium channel blockade to ameliorate AP [160].  
 
2.5 Acute Pancreatitis as a model of sepsis  
 
AP has now been well established in the literature as a clinical example of immune response 
in sepsis and indeed, the complications and outcomes of the two closely resemble each other 
– organ dysfunction and failure [178]. This suggests the intricate and absolute involvement of 
pro-inflammatory cascade, initiated by perhaps, different aetiologies to be the main driving 
force.  
As mentioned earlier, SIRS is likely to be the main contributor towards early mortality of the 
disease, with MODS occurring as a complication of the SAP in 20-80% of the cases [179]. 
Distinction between SIRS and sepsis can often be tricky, as the presentation may be very 
similar. The involved pathophysiological mechanisms are complex and similar and comprise 
of activation of several inflammatory mediators and components of the complement cascade. 
Polymorphonuclear leukocytes (PMNs) not only contribute towards the initiation of the 
pathological response but also extend the inflammatory process. Ischaemic injury is incited 
by cytotoxic insult and sequestration of platelets, PMNs and red blood cells (RBCs) in the 
microcirculation, leading to systemic hypotension, low peripheral resistance and a hyper-
dynamic circulation. This eventually translates into anaerobic metabolism and subsequent 
lactic acidosis, culminating into tissue injury and organ failure.  
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Another important consideration into the two disease states is the ability of the triggering 
factor to activate the host inflammatory response in an uncontrolled fashion with resultant 
dissemination into the system, leading to multiple systemic effects – organ 
dysfunction/failure. TNF α, IL-1 and nitric oxide are the most common mediators involved in 
this. 
Coagulation abnormalities are an important contributor to the inflammatory process in both 
sepsis and AP. These are initiated, in part, by the pro-inflammatory cytokines and activated 
endothelial cells [180] and can lead to widespread thrombosis, culminating in disseminated 
intra-vascular coagulopathy (DIC) and hence, organ failure [181]. Indeed, these 
microcirculatory disorders affecting the capillary blood flow, capillary permeability and 
leukocyte endothelial interaction have been demonstrated in the colon, liver, and lungs, in 
addition to the pancreas, in studies [129]. 
A landmark study in 2004 also implicated genetic polymorphisms for cytokines to be 
associate with prognosis, both in sepsis and AP. This especially applies to the polymorphisms 
involving glutathione levels in acinar cells. This may lead to increased oxidative stress and 
further clinical deterioration [12]. 
 
 
A recent interesting concept has also endeavoured to explain the pathophysiological 
similarities between SAP, SIRS and Sepsis. This is tied in by the ‘endotoxin tolerance’ (ET). 
Essentially, it is the diminished capacity of the host or macrophage/monocyte to respond to a 
Lipopolysaccharide (LPS) challenge after a first exposure to this stimulus [182, 183]. 
Experimental works have verified, to an extent, the hypothesis that the innate immune system 
of patients with SAP, SIRS and sepsis has characteristics of endotoxin tolerance. Works of 
Vasilescu and others [184] have placed merit on the role of TNF α related mechanisms as the 
underlying cause behind the phenomenon. They showed that the TNF α releasing capacity of 
the whole blood is lower in SAP than in trauma patients but higher than in diffuse peritonitis. 
Similar findings have previously been recorded by Ertel et al [185]. These TNF α releasing 
mechanisms form basis of the pathophysiological similarities in SAP and severe sepsis. There 
has been increasing evidence to place more significance on ET in response of innate 
immunity in SIRS, SAP and sepsis, assuming the role of a pivotal component of immune 
dysregulation that sits at the heart of clinical evolution of patients with SAP. Further studies 
on the matter will elaborate on the more intricate and complex components of the process but 
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the concept that the immune depression of patients with SAP, SIRS and sepsis is based on a 
mechanism similar to endotoxin tolerance, and that in SAP, the amplitude of the immune 
depression is of an intermediate degree between SIRS and sepsis, presents a very plausible 
theory, rendering SAP a very good clinical model for these conditions.  
 
2.6 Oxidative Stress in Acute Pancreatitis 
 
Our understanding of role of oxygen metabolites in inflammation has improved considerably 
and perhaps, dramatically over the last decade or so. These are important contributors 
towards release of inflammatory mediators and their sequestration within tissues, 
development of pancreatic oedema and also play an important role in controlling extent of 
necrosis at cellular level, both in acinar and non-acinar cells. Imbalance of free radicals 
release-clearance mechanisms and reduced anti-oxidative capability, demonstrated in both 
patients and animal models, has been proposed to be at the centre of the disease process in 
AP and SIRS. [186-189].  Animal models and human studies have placed significant value on 
oxidative stress as the common pathway in the pathogenesis of AP [190-194]. Experimental 
data have also suggested for a very early involvement of pancreatic oxidative stress in the 
disease process of AP. These assumptions and notions are supported by further studies on the 
topic, which have demonstrated conveniently, decreased antioxidant levels and increased 
release of peroxidation by-products in AP.  
 
Although some studies have shown excessive production of free radicals to be associated 
with increased cell damage and necrosis and pancreatic edema [195], a landmark study by 
Booth et al [187] showed for the first time that in animal model, free radical production led to 
apoptosis and inhibition of the same caused necrosis. These findings suggest that free radical 
generation within acinar cells may be a protective response during pancreatitis. It was also 
postulated in the same study that oxidative stress in the neutrophils activated during 
inflammatory response to acinar injury may be responsible for further propagation of local 
and systemic inflammation. As it materialises, oxidative stress may well have a dual role in 
pancreatic injury. 
 
 
Hydrogen peroxide, superoxide, hydroxyl radical and singlet oxygen all cause destruction of 
lipid membranes and lysosomal membranes by peroxidation of fatty acids, leading to cellular 
45 | P a g e  
 
and endothelial injury in AP. These act on arachidonic acid cascade and through their platelet 
aggregation and vasoconstricting effects, lower tissue circulation [196]. These also exert their 
pro-inflammatory influence and promote activation of leukocytes and lysosomal discharge 
[197]. A vicious cycle develops when the activated leukocytes cause respiratory burst, 
culminating in more free radical formation and hence, more tissue and acinar cell damage 
[139, 198, 199]. This oxidative stress in the neutrophils, accentuating the further propagation 
of local and systemic inflammation [187], may well be the driving force providing synergy 
between pro-inflammatory cytokines and oxidative stress in AP, perhaps through activation 
of mitogen activated protein kinases and nuclear factor-kappa B (NF-kB) and inactivation of 
protein phosphatises [200-203]. 
 
 Nitric oxide (NO), on the other hand, has a dual role. Its protective role is shown by its 
ability to relax smooth muscle, especially sphincter of Oddi and to improve pancreatic 
microvascular blood flow by vasodilation. Pancreatic damage is caused due to its free radical 
action and its association with bacterial translocation, putting endotoxemia in the centre of 
pathogenesis of MOF and septic complications of AP.  Indeed high levels of NO have been 
correlated with sepsis and mortality in AP [204]. These different roles can be explained by 
difference in concentration and synthesis of NO at different stages of the disease. Early phase 
of AP is characterised by low concentration of NO, which only causes muscle relaxation and 
vasodilation and hence, is protective. The concentration increases as the disease progresses 
and NO starts acting as a free radical participating in oxidative reactions [205]. 
 
Whether the oxygen free radical species are the initiators of the tissue damage in AP remains 
to be elucidated but these have been proven to be important mediators in the early and later 
courses of AP, correlating with clinical severity in many studies [206, 207]. 
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CHAPTER 3: PROGNOSTICATION IN 
ACUTE PANCREATITIS 
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3.1 Significance of severity stratification in acute pancreatitis 
 
Acute pancreatitis resolves spontaneously in approximately 80% of the patients, without 
requiring any intervention. However, a subset of the patients goes on to develop the severe 
form of the disease, including local and systemic complications and require intensive 
management. These patients should be monitored and managed in high dependency/critical 
care units as their condition demands. Unfortunately, it is not possible to accurately identify 
such patients when they present with the disease. Similarly, it is not feasible to manage all the 
patients who are diagnosed with acute pancreatitis to be managed in the critical care settings. 
Current scoring and predicting systems have their short comings and fail to achieve what is 
required. Therefore, it becomes difficult to allocate the health resources to the patients who 
need them the most. If patients, who potentially will develop severe acute pancreatitis in the 
course of their disease, can be accurately identified immediately on admission through a 
scoring system/biochemical parameter, it will not only enable the medical team to single out 
these patients and provide them with the best care possible, it will also ensure that the health 
resources are appropriately and efficiently used.   
 
3.2 An ideal biomarker does not exist 
 
An ideal prognostic system/marker doesn’t exist, and current approaches fall short of what is 
needed when dealing with individual patients. It has been 35 years since Ranson et al. [208] 
showed that it was possible to stratify patients with acute pancreatitis according to their risk of 
dying. Since then, there have been thousands of articles promoting hundreds of prognostic 
markers and systems. The fact that very few of these have actually found place in the clinical 
practice goes on to show that we still haven’t found what we are looking for. 
An ideal or desirable detection scoring system/biomarker should: 
 Have high sensitivity and positive prediction value (PPV). 
 Be able to predict necrosis early (<48 hours) 
 Be performed rapidly (<4 hrs) 
 Be available in most hospitals 
 Be relatively inexpensive 
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 Be objective and not observer-dependent [209]. 
The extent to which different clinical, laboratory and radiological detection methods satisfy 
these requirements vary greatly and show distinct limitations peculiar to each individual 
system.  
 
3.3 Current scoring methods 
 
3.3.1 Scoring systems 
 
APACHE II (Acute Physiology and Chronic Health Evaluation II) is a classification 
system designed to measure the severity of a disease for acutely unwell adult patients [210]. In 
the prediction of mortality for acute pancreatitis, it has been analysed in various studies and 
has been found to have a sensitivity of 65-81%, specificity of 77-91%, PPV of 23-69% and 
NPV of 86-99% [211]. Some studies have found a significant association of APACHE II with 
mortality, but conflicting results were found within these as well [212-214]. Moreover, it relies 
very heavily on age. In fact, a 76-year-old (6 points) would require very little physiologic 
disruption to be classified in the category of ‘severe acute pancreatitis’ (>8 points). This has 
been one of the arguments all along of defined number of APACHE II points when the age is 
high. Hence, the need for more accurate predictors of mortality.  
Ranson’s Criteria were initially introduced in 1974 for the assessment of severity of acute 
pancreatitis [208]. It is an objective indicator of diseases severity and is particularly useful at 
the two ends of the scale. Pancreatitis is mild when the score is ≤2, whereas pancreatitis is 
severe when the score is >6. The correlation of severity of disease or development of necrosis 
in patients with a score of 3-5 (which is a common occurrence) is deficient [215, 216]. 
Moreover, the system requires the completion of 11 measurements, which necessitates a total 
of 48 hrs of observation for proper evaluation [217]. Although a modification of the Ranson’s 
scoring was introduced by Blamey et al [218], the overall sensitivity of these numeric systems 
in the initial staging of an attack of pancreatitis remains 65%, with specificity of 70%, PPV of 
20-63% and NPV of 86-94% [211]. Some studies have found conflicting results between 
patients who died compared with those who survived [208, 209, 219, 220].  
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The Glasgow Criteria were originally presented in 1978 [221] and the original system used 
nine data elements. This was subsequently modified to eight data elements, by the removal of 
the contribution of transaminase levels (either AST or ALT (>100 U/l) [218]. The Glasgow 
criteria have been analysed in multiple studies and the sensitivity was found to be 94%, 
specificity 28%, PPV 18-66% and NPV 86-100% [211]. The score, however, is not valid for 
repeated measurements beyond 48 hrs and like Ranson’s criteria, has not been validated for 
use in children.  
Other scoring systems like, Mortality Probability Model (MPM) [222] and APACHE III 
[223] (a modified version of APACHE II including the prior site of health care- i.e. hospital 
floor, emergency room etc. – and additional physiological parameters – urine output, blood 
urea nitrogen, albumin, bilirubin, glucose) at 96 hrs have been calculated and brought forward 
but without creating much influence on the current clinical practice.   
 
3.3.2 Organ failure scores 
 
It has been shown in various studies that development of organ failure in the first week of 
acute pancreatitis is not only marker of poor prognosis but also translates into local 
complications later on [224]. According to Atlanta classification (AC) [5], patients with 
persistent organ failure in the first week are likely to have severe acute pancreatitis. Various 
organ failure scoring systems have been validated and are in clinical use. Ideally for ICU use, 
these scoring systems can be used to assess patients outside the intensive care environment as 
well. These include Sequential Organ Failure Assessment (SOFA) [225], Marshall’s scoring 
system [226] and Goris system [227], among others. 
 
3.3.3 Radiology scores 
 
Unlike clinical scores, radiological scores are based on local anatomic changes in the 
pancreatic and peri-pancreatic tissues. Contrast-enhanced CT scans can be used to assess 
pancreatic necrosis, since loss of perfusion consequent upon necrosis results in a reduced 
enhancement. In 1985, Balthazar et al [228] proposed a scoring system for the grading of 
disease severity based on the CT findings. The severity of pancreatitis is divided into 5 distinct 
groups, from A to E. Most patients with severe acute pancreatitis (SAP) exhibit one or more 
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pancreatic fluid collections and are classified as grades D or E according to the Balthazar score. 
Furthermore, when the score is >5, this is defined as SAP on the CT severity index (CTSI) – a 
development of the Balthazar score in which is included the pancreatic necrosis. Even in these 
cases, as with the clinical scores, the commonly used radiological scores are particularly useful 
in predicting survival in the absence of peri-pancreatic fluid collections (Balthazar score) or 
collections/pancreatic necrosis (CTSI), but when these abnormalities are present, the scores 
may miss up to 50-59% of patients who eventually die from the disease [211]. 
From the above mentioned facts, it is evident that there is no one most reliable predictor of 
mortality and all scores and parameters seem to show a good NPV but a relatively low PPV. 
The ability to confidently exclude a large cohort of patients with a low risk of mortality is of 
value in the management of patients with acute pancreatitis. However, all scoring systems and 
prognostic factors suffer from a low PPV and patients scoring highly on such parameters do 
not necessarily progress to a fatal outcome.  
 
3.3.4 Biochemical parameters 
 
Much effort has been directed to develop a single, simple, rapid, affordable and reliable 
laboratory test for the prediction of severity and to monitor disease progression. So far, several 
single biological parameters, which represent important steps in the pathophysiology of acute 
pancreatitis, have been evaluated, and several tests have been developed.  
Trypsinogen Activation Peptide (TAP) is the most studied activation peptide in acute 
pancreatitis. It is specifically related to the onset of acute pancreatitis and therefore, seem to be 
a good marker for it [229-231]. It is rapidly cleared by the kidneys and excreted into the urine 
[232], so that its detection in urine is easier than in serum. However, 30% of all patients with 
acute pancreatitis have normal TAP values in urine on admission [229]. Similarly, urinary TAP 
has not been able to predict mild pancreatitis following ERCP [233]. Two multicentre studies 
investigated the predictive value of urinary TAP [230, 234]. The American study showed a 
very high sensitivity of 100% and a specificity of 85% within 48 hrs, while the European trial 
demonstrated a sensitivity of only 58% and a specificity of 73% within 24 hrs after the onset 
of symptoms. Likelihood ratios for a positive urinary TAP assay at 48 hrs showed a small 
increase in the positive likelihood of severe acute pancreatitis from 20% to 35% [235]. This 
finding may limit the clinical usefulness of urinary TAP measurements for the prediction of 
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disease severity. The general accuracy of TAP alone does not qualify for clinical decision-
making. The elevated TAP concentration in severe cases decreases quickly in serum and within 
72 hrs in urine, so that the prognostic accuracy declines rapidly [229-231, 234]. Moreover, the 
TAP-ELISA is still too complex and too expensive to be used as a routine test in everyday 
practice. 
In patients with acute pancreatitis, elevated Tumour Necrosis Factor (TNF) levels have been 
well documented [236]. However, TNF measurements are inconsistent even in severe disease 
because of intermittent release and rapid clearance by the liver before it reaches the general 
circulation.  
The importance of Interleukin-6 (IL-6) in the acute phase response has been confirmed by the 
observation that it stimulates the synthesis of acute phase proteins, including C reactive protein 
(CRP), from hepatocytes in vitro and in vivo [237, 238]. Its concentrations peak already 24 hrs 
after the onset of the disease, but decrease to baseline within four days [239]. A large series of 
patients with acute pancreatitis confirmed that IL-6 levels on admission correlate well with the 
subsequent course of pancreatitis [240]. But due to its rapid decline, IL-6 does not seem to be 
a useful marker for monitoring disease progression. Similarly, Interleukin-8 (IL-8) levels 
have been shown to increase even earlier than IL-6, with a peak detected 12 hours after the 
onset of acute pancreatitis [241]. However, similar to IL-6, IL-8 decreases rapidly within 3-5 
days [242] and consequently, disease progression cannot be recorded with these markers.  
The most famous acute-phase reactant and most commonly used serum parameter for the 
staging of acute pancreatitis is C-Reactive Protein (CRP). The importance of CRP in 
predicting severity of acute pancreatitis has been shown in numerous clinical studies over the 
past years [243-245]. Increased levels of CRP are a direct effect of hepatocytes stimulation by 
cytokine release. This also explains the chronological delay of increased CRP levels compared 
to IL-6 and IL-8 concentrations, with peak levels occurring 48-96 hrs after symptom onset. 
Pezzilli et al [242] found the highest sensitivity and specificity for predicting severity of acute 
pancreatitis for IL-6 and IL-8 on days 1 and 2, while on day 3 CRP surpassed both of these 
mediators. This is due to the relative rapid decrease of the two cytokines. Although, CRP is a 
valuable parameter for predicting severity of acute pancreatitis more than 48 hrs after the onset 
of the disease and for monitoring disease progression, it does not help with prediction within 
the first 48 hours of the disease onset.  
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Serum Amyloid A (SAA) proteins constitute a family of apolipoproteins mainly synthesized 
in liver in response to cytokines [246]. SAA has been found to be of similar value for the 
discrimination between oedematous and necrotising pancreatitis as CRP [247, 248]. However, 
SAA was less accurate than CRP in predicting infection, multi-organ failure and death. 
Moreover, in contrast to CRP, SAA does not have an accepted cut-off value. The European 
multicentre trial [248] was able to demonstrate that SAA distinguishes mild from severe acute 
pancreatitis already at the onset of the disease and that this difference was significant for the 
whole observation period of five days. However, the other trial could not demonstrate the early 
predictive value of SAA [247].   
It is very clear from the discussion above that despite the proliferation of scoring systems and 
biochemical parameters for grading acute pancreatitis, there is still no single system or 
biomarker which is completely reliable in accurately predicting the severity of the disease 
within the first 48 hrs. 
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CHAPTER 4: GENE EXPRESSION AND 
MICRO RNA PROFILING 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1 Circulatory blood (peripheral) gene expression profiling 
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Gene expression profiling represents a new and promising tool which could enable us to come 
up with a more comprehensive management of human diseases and disease risk factors. In 
particular, microarray based transcriptional portraits (transcriptomes) of disease can identify 
disease-specific signatures [249, 250], which will ultimately be translated into clinically useful 
molecular biomarkers. Recently, investigators have measured gene expression of the pancreas 
in experimental pancreatitis and have identified several novel genes which are likely to be 
important in the development and severity of acute pancreatitis [251, 252]. Ji et al [251] utilized 
microarrays to identify genes commonly induced in rat pancreatic acinar cells within 1-4 hours 
in two in vivo models (caerulein and taurocholate) and observed that a complex programme of 
gene expression was rapidly initiated early in the course of the disease. Their data suggested a 
model in which early signalling events led to activation of transcription factors which regulated 
the expression of specific cellular and secreted molecules. These secreted factors were 
hypothesised to be useful prognostic indices for the disease. Similarly, some researchers have 
identified genes likely to be involved in the endogenous self-protection mechanisms in acute 
pancreatitis using experimental animal models [253], while others have studied changes in the 
population of leukocytes in pancreatitis and have emphasized on a pathogenetic role of immune 
system in the development of acute pancreatitis [254].  
Although the early acinar cell expression is important for the subsequent severity of acute 
pancreatitis and could provide insight into the mechanisms involved in the initiation of acute 
pancreatitis [251], obtaining pancreatic tissue to analyse acinar cell gene expression is not a 
practical option in human patients. This difficulty in obtaining pancreatic samples has clearly 
impeded transcriptomic research in this area.  
Circulating blood is easily accessible and has been suggested as an alternative to tissue samples 
for molecular profiling of human disease and disease risk. This is based on the capacity of 
peripheral blood to reflect pathological changes in the body and the identification of these 
alterations as a blood molecular signature. Since sample acquisition is a daunting challenge for 
the application of molecular profiling as a diagnostic tool or for the identification of candidate 
risk factors, possibility of utility of peripheral blood cells as ‘surrogate’ for biopsy tissue for 
profiling in humans [255] appears to be an attractive option.  Blood sampling enables relatively 
large samples to be collected and is highly amenable to standardisation of technical procedures. 
Thus, blood represents an attractive alternative sample for profiling human diseases and 
discovering new biomarkers.  
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Recent studies have shown that the peripheral blood leukocytes have the ability to respond 
differentially to varying environmental, physiological and pathological insults or perturbations 
occurring anywhere in the body. Indeed, these cells have been found to share more than 80% 
of the transcriptome with each of the nine tissues tested in one of these studies, namely: brain, 
colon, heart, kidney, liver, lung, prostate, spleen and stomach [256]. It also showed that these 
blood cells expressed organ specific genes, such as β-myosin heavy chain (heart) and insulin 
(pancreas). 
Early profiling studies of the peripheral blood leukocytes involved analysis of haematological 
malignancies where these cells displayed disease-specific gene-expression signatures accurate 
enough to identify clinically relevant patient subgroups (i.e. subgroups associated with 
response to treatment, prognosis and novel malignancy subtypes) [257]. Others profiled gene 
expression of peripheral blood leukocytes in a wide range of non-haematological disorders and 
demonstrated that monitoring gene expression in blood results in distinct transcriptional 
signatures for more than 35 different conditions in humans [256], including, osteoarthritis 
[258], schizophrenia [259], cardiovascular disease and various types of cancers: bladder [260], 
colorectal [261] and breast [262]. 
In the recent years, the peripheral blood leukocyte gene expression in cardiovascular disease 
has been the target of extensive investigations. In one of the initial studies, Ma et al identified 
significant differences between blood samples from coronary artery disease (CAD) patients as 
compared to healthy controls [263]. Some of these changes could be interpreted in terms of 
potential contribution of peripheral blood leukocytes to the pathogenesis of CAD [263]. In 
another study, peripheral blood leukocytes responded to changing plasma lipid levels by 
regulating a network of genes, including genes involved in immune responses and 
inflammation and in lipid and fatty acid metabolisms [264]. This study provided further data 
on the inert relationships between plasma lipid levels and leukocytes in the atherogenic process. 
It also suggested that peripheral blood leukocyte gene expression profiling was not only useful 
for identifying disease biomarkers but might also shed light on disease pathways involved. 
Similarly, Chon et al [265] studied changes in mRNA levels in leukocytes from untreated or 
treated hypertensive patients. Their findings indicated that microarray gene expression 
profiling of peripheral leukocytes can distinguish hypertensive patients from age- and sex-
matched controls. 
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In oncology studies, Twine et al [266] tested for surrogate transcriptional markers in peripheral 
blood mononuclear cells of patients with renal cell carcinoma; an eight-gene classifier set was 
identified to best predict renal cell carcinoma versus normal. Subsequently, the same group 
showed significant correlation with overall survival and progression-free survival in patients 
in a phase II study of CCI-779 [267]. In another study, Sharma et al [262] reported a 37-gene 
signature that detected breast cancer correctly in more than 80% of cases. In this study, female 
patients without cancer but with other comorbidities were classified correctly as ‘non-cancer’, 
highlighting the specificity of the breast-cancer signature identified from blood.  
 Many other studies support the power of blood leukocyte gene-expression profiling in disease 
detection, classification and diagnosis. Such studies have investigated profiles in asthma [268], 
severe lupus erythematous [269], rheumatoid arthritis [270], Crohn’s disease and ulcerative 
colitis [271], pulmonary arterial hypertension [272], ischemic stroke and Alzheimer’s and 
Huntington’s diseases [273, 274].  
 
4.1.1 Peripheral blood gene expression profiling in acute pancreatitis 
 
Based on all the above mentioned evidence, it can be confidently stated that microarray based 
peripheral blood leukocyte gene-expression profiling holds great promise. But to date, no one 
has actually studied the role of blood derived inflammatory cells as markers for pancreatic 
inflammation. It is hypothesised, for this project, that the peripheral blood leukocytes can serve 
as a ‘reporter function’ as biomarkers of acute pancreatitis, and as such would express unique 
genes during pancreatitis. Further, as discussed before, these cells represent an easily 
accessible, non-invasive source of material. This easy availability of blood leukocytes to 
provide reporter function for solid organ disease will likely prove useful in pancreatitis. It is 
therefore, postulated, for the reasons stated above, that the response to pancreatitis and 
potentially the prognostic indicator of disease severity, rests in the peripheral blood leukocytes. 
These are the cells which mediate the immunologic reaction to pancreatitis. The genetic map 
of these leukocytes during this disease has not been looked into before. Recently, Bluth et al 
[275] looked into the gene expression profiles in cells of peripheral blood in a rat model of 
experimental pancreatitis (sodium taurocholate) and used a model of septic shock and saline 
controls as controls to identify new molecular markers of acute pancreatitis using microarray 
technology. They found 140 genes which showed unique significant changes in expression of 
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PBMCs during the acute phase of acute pancreatitis, but not in sepsis. They concluded that 
pancreatitis related genes are induced in cells outside the pancreas – in peripheral blood 
mononuclear cells during necrotising pancreatitis. It should not be surprising that such genes 
are induced since these genes were originally identified from inflamed pancreatic tissue which 
likely already had similar peripheral blood mononuclear cells infiltrating them. 
 
4.1.2 Gene expression Microarrays 
 
Gene expression microarrays have revolutionised the advances in genomics. From analysis of 
378 arrayed lysed bacterial colonies in 1982 [276] to complete eukaryotic genome expression 
on a microarray in 1997 [277], the microarray technology has come a long way in developing 
our understanding of molecular mechanisms underlying normal and pathological biological 
phenomena. It has enabled us to measure expression of the whole human genome with a 
single biological sample and provide a snapshot of all the transcriptional activity in it. 
Microarrays have facilitated the discovery of totally novel and unexpected functional roles of 
genes, as opposed to study of a single gene or a subset of genes which was the only possible 
molecular biology application available in the past. These tools have helped molecular 
biologists in discovering novel disease subtypes, developing new diagnostic tools, and 
identifying underlying mechanisms of disease or drug response. 
 
4.2 MicroRNA Profiling 
 
MicroRNA (miRNA) have emerged as the most significant scientific discovery of the decade. 
Their role in understanding pathophysiology of many disease processes, as diagnostic, 
prognostic and predictive tissue specific biomarkers, is only just beginning to be unravelled 
[278-288].  
 
These are small (18-22 nucleotide), non-coding RNA that arise from a longer precursor RNA, 
exhibiting a hairpin structure. The active 22 nucleotide moiety then gets incorporated into the 
composite machinery – this results in translational silencing when it forms a partial duplex 
with the 39 untranslated regions of the targeted mRNA [289, 290]. Other mechanism 
proposed for its gene expression control is by degradation of mRNA.  
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MicroRNA regulate gene expression and are implicated in many biological and pathological 
processes, including modulation of haematopoietic lineage differentiation, insulin secretion, 
apoptosis, stress response and cell and organ development [291-295]. A single miRNA can 
regulate an average of 200 mRNA targets and concurrently, a single mRNA can be regulated 
by several miRNA, leading to a very complex genomic regulation of the disease process 
[289].  
 
MicroRNA have been particularly appealing due to their stability in various tissues samples, 
even post-fixation. These can still be extracted and assessed with incredible efficiency and 
reliability [296]. Since circulating nucleic acids usually occur in very small amounts in the 
body fluids and are very difficult to extract and detect reliably [297], this miRNA stability 
can certainly be exploited into development of practical detection methods, rendering them 
almost perfect to act as clinical biomarkers. Recent studies have also revealed the possible 
superiority of miRNA over mRNA in terms of accuracy as biomarkers since mRNA has to be 
translated into a protein for it to exert its effect, whereas, miRNA are an active moiety in 
themselves, impacting the expression of multiple genes and therefore, are more likely to 
emulate the real biological and pathological events. Also, it is postulated that powerful and 
yet simple approaches to miRNA characterisation and quantification will far outweigh 
traditional, more cumbersome and inconvenient proteomic biomarker discovery techniques in 
terms of biomarker validation [298]. Furthermore, miRNA are more likely to predict clinical 
behaviour, prognosis and therapeutic response in pathological states with more accuracy 
since these influence the behaviour and phenotype of the tissue these are expressed from. 
Additionally, it has been established in some well-designed recent studies that miRNA enter 
circulation and stay in it in unaltered form. The reasons behind this remarkable stability are 
predicated to be them being packaged within exosomes secreted from cells [299] or found in 
protein associations – Argonaute [300] or Nucleophosmin [301, 302]. This protects them 
from degradation from endogenous RNAses, contributing towards their inherent stability and 
making them an ideal candidates for serum/plasma based biomarkers. This also makes them 
best suited for affecting the distant cells in way of novel signalling molecules and mediating 
short and long range inter-cellular communication as extra-cellular messengers.   
 
4.2.1 MicroRNA profiling in sepsis and acute pancreatitis 
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Sepsis usually results from malfunction of regulatory mechanisms, precipitating loss of 
control of inflammation, immunosuppression and tissue/organ damage [303-305]. MiRNA 
have been found to play a pivotal role in sepsis – these strictly regulate the expression of pro 
and anti-inflammatory genes involved in disease process, mainly correlated with cytokines 
[306] and therefore, their aberrant expression can be investigated to be used as diagnostic, 
prognostic and predictive marker.  
 
Sepsis provides a good model for acute pancreatitis, where many patho-physiological 
processes are similar and the critical driving immune responses are identical. Therefore, it 
doesn’t come as a surprise that the prognostic role of miRNA in acute pancreatitis has been 
investigated on the similar lines.  
Current literature and body of research has identified at least three potential roles for miRNA 
in the setting of acute pancreatitis - as a diagnostic/prognostic marker, as a marker of 
pathophysiological processes in the pancreatic tissue and as a marker of mediation of end-
organ/distant organ failure due to their ability to act as inter-cellular signalling molecules. 
The last one is especially intriguing since the evidence on distant organ failure in acute 
pancreatitis is not as well defined as local complications.  
 
4.3 Messenger RNA and Micro RNA interaction 
 
The complex genomic relationship that results from mRNA and miRNA interactions 
translates into a stringent control that is exerted by miRNA on cellular protein output and 
function. Needless to say, learning more about mRNA and miRNA interactions is absolutely 
crucial in identifying important cellular pathways that are pivotal to patho-physiology of the 
disease.  
Currently, there are few methods in place to identify regulatory miRNAs. The most 
traditional method remains based on microarray expression data, using prediction algorithms 
such as TargetScanS [307], PicTar [308] and miRanda [309] and gene set testing [310]. 
Another newer and perhaps a better method has been put forward which is based on Odds 
Ratio [311]. This methods takes expression data from both miRNA and mRNA into 
consideration and determines if there is an association between miRNA expression and its 
predicted targets. If the association is found to be statistically significant, the miRNA is 
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considered to be regulatory. Some of the other publications have also put forward varying 
integrative methods but these are not without their limitations – these do not take into 
consideration the fact that miRNA may co-regulate a group of mRNAs [311]; these may not 
provide any information on miR-mR pairs of interest [312, 313]; expression data correlation 
between miRNA and mRNA is not taken into account [312]; Identification of the modules is 
always based on negative correlation between miRNA and mRNA [314] which is not always 
true, as has been recently shown in a study [315]. These limitations have been overcome and 
dealt with in a new statistical model proposed [316] that identifies regulatory miRNA clusters 
regulating mRNA clusters and estimates the association between the two, since both the steps 
are crucial for obtaining more useful biological information.   
With this in mind, the plan is to take a systems biology approach to attain better 
understanding of the biological processes and the disease. This will be in line with the key 
components already outlined for this approach – measurement of the molecules, integration 
of biological information, identification of molecular responses to the disease process, 
formatting models to be tested and consequent refinement of these models though hypothesis 
testing. These models can then be utilised to predict disease responses, identify new time 
points in the course of the disease and add to our understanding of the key pathophysiological 
events [317]. 
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CHAPTER 5: HYPOTHESIS AND AIMS 
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5.1 Hypothesis 
 
It is hypothesised that mild and severe acute pancreatitis are two distinct entities, associated 
with different disease courses. 
Gene expression and miRNA profiling can identify gene and miRNA signature/s which may 
be exploited to act as potential prognostic markers to predict severity of the disease at the 
time of admission. 
 
5.1.1 Aims  
 
 To establish protocol and Standard operating procedures for collection of samples from 
patients with acute pancreatitis and establish and an Acute Pancreatitis Biobank, 
associated with Acute Pancreatitis Database, housing demographic and clinical 
information for the recruited patients. 
  
 To develop a gene expression profile of peripheral blood in patients with acute 
pancreatitis and identify differentially expressed genes between mild and severe acute 
pancreatitis. 
 
 To develop a micro RNA profile of peripheral blood in patients with acute pancreatitis 
and find a micro RNA signature which will accurately stratify patients in mild and 
severe groups.  
 
5.1.2 Objectives 
 
 To measure gene expression profiles in patients with mild and severe acute 
pancreatitis, using RNA extracted from peripheral blood collected within the first 24 
hours of disease presentation. 
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 To measure micro RNA profiles in patients with mild and severe acute pancreatitis, 
using RNA extracted from plasma samples of patients collected within the first 24 
hours of disease presentation. 
 
 To develop a protocol which not only suits the needs and demands of the project but 
is also robust and reproducible for the main study. 
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CHAPTER 6: LIVERPOOL PANCREAS 
RESEARCH UNIT ACUTE PANCREATITIS 
BIOBANK, DATABASE, SAMPLE 
COLLECTION AND CLINICAL DATA 
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Acute pancreatitis research is severely limited by the availability of biological samples at 
appropriate and clinically relevant time points. The first 24 hours are the most crucial in 
terms of diagnosing, predicting the severity of the attack and intervening in the right patient 
group. For all of this to happen, it is fundamental that the biological processes during this 
time period are properly understood at the cellular and molecular level.  
 
The Liverpool NIHR Pancreas Biomedical Research Unit (PBRU) was established in 2008 
with the mandate to translate basic pancreatic research into a clinical setting, in order to 
improve the treatment of patients with acute pancreatitis, chronic pancreatitis and pancreatic 
cancer.   
 
The three main themes of research are:  
 
 Drug discovery and development of new interventions  
 Application of new diagnostic and imaging strategies  
 Validation of new biomarkers and screening protocols   
 
In 2010, the Liverpool NIHR Pancreas Biomedical Research Unit (PBRU) Acute pancreatitis 
(AP) Biobank was established to enable us to create a pool of patient samples which will 
contribute towards various research projects in the fields of proteomics, genomics, 
metabolomics and pharmacology. This was established under the ethical approval awarded by 
the Sheffield Ethics Committee (reference number 10/H1308/31).  
 
The PBRU Biobank is managed on the basis of set of rules and regulations governing the 
collection, storage and future use of these samples. The samples for the PBRU AP Biobank 
are obtained and stored from donors for research purposes in compliance with the Human 
Tissue Act, 2004. All individual studies, where the biobanking of samples is required, have to 
have the approval of the Executive Director and full ethical approval before the study begins.  
All studies have to be transparent, auditable, and allow the chain of custody of all samples to 
be followed at all times.  Samples are only taken from donors following full, informed 
consent given by the donor.  
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Standard Operating Procedures (SOPs) are in place to control all aspects of sample storage. 
SOPs contain details and follow procedures concerning:- 
 Donor identification 
 Obtaining consent 
 Sample anonymisation 
 Sample collection 
 Sample processing 
 Sample storage (including database storage of sample information and coding) 
 Sample analysis (samples to be analysed according to ethically approved sample 
protocols for the study) 
 All procedures are COSHH (Control of Substances Hazardous to Health Regulations) 
and risk assessed and obey University of Liverpool (and where applicable NHS) 
Health and Safety rules 
 SOPs are signed off by the author, with two signatories to approve the SOP and 
Quality Assessment (QA) review, which ensures that only approved SOPs that comply 
with the applicable regulatory requirements for the study are produced 
 All SOPs are version controlled (by the Liverpool Cancer Trials Unit Document 
Management System) and only issued to designated copyholders 
 The location of the freezers where the samples are to be stored, and the electronic 
database are clearly identified 
 A Disaster Recovery Plan is in place in the event of equipment failure  
 
The Biobank stores samples obtained from patients who present and are admitted to Royal 
Liverpool University Hospital (RLUH) with provisional diagnosis of acute pancreatitis. After 
obtaining informed written consent, these samples are collected at specific time points – 24 
hours, 48 hours, week one, two and four of patient’s hospital stay. Once a patient is 
discharged, no follow-up is undertaken and patients are not contacted for further 
samples/information. The whole blood collected from these patients is taken to PBRU 
laboratory immediately and processed according to specific Good Clinical and Laboratory 
Practice (GCLP) approved Standard Operating Procedures (SOPs) to render plasma, serum 
and white cell pellets. Whole blood is collected into PAXgene Blood RNA tubes and stored 
in -800C freezer for RNA isolation to be undertaken later on.  
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Clinical data from these patients is recorded in the Acute Pancreatitis database. It consists of 
two linked databases, first of which is an identifiable database of demographic data that 
includes name, date of birth, address, General Practitioner details and hospital unit number, 
with a coded link to a second pseudo-anonymised clinical database. The identifiable 
demographic database is stored on a password-protected, separate Royal Liverpool 
University Hospital network drive. The separate pseudo-anonymised clinical database is 
maintained on a password-protected, separate University of Liverpool network drive. This 
specifically designed clinical database includes details of each coded patient's presenting 
features, diagnostic tests, clinical course, interventions, complications and outcome, obtained 
predominantly from patient medical records, and includes a coded link to the patient's banked 
research samples. The banked research samples are also coded and are not identifiable 
without reference to the pseudo-anonymised Clinical Database and from that to the 
demographic database. The clinical database contains all relevant Good Clinical Practice data 
on every research sample, including when taken, when processed and where stored. Only 
PBRU staff have access to the full data set and are able to link samples back to individual 
patients.  
 
6.1 Sample collection  
 
All samples for the project were obtained from the Liverpool NIHR PBRU Acute Pancreatitis 
Biobank. These samples have been collected following the SOP ‘Collection of Samples for 
the Acute Pancreatitis Biobank in the PBRU’ (version 3, document reference SOP 051). A 
brief overview of the process is described below. 
  
Patients with probable diagnosis of acute pancreatitis are identified first through biochemistry 
department of RLUH, where a list is generated of all patients who have presented with raised 
amylase levels (>450 U/l, three times the normal range) in the last 24 hours. These patients 
are then reviewed for their suitability for inclusion (clinical and biochemical picture 
compatible with the diagnosis). After obtaining written informed consent, blood samples are 
collected using premade kits with pre labelled tubes, in line with the Laboratory Information 
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Management System (LIMS). Kits are used according to the time point at which patient is 
being approached for the sample collection, e.g., Kit A is used for the first 24 hours samples, 
Kit B for the 48 hours, week 1, 2 and 4 samples and Kit C for all other time points. 
Approximately 20 mls of blood is drawn into two BD Vacutainer® K2 EDTA tubes (10 and 4 
mls) for plasma and cell pellet extraction, BD Vacutainer® SST™ tube for serum and 
PAXgene Blood RNA Tube (BRT) for RNA extraction to be undertaken later on. These 
samples are then taken to the PBRU laboratory and processed according to the SOP 
‘Processing of Samples for the Acute Pancreatitis Biobank in PBRU’.  
 
PAXgene BRTs were collected at 24 hours, 48 hours, week 1, 2 and 4 time points. These 
were either stored within 10 minutes of being collected in -800C freezer in the GCLP 
laboratory (time 0 hour samples) or incubated at room temperature for two hours after being 
collected before being stored at -800C (time 2 hours samples). For the sake of this project, 
only PAXgene BRTs collected within the first 24 hours of patient admission were included 
and RNA extractions undertaken from these. Since this part of the study was majorly 
intended for sample size calculations and for assessing baseline variability among our patient 
population, only patients with mild pancreatitis were included.  
 
The definitions of mild and severe acute pancreatitis are in accordance with the Atlanta 
Classification for acute pancreatitis [5]. Presence of organ failure (renal, respiratory, 
cardiovascular, hepatic, nervous system) within the first week of admission or development 
of pancreatic parenchymal necrosis after that is considered as severe form of the disease. The 
severity of the disease was estimated only when patients had been discharged or had died. 
Data pertaining to these would be derived from the PBRU Acute pancreatitis database which 
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is a prospective database storing all the clinical and demographic information on our patients 
who have donated samples to us.  
 
In order to determine if there was a difference in the gene expression of the samples stored at 
different time points from the time of collection, two PAXgene BRTs were collected from six 
patients, one stored within 10 minutes of being collected (time 0 hour samples) and the other 
one after two hours of incubation at room temperature (time 2 hours samples). All these pair 
matched samples were stored in the -800C freezer in the GCLP laboratory. 
 
6.2 Clinical Data 
 
Clinical characteristics were collected for all included patients. These were retrieved from the 
Liverpool NIHR PBRU Acute Pancreatitis Database that houses information on patients who 
are recruited to the Acute Pancreatitis Biobank. This information includes their demographic 
data and detailed account of their hospital admission. These are as follows:- 
 Details of hospital admission (symptom onset, date and time of admission, length of 
stay, aetiology) 
 Details of co-morbidities (in the form of Charlson’s scoring), past surgical and 
specifically, biliary surgery and in use medication 
 Details of haematology and biochemistry (blood tests) and scoring systems (APACHE 
II) 
 Details of imaging (ultrasound, CT scans) and microbiology 
 Details of surgical procedures (if undertaken) 
 Details of intensive care admission – supportive treatments used 
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 Details of complications and outcomes 
These data were used to label these patients as mild and severe according to Atlanta 
classification (1992) for the purpose of data analysis. During the course of the project, revised 
Atlanta classification was published, which was soon followed by determinant based 
classification. Since this project was conceived and started, with samples collected, before the 
new classifications were proposed, it was deemed best to continue with the old Atlanta 
classification and therefore, data analysis was undertaken according to that.  
Keeping in mind the objectives of this study, it was obvious that Atlanta classification [5] 
would be used to include/exclude patients for this study. Accurate characterisation of the 
patient cohort would be of paramount importance. Sample size calculations had indicated a 
sample size of 40 in mild and severe categories. Patient characteristics were retrieved from 
the Acute Pancreatitis Database. This is a database set up in 2010 in line with the Acute 
Pancreatitis biobank. The aim was to collect phenotypic information on all the samples being 
collected for research so that genotype could be correlated with the phenotype of these 
patients. The database contains comprehensive data on clinical features and outcomes of 
these patients who have been recruited to donate samples to the biobank. 
Diagnosis of acute pancreatitis was based on two of the following three features: 1) 
abdominal pain suggestive strongly of acute pancreatitis, 2) serum amylase activity at least 
three times greater than the upper limit of normal 3) characteristic findings of acute 
pancreatitis on trans-abdominal ultrasonography or on Contrast Enhanced CT (CECT) scan. 
As indicated, patients who developed organ failure (OF) lasting for more than 48 hours (i.e., 
organ failure recorded at least once during each of three consecutive days) or developed 
>30% pancreatic necrosis were classified as severe patients. The first hospital day was 
designated as day 1; day 2 started at 8 AM on the following day and lasted for 24 hours. 
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Persistent evidence of organ failure (one or more organ systems) on at least one occasion on 
three consecutive days was recorded for each patient. Patients with no complications or 
transient OF were classified and included in the mild group.  
 
6.2.1 Definitions of organ failure   
 
This was defined according to Sepsis-related Organ Failure Assessment (SOFA) scoring 
[225]. As per AC, only respiratory, renal and CVS failures were considered for severity 
assessment. A score of ≥2 was considered. Although Atlanta classification advises use of 
Marshall Scoring system for organ failure, SOFA score was chosen for the ease of recording 
on patients. Marshall scoring requires assessment of cardiovascular status by taking into 
consideration patient’s response to fluid resuscitation. This can only be undertaken 
prospectively, while one attends to the patient. Accurate quantification of the same may 
become problematic and potentially, impossible retrospectively. SOFA is easy to use and 
record and takes six organ systems into consideration. It is also important to note that point 
criteria and hence points scored on both the scoring systems are more or less the same, 
therefore, organ failure for the purpose of this project was assessed through SOFA scoring. 
Definitions are detailed in table 1. 
Table 6.2 - SOFA Scoring System 
System 1 2 3 4 
Respiratory 
PaO2/FiO2 
mm Hg 
<400 <300 <200* <100* 
Coagulation 
x 103 mm3 
<150 <100 <50 <20 
Liver (bilirubin) 20-32 33-101 102-204 >204 
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µmol/L 
Cardiovascular 
Hypotension 
MAP < 70 
mm Hg 
Dopamine ≤ 5, 
Dobutamine any 
dosea 
Dopamine >5 
Epinephrine/Norepinephrine 
≤ 0.1 
Dopamine >15 
Epinephrine/Norepinep
hrine > 0.1 
CNS (GCS) 13-14 10-12 6-9 <6 
Renal 
Creatinine 
µmol/L 
110-170 171-299 300-440 >440 
*with respiratory support  
a
Adrenergic agents administered for atleast 1 hr 
It has to be borne in mind that Liver score wasn’t taken into consideration in these patients, as 
bilirubin can be raised due to gallstone disease.  
 
6.2.2 Definition of Outcome/Severity Assessment 
 
CECT findings were used for definitive diagnosis and extent of the necrosis. Quantification 
of the necrosis was undertaken using a morphometric technique which is traditionally used by 
histopathologists to qualitatively and quantitatively assess tissue. A grid would traditionally 
be placed over a histological image and the number of points within the region of interest 
would be counted. The number of points within the image as a whole would also be counted 
and the area of the region of interest expressed as a fraction of the area of the histological 
image as a whole. When applied over consecutive images, it allows the 3-dimensional 
quantification of a tissue from 2-dimensional axial slices. This method was adapted for axial 
CT images with a 2mm grid placed over consecutive axial slices covering the pancreas. The 
grid was applied using COREL® PHOTO-PAINT™ X4. This software is not specifically 
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designed for use in morphometry. It is primarily used as an editing package for digital 
photographs. However, it contained several features which allowed it to be used for 
manipulating the CE-CT images for the morphometric analysis. It also allowed for the 
magnification of the images if required. The whole of the pancreas was clearly identified, 
outlined and divided into head, body and tail before the point-counting was commenced. 
Both viable and non viable areas in each part of the pancreas were assessed using this method 
and this was expressed as a fraction of the area of the pancreas as a whole. This process was 
repeated for all axial slices of the abdomen which included the pancreas (average of 60 slices 
per CE-CT scan) and the average of each consecutive fraction was calculated as the 
percentage necrosis of the pancreas. The percentage necrosis was assessed for each part of 
the pancreas for each CT scan included in the study. 
 Axial slices obtained in the portal phase of contrast enhancement (approximately 70 
seconds) were reviewed.  
There is no consensus on the exact boundaries of the different parts of the pancreas. Major 
anatomy [318] and pancreas [319] textbooks, although divide pancreas in to head, neck, body 
and tail, do not define the boundaries between these major parts. For the purpose of this 
project, it was imperative that we defined these anatomic divisions precisely. According to 
‘Radiology of Pancreas [320] (a textbook on dedicated pancreatic radiology), the head of the 
pancreas along with the uncinate process is taken as the part of the pancreas which is seen on 
the right of the mesenteric and portal veins. Neck is constricted portion of the pancreas lying 
to the left of the right border of the superior mesenteric vein and to the right of its left border. 
According to the classification proposed by the Japanese Pancreas Society, portion of the 
gland left to the left border superior mesenteric vein is bisected into the body (the right half) 
and the tail (the left half). However, it was important that these boundaries would be visible 
on the CE-CT too. 
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Pancreatic necrosis was defined as the loss of normal enhancement of the pancreas when 
compared with the liver and spleen as well as loss of the normal lobulated pancreatic outline. 
Reduced enhancement without loss of normal architecture was not considered to be necrosis. 
For the purposes of this study, pancreatic pseudocyst, phlegmon and peripancreatic abscesses 
were noted but not included in the pancreatic necrosis estimation. Pancreatic abscesses were 
quantified in a similar manner but separate to necrosis. 
Pancreatic pseudocysts and peri-pancreatic abscesses were noted when present. 
 
6.3 Classifications of severity of acute pancreatitis 
 
When the project was conceived, Atlanta classification [5] was taken as the guide for 
defining the severity of the disease. Definitions considered are as follows:- 
Mild acute pancreatitis is defined as the absence of organ failure or the presence of organ 
failure that does not exceed 48 hours in duration (Transient organ failure). 
 
Severe acute pancreatitis was defined as persistence of organ failure – organ failure 
documented at least once in three consecutive days (Persistent organ failure) and/or presence 
of >30% pancreatic necrosis.  
 
However, during the course of the project, at least two more clinically relevant and 
internationally agreed upon classifications were published and widely discussed. These 
were:- 
 
Determinant Based Classification (DBC) [321] – This one hypothesised that the spectrum 
of the disease was too wide to be classified into just two categories and therefore, more 
classes were needed for more accurate description of the disease as the outcomes varied with 
each. This classification proposed four different groups:- 
Mild – No peri-pancreatic necrosis or organ failure 
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Moderate – Sterile pancreatic necrosis and/or transient organ failure  
Severe – Infected pancreatic necrosis or persistent organ failure 
Critical – Infected pancreatic necrosis and persistent organ failure 
 
Revision of Atlanta Classification [322] – Like DBC, this web based consensus also 
recognised the short-comings of the old AC and aimed to improve the assessment of severity 
through sensible integration of new concepts of the pathology in with the existing 
information which should then consequently, help with standardised reporting of the data and 
of the disease management across the globe. Their revision classified the disease into three 
different categories:- 
 
Mild – No organ failure/local or systemic complications 
Moderately severe – Transient organ failure, local complications or exacerbation of a 
comorbid disease. 
Severe – Persistent organ failure  
 
Local complications have been defined as peri-pancreatic ﬂuid collections, pancreatic and 
peri-pancreatic necrosis (sterile or infected), pseudocyst and walled-off necrosis (sterile or 
infected). 
 
As mentioned and explained above, this project only concerns the old Atlanta classification. 
 
6.4 Clinical Data 
 
 
During the time of my PhD, I managed to recruit 315 patients with acute pancreatitis to the 
Acute Pancreatitis Biobank. These included patients who had primarily presented to Royal 
Liverpool University Hospital (RLUH) with the disease and also the ones who had been 
transferred from other hospitals for more definitive and ongoing management of their 
complicated disease course. I obtained and processed samples from them at different time 
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points, for the biobank. These were at the time of admission, 48 hours, 72 hours, week 1, 2 
and 4. This amounted to approximately 800 samples in 18 months duration. 
For this project, I only included fifty eight patients, who had presented primarily to RLUH 
and their samples were collected within 24 hours of hospital presentation. They had been 
recruited prospectively to Acute Pancreatitis Biobank from June 2010 to June 2012 and 
samples were collected prospectively at the time of admission. Baselines characteristics were 
also recorded for each patient and clinical details observed for the length of the stay. Severity 
assessment was then undertaken retrospectively (at the end of the clinical episode), using 
Atlanta Classification to see if the patient had a severe or mild attack. Baseline demographic 
characteristics are given below in table 6.1.  
 
Table 6.2 – Demographic characteristics of included patients 
Characteristics Mild Severe 
 Median Median 
Number 35 23 
Gender (Male/Female) 20:16 14:9 
Age (years) 64 63 
Aetiology 
Gallstones 
Alcohol 
Post-ERCP  
Idiopathic 
 
20 
9 
2 
4 
 
 
16 
5 
1 
1 
Duration (Symptoms to 
admission) (hours) 
6 4 
Duration (Admission to 
sampling) (hours) 
14.6 15.5 
Duration (Symptoms to 
sampling) (hours) 
22.75  20.25 
History of acute pancreatitis 9 5 
Length of hospital stay 
(days) 
10 16 
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Clinical co-morbidities were also taken into consideration for the recruited patients using 
Charlson’s Co-morbidity index. Smoking and alcohol history was ascertained using World 
Health Organisation’s recommended Alcohol, Smoking and Substance Involvement 
Screening Test (ASSIST) (Version 3). These data are presented in table 6.3. 
 
Table 6.3 – ASSIST and Charlson’s scores for included patients 
 
Parameters Mild Severe 
 Median Median  
Smoking 20 15 
ASSIST score - Smoking 25 20 
ASSIST score - Alcohol 27 26 
Charlson’s score 2 3 
 
Prediction of severity of the disease was recorded using Glasgow’s criteria, and CRP values 
at the time of admission, at 48 hours and at the end of week one.  These values are illustrated 
in table 4. Glasgow and APACHE II scores were not found to be of significance in our 
dataset, with non-discriminatory values between the two groups. Only CRP values at 
admission, 24 and 48 hours were significantly different between mild and severe groups.  
 
Table 6.4 – Prediction of Severity of included patients 
 
 Mild Severe 
 Median Median  
Glasgow score on admission 1 2 
Glasgow score at 48 hours 1 2 
CRP on admission (mg/dl) 31 78 
CRP at 48 hours (mg/dl) 130 216 
CRP at 72 hours (mg/dl) 136 272 
APACHE II score on admission 7 8 
APACHE II score at 48 hours 7 8 
 
 
Approximately 76% of MAP patients underwent ultrasound scanning to assess for presence 
of gallstones. This amounted to 56% in SAP patients. Almost the same number in both the 
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groups had CT scan to assess severity of the disease. CT severity index (CTSI) was 
understandably higher in SAP than in MAP group, largely due to severe localised disease in 
the form of fluid collections in SAP. Also, extent of pancreatic parenchymal necrosis was 
more prevalent in SAP than in their counterparts. While similar number of patients in both 
the groups had two CT scans, slightly more patients went on to have a third and then a fourth 
scan in SAP group (3 vs. 5; 1 vs. 3 respectively). Extra-pancreatic complications, identified 
on the CT scans, included, gastric outlet obstruction, ascites, pleural effusion, thromboses 
(portal vein, splenic vein, superior mesenteric vein), splenic infarcts and liver abscesses. 
Details of radiologic findings are summarised in the table below. 
  
Table 6.5 – Imaging details of included patients 
 Mild Severe 
 Median Median 
Ultrasound undertaken 26 13 
CT undertaken 19 20 
CTSI 4 6 
Balthazar Score 2 14 10 
Balthazar Score 4 3 9 
No Pancreatic necrosis  13 10 
Pancreatic necrosis < 30% 15 2 
Pancreatic necrosis >30% 0 6 
 
Only five patients needed intubational feeding. Interestingly, two belonged to MAP and three 
to the SAP group. The duration of the feeding averaged to five days. None of the patients 
required total parenteral nutrition. Only two patients underwent minimal access 
retroperitoneal pancreatic necrosectomy (MARPN). One patient required two procedures, 
whereas, adequate debridement was achieved after three procedures in the other. Another 
patient required open necrosectomy. One patient in the MAP group and two in the SAP 
needed percutaneous drainage of peri-pancreatic collections.  
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Thirteen (56%) SAP patients needed intensive care admission and care – mainly for 
respiratory and cardiovascular support, in the form of inotropes and ventilation. The average 
ITU/HDU stay was eight days. As anticipated, none of the MAP patients needed such input 
and were all managed on the wards, without additional organ support.   
Table 6.6 shows the daily SOFA scores between the two groups. The scores are distinctly 
higher for the SAP patients – this becomes more evident and significant from day four 
onwards when the scores become almost normal for the MAP, but increase or are consistently 
the same for the SAP. It would not be wrong to say that the discriminatory value of SOFA 
scores increases after 72 hours, based on our dataset.   
Table 6.6 – SOFA scoring of included patients 
 Mild Severe 
 Median Median 
SOFA score Day 1 1 2 
SOFA score Day 2 1 2 
SOFA score Day 3 1 3 
SOFA score Day 4 0 3 
SOFA score Day 5 0 4 
SOFA score Day 6 0 3 
SOFA score Day 7 0 3 
 
Table 6.7 shows the overall and organ specific complications in our dataset. While all SAP 
patients, by definition, had complications, 12 out of 35 MAP also had various complications 
but not fitting the SAP criteria. These included pleural effusion (n=3), acute coronary 
syndrome (n=2), Portal vein thrombosis (n=1), cardiac arrhythmias (n=1) and pancreatic 
parenchymal necrosis of less than 30% (n=4). Five of the SAP (21%) had acute circulatory 
failure for more than 48 hours. Vascular complications in four SAP patients comprised portal, 
splenic and superior mesenteric vein (SMV) thromboses and pseudo-aneurysm. Almost half 
of all the SAP patients developed respiratory complications – five had respiratory failure for 
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more than 48 hours; others had pleural effusion (n=5), atelectasis (n=4) and hypoxia (n=2). 
Approximately 49% of all SAP patients were found to have pancreatic parenchymal necrosis 
of more than 30%, categorising them into the severe category. Pseudocysts were identified in 
four cases, along with a liver abscess and a small bowel fistula.  
None of the included patients had any neurological complications. 
Seven patients (30%) with SAP died during the course of the disease, accounting for an 
overall mortality of 12%.  
Table 6.7 – Complications of included patients 
 Total Mild Severe 
 Number of patients Number of patients Number of patients 
Complications 
developed 
35/58 12 23 
Cardiac 10/58 3 7 
Vascular 5/58 1 4 
Respiratory 16/58 4 12 
Abdominal 18/55 5 13 
Death 7/58 0 7 
 
Specific complications of the patients with SAP are listed in table. Nine patients only had 
local complications, whereas, nine patients had isolated organ failure. Five patients had both. 
 
Table 6.8 – Local and systemic complications in SAP patients 
ID Local complications Systemic complications/Organ 
Failure 
Mortality 
    
AP09 >50% pancreatic necrosis Respiratory failure in the first week  
AP011  Respiratory failure in the first week  
AP29  Circulatory and respiratory failure 
in the first week 
Yes 
AP34 45% pancreatic necrosis   
AP46 Pancreatic abscess > 3 cm   
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AP51 >50% pancreatic necrosis, 
SMV thrombosis, splenic 
infarcts 
  
AP57 40% pancreatic necrosis   
AP58 Peri-pancreatic fluid 
collections 
Respiratory failure in the first week  
AP63  Respiratory failure in the first week  
AP66 Peri-pancreatic fluid 
collections 
Circulatory failure in the first week Yes 
AP81  Circulatory failure in the first week Yes 
AP99 35% pancreatic necrosis   
AP103 >50% pancreatic necrosis   
AP117 Peri-pancreatic fluid 
collections, splenic and 
SMV thromboses, small 
bowel fistulae 
Respiratory failure in the first week  
AP144 30% pancreatic necrosis Respiratory failure in the first week  
AP168  Respiratory and circulatory failure 
in the first week 
Yes 
AP177  Respiratory failure in the first week  
AP187  Respiratory and circulatory failure 
in the first week 
Yes 
AP192  Respiratory, renal and circulatory 
failure in the first week (multi-
organ) 
Yes 
AP234 40% pancreatic necrosis   
AP273 75% pancreatic necrosis   
AP307 50% pancreatic necrosis   
UHA08  Respiratory and circulatory failure 
in the first week 
Yes 
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CHAPTER 7: GENE EXPRESSION 
PROFILING 
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7.1 Sample preparation – the RNA extraction 
 
The RNA samples to be used for the project were manually extracted from the PAXgene 
BRTs using the PAXgene Blood RNA kit (Qiagen). All samples were processed following 
the same protocol. 
 
Before the procedure – All PAXgene BRTs were taken out of the -80 o C freezer and 
incubated at room temperature (15-25o C) for 2 hrs after thawing.  
 
 PAXgene BRTs were centrifuged for 10 minutes at 4000 x g using a swing-out rotor. 
 Supernatant was removed by decanting. RNase-free water (4 mls) was added to the pellet. 
 Mixture was vortexed until the pellet was visibly dissolved, and then, centrifuged for 10 
minutes at 4000 x g using a swing-out rotor. Entire supernatant was discarded. 
 Buffer BR1, which is a resuspension buffer, (350μl) was added and vortexed until the 
pellet was visibly dissolved. 
 Sample was pipetted into a 1.5 ml microcentrifuge tube (MCT). Buffer BR2, a binding 
buffer (300μl) and proteinase K (40 μl) were added to the sample and mixed by vortexing 
for 5 seconds, and incubated for 10 minutes at 55°C using a shaker–incubator at 400 rpm. 
Proteinase K was added to ensure adequate protein digestion. 
 Lysate was then pipetted directly into a PAXgene Shredder spin column (PSC) and 
centrifuged for 3 minutes at 17,000 x g to homogenise the cell lysate and remove residual 
cell debris.  Entire supernatant of the flow-through fraction was transferred to a fresh 1.5 
ml microcentrifuge tube without disturbing the pellet in the processing tube.  
 Ethanol (350 μl - >99%) was added to the supernatant to adjust binding conditions and 
mixture was then mixed by vortexing, and centrifuged briefly (one second at 700 x g) to 
remove drops from the inside of the tube lid. 
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 700 μl of the sample was pipetted into the PAXgene RNA spin column (PRC) and 
centrifuged for one minute at 17,000 g. Spin column was placed in a new 2 ml processing 
tube, and the old processing tube containing flow-through was discarded. 
 The remaining sample was pipetted into the PAXgene RNA spin column, and centrifuged 
for one minute at 17,000 x g. Spin column was placed in a new 2 ml processing tube, and 
the old processing tube containing flow-through was discarded. 
 350 μl of Buffer BR3, a wash buffer, was pipetted into the PAXgene RNA spin column 
and centrifuged for one minute at 17,000 x g. Spin column was placed in a new 2 ml 
processing tube, and the old processing tube containing flow-through was discarded. 
 DNase I incubation mix was then prepared by mixing gently DNase I stock solution to 
DNA Digestion Buffer in a 1.5 ml microcentrifuge tube. 
 DNase I incubation mix (80 μl) was then directly pipetted onto the PAXgene RNA spin 
column membrane, and placed on the bench top (20–30°C) for 15 minutes to ensure 
removal of trace amounts of bound DNA. 
 PAXgene RNA spin column was again washed with Buffer BR3, and centrifuged for one 
minute at 17,000 x g. Spin column was placed in a new 2 ml processing tube, and the old 
processing tube containing flow-through was discarded. 
 500 μl of Buffer BR4 was pipetted to the PAXgene RNA spin column for another wash, 
and centrifuged for one minute at 17,000 x g. Spin column was placed in a new 2 ml 
processing tube, and the old processing tube containing flow-through was discarded. 
 Wash with Buffer BR4 was repeated and centrifuged for 3 minutes at 17,000 x g. 
 The tube containing the flow-through was discarded. PAXgene RNA spin column was 
placed in a new 2 ml processing tube and centrifuged for 2 minute at 17,000 x g to dry off 
the ethanol. 
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 The tube containing the flow-through was discarded. RNA was eluted by pipetting 40 μl 
of elution buffer BR5 into the PAXgene RNA spin column placed in a 1.5 ml 
microcentrifuge tube and centrifuged for 1 minute at 17,000 g to elute the RNA. 
 This 1st elute was stored in two aliquots, 15 μl each, and the rest was reserved for 
qualitative and quantitative assessments. 
 PAXgene spin column was placed in a fresh 1.5 ml microcentrifuge tube and 40 μl of 
elution buffer was pipetted on to elute the remaining RNA. It was centrifuged for one 
minute at 17,000 x g.  
 This was stored as one aliquot and called 2nd elute. 
 All the extracted samples were labelled and stored in the -80°C freezer until further 
processing.  
 
7.2 Quality control Assessments 
 
Aliquots for quality control assessments were taken at the time of extraction. Concentration 
of the samples was analysed using Thermo Scientific NanoDrop™ 1000 Spectrophotometer 
and the qualitative assessment was undertaken using Agilent 2100 Bioanalyzer with the 
Agilent RNA 6000 Nano Kit.  
 
Since 100 ng of RNA was required in a total volume of 3 μl, concentration of the sample was 
adjusted accordingly. Highly concentrated samples were diluted with RNase free water and 
diluted samples were speed vacuumed to achieve uniform concentration throughout. Samples 
were renamed for feasibility with further analyses.  
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7.2.1 Qualitative assessment of RNA samples using Agilent 2100 
Bioanalyzer 
 
Before starting: All reagent and reagent mixes, except RNA ladder, were kept at 4°C. 
Reagents were taken out of the fridge to warm at room temperature for at least 30 minutes.  
 
The dye and gel-dye mix was wrapped in aluminium foil and put in the drawer to protect 
from light. 
 
Gel matrix was prepared by adding 550 μl of gel matrix to a spin filter and spun for 10 minutes 
at 4000 rpm.  
Electrode cleaners were used, one with RNase Zap and the other with RNase free water (350 
μl). These were put in machine and run for 1 minute each.  
 
Gel-dye matrix was prepared by adding 1 μl of dye to a 65 μl tube of gel matrix and 
vortexed. Mix was then centrifuged at maximum speed at 14000 rpm for 10 minutes.  
9 μl of gel-dye matrix was loaded into the well marked G. Another 9 μl of the gel dye matrix 
was pipetted in the two additional wells marked G. 5 μl of marker was then pipetted into the 
well marked ladder and each of the 12 RNA wells 
 
The RNA samples and RNA ladder were denatured by incubating in the 70° C heating block 
for 2 minutes and put on ice for 5 minutes.   
 
1 μl of ladder was loaded into the well marked “ladder” and 1 μl of RNA into each of the 12 
wells. 
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After being placed in the adapted vortexer and mixed for one minute at 2400 rpm, the loaded 
chip was placed in the Bioanalyzer and run for 30 minutes to obtain the traces. 
 
Once it was ensured that the samples were of high quality, as assessed by the Bioanalyzer 
traces, these were processed through for preparation for the microarray experiments. 
 
7.3 Protocol A – 3’ IVT Express protocol 
 
Since HG U133 Plus 2.0 arrays were intended to be utilised for the project, the 3’ IVT 
Express protocol was used for preparation of the targets. 
 
The overview of the protocol is summarised in figure 7.1.   
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Figure 7.1 - 3’ In vitro Transcription protocol (Adapted with permission) 
 
 
7.3.1 Step 1 – Preparation of Poly-A RNA control mixture 
 
Poly-A RNA control mixture was prepared. Poly-A controls are prokaryotic genes which are 
absent in eukaryotic samples (dap, thre, phe, lys). These are in vitro synthesised and the 
polyadenylated transcripts for B. subtilis genes are premixed at staggering concentrations. 
Examining the hybridization intensities of these controls on the Genechip arrays helps to 
monitor the labelling process independently from the quality of the starting RNA.  
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 Serial dilutions required to prepare poly A control mixture depend on the amount of the 
starting material. Since I used 100 ng as the input amount of RNA, the serial dilutions 
selected were: 1:20 (1st dilution), 1:50 (2nd dilution), 1:50 (3rd dilution), 1:10 (4th dilution). 
 
 For 1st dilution, 2 µl of Poly A control stock was added to 38 µl of Poly A control dilution 
buffer. 2 µl of this solution was added to 98 µl of dilution buffer to produce the 2nd 
dilution. 2 µl of the 2nd dilution was mixed with 98 µl of dilution buffer to produce the 3rd 
dilution. Finally, 4 µl of the solution was mixed with 36 µl of dilution buffer to produce 
the 4th dilution.  
 
 2 µl of the 4th dilution was added to 3 µl of each RNA sample to make a 5 µl solution, 
ready for the 1st strand synthesis.  
 
 
7.3.2 Step 2 – 1st strand cDNA synthesis (using reverse transcription) 
 
 First strand master mix was prepared by mixing 4 μl of buffer mix with 1 μl of enzyme 
mix for each sample.  
 5 μl of the master mix was aliquotted to 12 PCR tubes. 
 5 μl of the Total RNA/poly-A Control Mixture (from step 1) was added to each aliquot of 
the first strand master mix to achieve a final volume of 10 μl. 
 Samples were incubated for two hours at 42 °C in a thermal cycler. 
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7.3.3 Step 3 – 2nd strand cDNA synthesis  
 
 Second strand master mix was prepared by mixing 5 μl of buffer mix, 13 μl of nuclease 
free water and 2 μl of enzyme mix for each sample. 
 20 μl of the master mix was transferred to each (10 μl) cDNA sample.  
 Samples were placed in a 16 °C thermal cycler block and incubated for an hour followed 
by 10 minutes at 65°C.  
 
7.3.4 Step 4 – synthesis of labelled aRNA (using In Vitro Transcription 
IVT) 
 
 IVT master mix was prepared by mixing together IVT biotin label (4 μl), labelling buffer 
(20 μl) and enzyme mix (6 μl) for each sample.  
 IVT Master Mix (30 μl) was transferred to each (30 μl) double-stranded cDNA sample 
and the reactions were incubated for 16 hours at 40 °C in thermal cycler. 
 
7.3.5 Step 5 – Purification of aRNA 
  
After synthesis, the aRNA was purified to remove enzymes, salts, and unincorporated 
nucleotides.  
 aRNA Binding Mix was prepared by mixing RNA binding beads (10 μl ) and aRNA 
binding buffer concentrate (50 μl) for each sample. 
 60 μl of aRNA Binding Mix was added to each sample and the resultant 120 μl was 
transferred to the U-bottom plate. 
 120 μl of 100% ethanol was added to each sample and mixed adequately to allow aRNA 
to bind to the RNA binding beads. 
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 Magnetic beads were captured using the magnetic stand. Once capture was complete and 
RNA binding beads had formed pellets, supernatant was discarded and plate removed 
from the stand. 
 RNA binding beads were washed using aRNA Wash Solution (100 μl/sample) and shaken 
at a moderate speed for 1 min on lab-line titre plate shaker. Magnetic beads were captured 
using the magnetic stand. Once capture was complete and RNA binding beads had 
formed pellets, supernatant was discarded and plate removed from the stand. 
 Another wash was performed following the same procedure and the plate shaken at very 
high speed for one min on lab-line titre plate shaker to evaporate residual ethanol.  
 Purified aRNA was eluted from the RNA binding beads by adding 50 μl of preheated 
(50–60 °C) aRNA Elution Solution to each sample. The plate was then shaken vigorously 
for 3 minutes on the lab-line titre plate shaker. RNA binding beads were captured by 
moving the plate to the magnetic stand. Supernatant (containing the eluted aRNA) was 
transferred to a nuclease free PCR tube. 
 
7.3.6 Step 6 – Analysis of aRNA size 
 
The size distribution of aRNA was evaluated using Agilent 2100 Bioanalyzer with the 
Agilent RNA 6000 Nano Kit. Concentration of aRNA was assessed using Thermo Scientific 
NanoDropTM 1000 Spectrophotometer to ensure adequacy of the amplification process. 
 
7.4 Protocol B – Ovation whole blood protocol  
 
The overview of the protocol is summarised in figure 7.2.  
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Figure 7.2 - Ribo-SPIATM 3’ RNA Amplification Protocol (Adapted with permission) 
 
Before proceeding with the protocol, concentration of RNA samples was analysed using 
Thermo Scientific NanoDrop™ 1000 Spectrophotometer and the qualitative assessment was 
undertaken using Agilent 2100 Bioanalyzer with the Agilent RNA 6000 Nano Kit.  
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7.4.1 Step 1 – Preparation of Poly-A RNA control mixture 
 
Since serial dilutions required to prepare poly A control mixture depend on the amount of the 
starting material and the starting RNA input for this protocol was 40 ng, the serial dilutions 
selected for this protocol were : 1:20 (1st dilution), 1:50 (2nd dilution), 1:50 (3rd dilution), 1:25 
(4th dilution). 
 
For 1st dilution, 2 µl of Poly-A control stock was added to 38 µl of Poly A control dilution 
buffer. 2 µl of this solution was added to 98 µl of dilution buffer to produce the 2nd dilution. 2 
µl of the 2nd dilution was mixed with 98 µl of dilution buffer to produce the 3rd dilution. 
Finally, 2 µl of the solution was mixed with 48 µl of dilution buffer to produce the 4th 
dilution (total volume of 50 µl).  
 
2 µl of the 4th dilution was added to 3 µl of each RNA sample to make a 5 µl solution, ready 
for the 1st strand synthesis. 
 
7.4.2 Step 2 - 1st strand cDNA synthesis 
 
 2 μl of first strand primer mix was mixed with 5 μl of the RNA sample to allow for 
primer annealing. 
 1st strand master mix was prepared by mixing buffer mix (12 μl) and enzyme mix (1 μl). 
13 μl of master mix was added to each reaction to make up a final volume of 20 μl. 
 Samples were incubated at 48°C for 60 minutes, at 70°C for 15 minutes and cooled to 
4°C in thermal cycler. 
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7.4.3 Step 3 - 2nd strand cDNA synthesis 
 
 Second strand master mix was prepared by combining buffer mix (18 μl) and enzyme mix 
(2 μl). 20 μl of the mix was added to each first strand reaction tube. 
 Samples were incubated at 37 °C for 30 minutes, at 75 °C for 15 minutes and then cooled 
to 4 °C. 
 
7.4.4 Step 4 - SPIA® Amplification  
 
 Master mix was made by combining sequentially the SPIA buffer mix (72 μl), SPIA 
primer mix (2 μl), nuclease free water (4 μl) and SPIA enzyme mix (40 μl). 
 118 μl of the SPIA master mix was added to the entire volume of the 2nd strand reaction. 
 Resultant 158 μl reaction volume was split into two 79 μl volume in new PCR tubes.  
 24 PCR tubes were left to incubate at 48 °C for 30 minutes and then cooled to 4 °C. 
 3 μl of Ovation whole blood reagent was added to each 79 μl of SPIA reaction. 
 All reactions were incubated at 48 °C for 30 minutes, at 95°C for 5 minutes and then 
cooled to 4 °C. 
 
7.4.5 Step 5 - Purification of amplified cDNA 
 
This was undertaken using the Qiagen QIAquick® PCR Purification Kit. 
 160 μl of amplified cDNA product (82 μl aliquots pooled together) was added to PCR 
tubes containing 800 μl of PB buffer each and mixed by vortexing. 
 480 μl of sample was loaded onto the QIAquick® spin column and centrifuged for one 
minute at 13,000 rpm. 
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 Remaining 480 μl of the sample was loaded onto the same column and centrifuged for 
one minute at 13,000 rpm. 
 700 μl of 80% ethanol was added to the column and centrifuged for one minute at 13,000 
rpm. 
 Ethanol treatment was repeated another time and to remove the remaining liquid, column 
was centrifuged for one additional minute at 13,000 rpm. 
 Nuclease-free water (30 μl) was added to the centre of each column and allowed to stand 
for five minutes at room temperature to elute purified cDNA. 
 Columns were then centrifuged at 13,000 rpm for one minute to collect 25 μl of purified 
cDNA.  
 
Concentration of the purified amplified cDNA was analysed using Thermo Scientific 
NanoDrop™ 1000 Spectrophotometer. Since 4.4 μg of RNA was required in a final volume 
of 25 μl for further labelling and fragmentation reactions, samples were diluted in nuclease 
free water to achieve desired concentration.  
 
7.4.6 Step 6 – Fragmentation of amplified cDNA 
 
 Fragmentation master mix was prepared by mixing together fragmentation buffer (5 μl) 
and enzyme mix (2 μl) together for each sample.  
 25 μl of the purified SPIA™ cDNA into a PCR tube was added to 7 μl of the 
Fragmentation Master Mix.  
 After adequate mixing, tubes were incubated at 37 °C for 30 minutes, at 95 °C for 2 
minutes and cooled to 4 °C. 
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7.4.7 Step 7 - Biotin Labelling 
 
 Fragmentation of amplified cDNA was immediately followed by the Biotin labelling.  
 Labelling master mix was prepared by combining together labelling buffer (15 μl), 
reagent (1.5 μl) and enzyme mix (1.5 μl). 
 18 μl of labelling master mix was added to each sample (32 μl), making up a total volume 
of 50 μl for the hybridization reaction. 
 Samples were mixed thoroughly by vortexing and spinning and incubated in a pre-
warmed thermal cycler at 37 °C for 60 minutes, at 70 °C for 10 minutes and then cooled 
to 4 °C. 
 
The fragmentation success and the size distribution of the final fragmented and biotinylated 
product was viewed on Agilent 2100 Bioanalyzer on an RNA 6000 Nano LabChip®.  
 
7.4.8 Step 8 - Hybridization 
 
The Affymetrix Genechip® Human Genome U133 Plus 2.0 arrays (HG-U133 Plus 2.0) were 
used. This particular array is comprised of 1,300,000 unique oligonucleotide features 
covering over 47,000 transcripts and variants, which, in turn, represent approximately 39,000 
of the best characterized human genes. The probe sets used for the design of the array have 
been selected from Genebank®, dbEST and RefSeq. Oligonucleotide probes are synthesized 
in situ complementary to each corresponding sequence. Eleven pairs of oligonucleotide 
probes are used to measure the level of transcription of each sequence represented.    
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 Hybridization Master Mix was prepared by adding together Oligo B2 (3.7 μl)), 20 x 
hybridization controls (11 μl), 2 x hybridization buffer (110 μl), 100% DMSO (22 μl) and 
nuclease free water (25.3 μl) for each sample.  
 48μl of fragmented cDNA was added to 172 μl of hybridization master mix to render a 
final volume of 220 μl. 
 Hybridization cocktail (master mix + fragmented cDNA) was heated to 99° C for 2 
minutes in a heat block and shifted to 45° C heat block for 5 minutes. It was later 
centrifuged at maximum speed for 5 minutes just prior to loading. 
 200μl of pre-hybridization mix was added to each chip and these were rotated in the 
hybridization oven for 10 minutes at 45°C. The mix was removed from each chip prior to 
sample loading. 
 200μl of sample was added to each chip and hybridized for 16 hours in the oven at 45° 
with a speed of 60 rpm. 
  
7.4.9 Step 9 - Washing, staining and scanning 
 
After 16 hours of incubation, chips were taken out of hybridization oven and placed at room 
temperature. 
 Prime fluidics station was primed using the GeneChip® Operating Software (GCOS) on 
computer, which took approximately seven minutes.  
 Hybridization cocktail was pipetted out of the chip and stored in an eppendorf at 20°C. 
 Each chip was then filled with wash buffer A (~300μl). 
 Stain cocktails 1 and 2 (600 μl each) and Array Holding Buffer (800 μl) were aliquotted 
and inserted appropriately (sample holder 1, 2 and 3 respectively) in the Fluidics Station 
450/250.  
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 Using the AGCC Fluidics Control Software, washing and staining of the gene chips was 
undertaken. 
 Once the protocol was completed, the arrays were ready to scan on the GeneChip Scanner 
3000 
 
Scanning: Affymetrix Command Console software was used to scan the genechips.  
 
 Genechips were inserted into the scanner.  
 Once scanning was completed, Affymetrix Expression Console was used to generate the 
quality control metrics to ensure adequate and appropriate processing of the arrays.  
 
7.5 Statistics 
 
Data analysis was undertaken using R software (R Development Core Team, 2006; Version 
2.10.1), Bioconductor (version 2.10) and Partek Genomics Suite software. Other packages 
used were simpleaffy (for generating QC metrics), affy (for generating probe level data from 
CEL files), Limma (to perform between-array normalisation and to construct and perform 
volcano plot) and siggenes (for performing power calculations). Mas5 transformation was 
used to convert probe level data into expression level data. Expression level data were 
quantile normalised before differential expression analysis of mRNAs of severe versus mild 
acute pancreatitis was performed using ANOVA with batch hybridization effects. The 
Benjamini and Hochberg multiple testing correction was applied to the resulting p-values. 
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7.6 Optimisation and selection of protocol and pilot study 
 
Since the HU 133 Plus 2.0 arrays were used for this particular project, we used the 3’ IVT 
express protocol (Protocol A), which is the complementary protocol to these arrays, to carry 
out the amplification and labelling processes. However, when the size of the resultant 
amplified unfragmented RNA was analysed, abnormal peaks were observed on the trace. A 
normal amplified RNA looks like the following figure 11.1. 
 
 
Figure 7.3 – Normal amplified RNA trace 
 
The unexpected peaks were observed throughout all the samples. Similarly, the 
electrophoresis gel image also showed abnormal bands in the region of 700-800 nucleotides.  
These abnormal findings were thought to be due to very high levels of haemoglobin mRNA 
in the samples. This is not an uncommon finding, especially when dealing with human whole 
blood samples. 
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The degree of globin message representation in mRNA in whole blood can vary widely, with 
globin mRNA species constituting up to 70% of whole blood mRNA in some patients [323] 
and can interfere with assessment of other genes.  
 
Increases in globin mRNA contributes to decreased sensitivity of detection of transcripts on 
microarrays [324]. It has been shown by several groups [325-327] that excessive level of 
globin transcripts can induce a data artefact through promiscuous cross hybridization to 
microarray probes. Consistent with this, both scale factor and percentage present calls are 
negatively impacted by increasing amounts of globin. 
 
Conversely, Globin reduction improves the detection of sensitivity of the microarrays by 
increasing the call rates from higher signal intensities and lower signal to noise ratios and 
permitting detection of additional ‘masked’ genes [326, 328].  
 
Therefore, it was decided that the Ovation whole blood protocol would be used to reduce 
globin levels. A justification of this is given below.  
 
7.6.1 Globin mitigation protocols 
 
To improve the laboratory assays and increase discovery power, several commercially 
available solutions have been developed to reduce or mitigate the effects of excess globin 
transcripts on microarray hybridization signal in the last few years. These can be classified 
into two strategies.  
Globin clear approach: The first approach focuses on minimizing the amplification of 
globin specific messages in amplified cRNA. These methods include physically removing 
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globin transcripts from total RNA by hybridization to anti-globin oligonucleotides affixed to 
magnetic beads (GLOBINclear™) [328]. Because of sample manipulation, GLOBINclear has 
the potential to adversely affect the integrity of total RNA [329], is difficult to scale up and 
requires species-specific reagents. 
Globin reduction PNA approach: This method blocks the amplification of globin 
transcripts by using oligonucleotides of nucleic acid analogs (PNA, LNA), which when 
bound to a transcript prevents its amplification by reverse transcriptase [330]. The PNA 
approach was once recommended by Affymetrix but has subsequently been withdrawn from 
the market. The PNA-based technique was simple and scalable, but PNA design was difficult 
and costly to expand for other species. Theoretically, the PNA-based process seemed to fit 
better into the established target preparation process because it was performed in the same 
tube as the cDNA synthesis reaction. However, the stability of PNA in the long term was 
unknown and the method required taking measures to prevent PNA aggregation and 
precipitation. The method had been shown by the manufacturers to increase detection of 
transcripts and reduce biological variation between samples. However, it was not known how 
it would transform a gene expression profile, or to what extent it could generate a profile 
similar to that of samples without high levels of globin mRNA. 
Disadvantages of Globin clear and PNA techniques: Despite globin reduction protocols, 
globin depletion is ∼75%. These techniques are mostly efficient at reducing globin mRNA 
from cRNA but can induce RNA type-dependent changes in quality of RNA during sample 
preparation and quality of microarray results. Both techniques generate a hybridization target 
composed of cRNA and rely on the post-RNA isolation manipulation of the samples prior to 
or at the first step of mRNA amplification, leading to potential processing bias in gene 
expression data. The globin reduction steps introduce particular transformations to the 
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original gene expression profiles, and even after globin removal, it would not be possible to 
recover a profile equivalent to that of an identical RNA sample without globin mRNA 
excesses. 
A study [326] compared these two methods (GLOBINclear and GeneChip Globin-Reduction 
PNA Kit) in a Jurkat cell line and showed that neither method could recover a profile 
equivalent to that of an identical RNA sample without globin mRNA excess. Therefore, none 
of these protocols could completely remove globin gene mRNA and the remaining globin 
genes in the blood samples still continue to drive the main eigenvector in the data set. 
Thus, despite the application of globin reduction protocols, overrepresentation of globin 
genes on the microarrays can be a confounder for biomarker discovery, particularly in 
diseases with subtle gene expression signature.  
7.6.2 cRNA versus cDNA targets 
 
Several groups have detected widespread cross-hybridization in microarray measurements 
[331, 332], and on the order of 10% of the probes on a common oligonucleotide array 
platform were predicted to be susceptible to cross-hybridization [332]. High level of 
promiscuity in DNA-RNA hybridisations underlies widespread cross hybridization in 
microarrays. This cross hybridisation can be reduced by using cDNA targets instead of 
cRNA.  
  
From its inception, microarray technology took advantage of either of two types of 
biochemical entities as the labelled target, cRNA [333] or cDNA [334]. Although in many 
aspects these two types of labelled target are considered to be equivalent for the purpose of 
microarray analysis, the use of cRNA has held an important methodological advantage. 
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Because RNA polymerase does not require a primer, it was rather straightforward to design a 
near-linear target amplification method, which has been extremely useful in experiments with 
small amounts of starting RNA [333], including most clinical studies. Even so, there are hints 
in the literature indicating that DNA-RNA hybridization might be less specific than DNA-
DNA hybridization and hence, more susceptible to cross hybridization. One such relevant 
observation is that in free solution DNA-RNA hybrids, certain mismatch ‘wobble’ base pairs 
are more stable than complementary base pairs [335]. This effect is, however, absent in 
DNA-DNA hybrids [336], indicating that targets made of DNA might be a more specific 
alternative to standard RNA targets. These characteristics also support the use of DNA as a 
means of mitigating the effects of globin, and potentially other highly abundant interfering 
transcripts. cDNA hybridizations have greater intensity (low Scale Factor) and better 
discrimination between true signal and background. Not only are there improvements in 
hybridization metrics, but the deleterious effects of globin cross-hybridization are reduced. 
Another study concluded that the cDNA target is better able to discriminate between the 
correct probe and similar but incorrect probes and that it is unlikely that the increased 
specificity using cDNA targets instead of cRNA targets comes at the price of decreased 
sensitivity [337]. 
 
7.6.3 The Ovation Whole blood protocol 
 
Ovation whole blood technique is a new single primer, isothermal linear amplification 
method, according to which, small amounts of total RNA are reverse transcribed into cDNA 
using a chimeric RNA/DNA primer containing oligo (dT) and a unique RNA sequence tag at 
the 5’ end. A single linear isothermal amplification reaction rapidly generates sufficient 
single stranded cDNA for multiple hybridization reactions.  
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This method does not specifically restrict amplification of globin transcripts; rather it relies 
on the high specificity of DNA-based hybridization [337, 338]. During this procedure, all 
transcripts, including globin, are amplified to produce complementary cDNA. It is believed 
that the high specificity of DNA-DNA interactions reduces cross hybridization signal due to 
excess globin, thereby reducing artifactual signals. The methodology amplifies target mRNA 
using a novel template generation and isothermal strand displacement strategy [338, 339]. It 
has recently been improved with the addition of the Whole Blood reagent (WB) that 
optimizes the amplification for whole blood samples. 
 A recent study by Parrish et al [325] compared and quantified the impact of various 
mitigation technologies by employing the cDNA hybridization and PNA protocol. Their 
results reiterated the fact that globin related cross hybridization is the main source of artefact. 
They also found that the cDNA amplification (ovation whole blood protocol) improved the 
percent present calls by 25%, as compared to 10% by the PNA treatment and also exhibited 
more uniform detection and discrimination of low expressed genes by increasing expression 
signal across a wider range of low intensity probes. Another important characteristic of the 
cDNA targets was found to be the reduction of background intensity.  
 
In a nutshell, the Ovation whole blood protocol is highly reproducible and sensitive, fast and 
simple to operate. Both whole transcript amplification and 3’ initiated RNA amplification 
reproducibly generate high quality cDNA amplification products suitable for undertaking 
transcriptomic studies on GeneChip microarrays. The system provides a means for global 
gene expression analysis from very small samples and is particularly useful for clinical 
research where supplies of biologic samples are limited. 
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7.7 Quantitative and Qualitative Analyses 
 
There were 6 paired samples for the pilot study. Prior to the amplification process, it was 
ensured that the concentration of total RNA was adequate for the downstream application. 
Table 11.1 lists the final concentrations of the samples. 
 
Table 7.1 – Concentration of RNA samples prior to amplification process 
 
Sample ID New ID Concentration (ng/ μl) Final concentration (ng/ μl) 
    
AP040 – 0 hr 1 31.6* 50.2 
AP040 – 2 hrs 2 41.6 41.6 
AP041 – 0 hr 3 41 41 
AP041 – 2 hrs 4 67.3 67.3 
AP042 – 0 hr 5 45.3 45.3 
AP042 – 2 hrs 6 243.9± 50.08 
AP043 – 0 hr 7 36.1 36.1 
AP043 – 2 hrs 8 30.2* 45 
AP044 – 0 hr 9 137.5± 50.9 
AP044 – 2 hrs 10 123.4± 51.4 
AP045 – 0 hr 11 36.5 36.5 
AP045 – 2 hrs 12 20.5* 43 
 
*these samples were speed vacuumed to achieve a concentration of >40 ng/ μl 
±these samples were diluted to achieve a concentration of >50 ng/ μl 
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Figure 7.4 – Bioanalyzer traces of the Total RNA prior to Amplification 
 
Amplified RNA (Protocol A) was found to be in adequate concentration as can be seen in the 
table 7.2. 
 
Table 7.2 – Concentration of amplified RNA 
 
ID Concentration (ng/μl) 
  
1 969.6 
2 1045 
3 1039 
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4 1114.7 
5 1080.2 
6 884.5 
7 965.3 
8 892.6 
9 558.3 
10 515.9 
11 866 
12 874 
 
For Protocol B, cDNA was synthesized and quantified. It was found to have amplified 
adequately and efficiently as is reflected in the concentration and Bioanalyzer traces.  
 
Table 7.3 – Concentration of amplified cDNA 
 
ID Concentration 
(ng/ μl ) 
Volume of sample 
required (μl)* 
Volume of nuclease free 
water required (μl)± 
Final 
volume (μl) 
     
1 351.5 12.60 12.4 25 
2 320.7 13.72 11.8 25 
3 298.7 14.75 10.25 25 
4 272.1 16.20 8.8 25 
5 251.1 17.55 7.45 25 
6 290.8 15.15 9.85 25 
7 296 14.90 10.1 25 
8 264 16.67 8.33 25 
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9 290.3 15.16 9.84 25 
10 270 16.30 8.70 25 
11 255.4 17.23 7.70 25 
12 234 18.82 6.18 25 
*4400/concentration = volume of sample required 
±25-volume of sample required = volume of nuclease free water require 
The qualitative assessment was undertaken using Agilent 2100 Bioanalyzer with the Agilent 
RNA 6000 Nano Kit.  
 
7.8 Data Analysis 
 
Table 7.4 shows the various parameters looked at for the HU133 plus 2.0 arrays.  
 
Table 7.4 – Quality control metrics  
 
  
QC metrics for HG U133 Plus 2.0 arrays 
     
             
 
1 2 3 4 5 6 7 8 9 10 11 12 
             
Scale 
Factor 1.51 1.652 1.39 1.417 1.658 1.62 2.222 1.604 1.293 1.372 1.746 1.618 
Backgro
und 
Avg: 
28.46 
Avg: 
31.33 
Avg: 
30.78 
Avg: 
32.66 
Avg: 
28.44 
Avg: 
30.44 
Avg: 
27.47 
Avg: 
29.55 
Avg: 
30.22 
Avg: 
30.56 
Avg: 
28.18 
Avg: 
30.80 
Corner
+ 
Avg: 
191 
Avg: 
193 
Avg: 
208 
Avg: 
205 
Avg: 
159 
Avg: 
209 
Avg: 
111 
Avg: 
127 
Avg: 
130 
Avg: 
136 
Avg: 
111 
Avg: 
123 
Corner- 
Avg: 
1330
7 
Avg: 
16526 
Avg: 
9921 
Avg: 
18193 
Avg: 
13220 
Avg: 
14850 
Avg: 
10296 
Avg: 
9593 
Avg: 
9034 
Avg: 
5890 
Avg: 
7465 
Avg: 
7848 
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Central- 
Avg: 
1338
6 
Avg: 
16870 
Avg: 
10469 
Avg: 
18377 
Avg: 
14220 
Avg: 
15135 
Avg: 
11638 
Avg: 
10366 
Avg: 
8681 
Avg: 
6339 
Avg: 
7475 
Avg: 
7939 
Number 
Present: 
2963
0 
54.% 
28667 
52.4% 
33152 
60.6% 
32677 
59.8% 
31571 
57.7% 
32714 
59.8% 
30964 
56.6% 
32153 
58.8% 
33664 
61.6% 
33202 
60.7% 
30174 
55.2% 
32135 
58.8% 
             
Internal 
Control
s 
Sig(3'
/5') 
Sig(3'/
5') 
Sig(3'/
5') 
Sig(3'/
5') 
Sig(3'/
5') 
Sig(3'/
5') 
Sig(3'/
5') 
Sig(3'/
5') 
Sig(3'/
5') 
Sig(3'/
5') 
Sig(3'/
5') 
Sig(3'/
5') 
             
GAPDH 1.38 1.41 1.41 1.35 1.58 1.61 1.42 1.55 1.47 1.64 1.65 1.88 
Beta 
Actin 2.35 2.08 2.32 2.68 2.34 2.78 2.06 2.81 2.81 3.07 2.84 4.72 
             
Spike 
Control
s 
            
Probe 
Set 
Sig 
(3’) Sig(3') Sig(3') Sig(3') Sig(3') Sig(3') Sig(3') Sig(3') Sig(3') Sig(3') Sig(3') Sig(3') 
             
bioB 
3739.
3 (P) 
3781.2 
(P) 
3215.5
6 (P) 
2838.3 
(P) 
3273.2 
(P) 
3575.2 
(P) 
3378.7 
(P) 
3185.7 
(P) 
2739.5 
(P) 
2769.6 
(P) 
3441.7 
(P) 
3546.0 
(P) 
bioC 
7623.
7 (P) 
7632.2 
(P) 
7116.9 
(P) 
6300.6 
(P) 
7128.4 
(P) 
7907.3 
(P) 
6865.1 
(P) 
6887.7 
(P) 
5783.4 
(P) 
5895.1 
(P) 
7465.1 
(P) 
7338.3 
(P) 
bioD 
2271
6.3 
(P) 
20763.
8 (P) 
20295.
7 (P) 
18121.
5 (P) 
20232.
0 (P) 
21844.
7 (P) 
21408.
7 (P) 
20077.
6 (P) 
16512.
8 (P) 
17844.
9 (P) 
21153.
8 (P) 
20629.
1 (P) 
cre 
3384
0.7 
(P) 
33171.
3 (P) 
32022.
7 (P) 
27645.
7 (P) 
32237.
7 (P) 
34509.
6 (P) 
35189.
8 (P) 
30979.
0 (P) 
26253.
1 (P) 
29001.
9 (P) 
33241.
7 (P) 
33513.
6 (P) 
dap 
6300.
8 (P)   
6850.4 
(P) 
6861.1 
(P) 
6919.9 
(P) 
9441.5 
(P) 
8453.6 
(P) 
8245.1 
(P) 
7505.8 
(P) 
5677.2 
(P) 
7502.0 
(P) 
8677.3 
(P) 
7639.4 
(P) 
lys 
942.3 
(P) 
913.3 
(P) 
1103.6 
(P) 
934.2 
(P) 
1741.0 
(P) 
1278.2 
(P) 
1145.2 
(P) 
1202.8 
(P) 
885.4 
(P) 
1306.8 
(P) 
1395.6 
(P) 
1973.5 
(P) 
phe 
731.0 
(P) 
924.6 
(P) 
874.5 
(P) 
963.5 
(P) 
1423.6 
(P) 
1584.1 
(P) 
989.0 
(P) 
1343.0 
(P) 
995.0 
(P) 
1265.9 
(P) 
1769.6 
(P) 
1283.9 
(P) 
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thr 
969.5 
(P) 
1037.1 
(P) 
982.5 
(P) 
1511.2 
(P) 
2249.3 
(P) 
1742.5 
(P) 
1824.1 
(P) 
1658.0 
(P) 
1172.2 
(P) 
1431.4 
(P) 
2006.4 
(P) 
1933.6 
(P) 
 
 
All arrays scanned for 54675 probe sets. Scale factor was found to be the same through all the 
samples, depicting uniformity in the quality of these. Background was found to be within a 
range of 27-33. Although there are no official guidelines regarding background, Affymetrix 
has found that typical Average Background values range from 20-100 for arrays scanned with 
the GeneChip® Scanner 3000. This may point towards a low probability of inappropriate 
hybridization and therefore, more accurate results. All 12 arrays had comparable background 
values. Note that the low background has shifted the mean intensity towards the left side. 
This is graphically represented in figure 7.5, (generated from the simpleaffy package). 
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Figure 7.5 – Quality control Statistics 
  
Corner+, Corner_ and Central_ values indicate adequate alignment of the grid to the 
microarray slide. Percentage of present calls varied from 51 to 62%, which is considerably 
high as compared to usual microarray results, where it averages around 30-40%.  
 
Several internal controls were checked for. B2 oligo, which serves as a positive hybridization 
control, was shown to have performed adequately as no grid misalignment was observed. 
Poly A control genes (dap, lys, phe, thre) were used to monitor the entire target labelling 
process. These were all called present with increasing signal values in the order of lys, phe, 
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thr, dap. Hybridization controls, bioB, bioC, bioD and cre were used to evaluate sample 
hybridization efficiency on eukaryotic gene expression arrays. All of these were called 
present with increasing signal values, reflecting their relative concentrations. Internal control 
genes, β-actin and GAPDH, were used to assess RNA sample and assay quality. The signal 
values of the 3’ probe sets for actin and GAPDH were compared to the signal values of the 
corresponding 5’probe sets (3’/5’ ratios). These were all within range (less than 3, since this 
was a one-cycle assay).  
 
The affy package was used to generate probe level data from CEL files for the 12 arrays and 
is shown in figure 7.6. 
 
                             
 
Figure 7.6 Probe level data and RNA degradation plot 
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 As can be seen from the figure, probe level intensities overlap and have a similar 
distribution.  RNA degradation plots showed similar pattern across all the arrays. Expression 
level data were generated from probe level data using the mas5 transformation and is 
represented in a box plot below (figure 7.7). 
 
Figure 7.7 – Expression level data 
 
A between-array normalisation was performed (from the limma package) to remove inter-
array differences. Data were filtered to remove control probes, probes flagged “Absent” in all 
samples and probes with a CV across all arrays greater than the 90th quantile. 
 
One of the objectives of the study was to see the variability between the samples stored 
immediately after collection (time 0 hour) and those stored after two hours of incubation at 
room temperature (time 2 hours). These treatments were used as factors in a fixed term linear 
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model of gene expression in paired patient samples which was constructed using limma, 
outputting ‘moderated t-statistics’ and associated FDR corrected p-values in the form of a 
volcano plot (plots log-fold changes versus log-odds of differential expression). 
Limma, a commonly used package for microarray analysis in BioConductor provides a 
‘moderated t-statistic’ as part of the test for significantly changed genes. This moderately t-
statistic borrows variability information from other genes on the array in order to calculate 
the t-statistic, rather than considering each gene in isolation. This moderated t-statistic is 
derived from the empirical Bayes method.  The approach in limma incorporates average 
differential expression and a measure of variability similar to that used in a t-statistic (i.e. a 
standard error), but the gene wise standard errors are modified.  
Volcano plot in figure 7.8 fails to demonstrate any significant difference in the differential 
expression between the two treatment time points. Since there is no difference between the 
differential expression at these time points, these samples can be treated equally and used 
together. 
 
Figure 7.8 – Volcano plot to demonstrate difference between the two groups 
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Power calculations were performed using the Siggenes package. Power was set at 80%, 
specificity (significance cut-off) at 0.05 and minimum fold change at 2. Figure 7.9 shows the 
minimum number of samples required in each group to achieve 80% power (in time 2 hours 
group) to be approximately 40.  
 
Figure 7.9 – Sample size calculation in time 2 hours group 
 
Figure 7.10 shows the same calculation performed with fold change increased to 4, giving a 
sample size of 20 in each group.  
116 | P a g e  
 
 
Figure 7.10 – Sample size calculation in time 2 hours group with fold change of 4 
The same calculations were repeated for the other treatment group (time 0 hour) with varying 
fold changes (2 and 4 in figures 7.11 and 7.12, respectively).  
 
Figure 7.11 – Sample size calculation in time 0 hour group with fold change of 2 
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Figure 7.12 – Sample size calculation in time 0 hour group with fold change of 4 
Solely using samples from time 0 hour group will require an unrealistically large number of 
patient samples for each group, but this number could be significantly reduced by using 
samples from time 2 hours group. This does point towards a varying difference in the 
differential expression of these groups which may mean that although there was no 
significant difference in the differential expression of the two groups on the volcano plot, 
there could be a difference in gene expression variance in these groups. In the light of these 
results, samples from time 2 hours group will be used for the main study, with 40 samples in 
each group (mild and severe).  
One of the other objectives of this pilot study was to establish and refine a protocol for 
processing samples and data analysis for the main study. Experience with the 3’ IVT express 
kit had shown an abundance of globin mRNA leading to potential problems with the 
processing and subsequent data analyses. A method was sought to remove haemoglobin from 
mRNA prior to hybridisation. The Ovation whole blood protocol was then used to check if it 
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neutralised the abundance of globin mRNA in our samples. Figure 7.13 shows a box plot of 
expression levels data with alpha and beta haemoglobin probes overlaid following treatment 
with the Ovation whole blood protocol. 
 
Figure 7.13 – Expression levels of haemoglobin probes 
All haemoglobin alpha- and beta-probes fall within the upper or lower quantiles of expression 
level, indicating that the abundance of globin mRNA has fallen to within expected limits. 
This provided the confidence that the Ovation whole blood system protocol not only solved 
the problem of abundance of globin mRNA in the samples, it also suited the project since a 
small amount of starting RNA was required and the procedure was very user friendly and 
highly reproducible. This protocol was therefore used for the main study.  
 
7.9 Qualitative Assessments of the sample preparation and 
processing 
 
Qualitative checks were undertaken at three important steps:- 
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 After RNA extraction – to assess quality and quantity of the RNA to be used for 
further experiments 
 After amplification of the resultant cDNA – to assess adequacy of the amplification 
process and of the quantity of the resultant amplified product 
 After fragmentation – to assess adequacy of the resultant fragment and its suitability 
for the hybridization process 
7.9.1 Qualitative and Quantitative Analyses after the RNA extractions 
 
All 58 samples were processed in a total of five batches so as to minimise batch effects. Care 
was taken to have a constant proportion of mild and severe patients in each batch so that there 
was homogeneity among the samples and any effects observed were due to the disease 
process and not due to the way samples were processed or handled. Details of the batches are 
given below:- 
 
Table 7.5 – Samples in each batch 
Batch 1 
 
AP034          AP047          AP052       
AP079          AP065          AP051 
AP059          AP046          AP055 
AP091          AP029          AP048 
 
 
Batch 2 
 
AP067          AP062         AP072      
AP0100        AP088         AP081 
AP097          AP066         AP103 
AP063          AP058         AP105 
 
Batch 3 
 
AP057          AP117          AP135       
AP077          AP124          AP137 
AP078          AP128          AP144 
AP099          AP129          AP149 
 
 
Batch 4 
 
AP164          AP191          AP230       
AP168          AP192          AP234 
AP177          AP203          AP300 
AP187          AP206           
 
Batch 5 
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AP009          AP227          AP273       
AP011          AP232          AP307 
AP021          AP251          UHA-08 
AP211          AP267           
 
Red highlighted samples are severe acute pancreatitis 
 
PAXgene Blood RNA kit (Qiagen) was used to extract RNA from stored PAXgene Blood 
RNA Tubes, as described in the methods section. Following table demonstrates the 
concentrations of the extracted RNA using Thermo Scientific NanoDrop™ 1000 
Spectrophotometer and the bioanalyzer traces using Agilent 2100 Bioanalyzer with the 
Agilent RNA 6000 Nano Kit are also shown below. Nanodrop Traces are provided in 
Appendix 1. 
 
Table 7.6 – RNA concentrations 
 
Sample Concentration RIN Sample Concentration RIN 
     (µg)     
AP034 40.2 8.90 AP057 126.7 7.70 
AP079 110.2 8.40 AP077 36 8.80 
AP059 274.5 7.90 AP078 50.6 8.50 
AP091 144.4 7.80 AP099 46.4 8.60 
AP047 235.7 8.70 AP117 58.8 8.50 
AP065 50.4 8.10 AP124 122.3 8.70 
AP046 225.8 8.30 AP128 41.6 8.40 
AP029 41.4 8.40 AP129 59.4 8.40 
AP052 61 2.50 AP135 160 8.40 
AP051 58.9 7.80 AP137 176 8.40 
AP055 331.1 8.10 AP144 78.2 NA 
AP048 165.7 8.40 AP149 44.3 8.20 
      
AP067 106.3 8.40 AP164 293.4 8.0 
AP100 84.5 8.10 AP168 54.2 8.7 
AP097 133 860 AP177 47.2 8.0 
AP063 112.9 8.60 AP187 111.1 8.3 
AP062 64.2 8.50 AP191 8.4 NA 
AP088 1109 7.80 AP192 134.5 7.50 
AP066 72.5 8.50 AP203 108.1 NA 
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AP058 49.6 NA AP206 58.4 8.7 
AP072 107.4 NA AP230 112.7 8.0 
AP081 138.6 8.30 AP234 37 7.80 
AP103 45.5 8.10 AP300 43.9 7.70 
AP105 45 NA    
      
AP009 155 8.4    
AP011 126 8.5    
AP021 84.5 8.9    
AP211 35.4 7.40    
AP227 92.2 9.10    
AP232 27.6 7.90    
AP251 16.1 6.60    
AP267 135.4 8.50    
AP273 115.4 8.50    
AP307 58.1 8.80    
UHA-08 45.2 NA    
 
 
 
Figure 7.14 – Bioanalyzer trace for extracted RNA (Batch 1) 
Since AP052 didnt show the usual 28S and 18S peaks, this was repeated to ensure good 
quality of the sample. This is shown in Figure 12.2. 
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Figure 7.15 – Repeat processing of AP052 
 
Additional peaks were seen in the traces for at least four samples in batch 2 (AP105, AP072, 
AP058 and AP066), four samples in batch 3 (AP099, AP117, AP144 and AP149), three 
samples in batch 4 (AP191, AP203 and AP300) and two samples in batch 5 (AP273 and 
UHA-08).  
 
Figure 7.16 – Bioanalyzer trace for extracted RNA (Batch 2) 
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Figure 7.17 – Bioanalyzer trace for extracted RNA (Batch 3) 
 
 
Figure 7.18 – Bioanalyzer trace for extracted RNA (Batch 4) 
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Figure 7.19 – Bioanalyzer trace for extracted RNA (Batch 5) 
 
These additional peaks didn’t appear to be due to RNA degradation which is 
characteristically a different trace, without the presence of distinct 18S and 28S bands (figure 
12.7). 
 
Figure 7.20 – Bioanalyzer traces demonstrating traces relating to varying RINs and hence degradation of 
RNA 
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To assess this better, another application called degradometer (Version 1.41) was used to 
ascertain the quality of these ‘affected’ samples. It provides quantitative data about the 
integrity and concentration of eukaryotic total RNA. The ‘DegFact’ represents the 
degradation – the higher the number, the more the degradation. T18S shows the timing of the 
18S rRNA peak; usually approximately 41.4 seconds, whereas T28S is the timing of the 28S 
rRNA peak; usually 48 seconds.18S is the signal intensity of the 18S rRNA peak and 18S is 
the signal intensity of the 28S rRNA peak. Finally, 28S/18S is the ratio of 28S/18S signal 
heights. This number decreases in apoptosis. A DegFact value of <8 is considered 
satisfactory and is indicative of minimal degradation. Following tables (7.7, 7.8, 7.9) show 
results from the first 3 batches. These provided enough assurance that the RNA was of high 
quality and without significant degradation and therefore, it was decided to proceed with the 
samples. 
Table 7.7 – Results of Degradometer Batch 1 
Sample DegFact 
RNA 
Concentration t18S t28S 18S 28S 28S/18S 
 
  ng/µl      
AP34 4.27 25.9 41.05 48 40.7 29.84 0.73 
AP46 5.02 201.2 41.1 48 39.01 26.92 0.69 
AP47 4.03 214.4 41.05 48 43.75 34.29 0.78 
AP48 3.56 221.2 41.2 48 45.27 30.13 0.67 
AP51 5.67 44.1 41.15 48 36.7 22.21 0.61 
AP52 9.58 49.1 40.95 48 27.07 19.77 0.73 
AP55 4.83 285.6 41.15 48 40.51 25.74 0.64 
AP59 4.66 217.1 41.1 48 48.99 27.33 0.56 
AP65 6.69 40.9 41.05 48 33.69 23.3 0.69 
AP79 4.56 94.2 41.1 48 44.61 30.85 0.69 
AP91 5.11 110.9 41.1 48 46.42 26.76 0.58 
 
 
 
 
Table 7.8 – Results of Degradometer Batch 2 
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Sample DegFact 
RNA 
Concentration t18S t28S 18S 28S 28S/18S 
  ng/µl      
AP58 7.85 24.5 41.2 48 28.75 32.6 1.13 
AP62 4.47 54.3 41.25 48 41.69 43.06 1.03 
AP63 3.78 94 41.2 48 45.6 46.51 1.02 
AP66 4.17 49.3 41.2 48 42.4 43.82 1.03 
AP67 3.86 97.6 41.25 48 48.3 39.54 0.82 
AP72 5.51 16.8 41.2 48 34.9 32.25 0.92 
AP81 4.64 124.9 41.1 48 42.23 44.64 1.06 
AP88 6.94 94.6 41.2 48 30.37 42.46 1.4 
AP97 4.22 114.2 41.25 48 42.59 44.51 1.05 
AP100 4.74 71.9 41.25 48 46.08 36.32 0.79 
AP103 6.74 38.3 41.1 48 32.02 33.05 1.03 
AP105 7.29 23.6 41.1 48 31.71 24.63 0.78 
 
Table 7.9 – Results of Degradometer Batch 3 
Sample DegFact 
RNA 
Concentration t18S t28S 18S 28S 28S/18S 
  ng/µl      
AP57 5.9 147.7 41.1 48 44.17 33.32 0.75 
AP77 4.46 30.8 41.1 48 39.62 38.43 0.97 
AP78 5.23 65.5 41.1 48 35.94 39.96 1.11 
AP99 4.21 30.1 41.15 48 41.55 48.3 1.16 
AP117 4.74 49.1 41.2 48 37.27 42.05 1.13 
AP124 3.97 143.2 41.15 48 44.11 47.86 1.09 
AP128 6.04 53.7 41.25 48 34.1 40.17 1.18 
AP129 4.28 69.7 41.25 48 44.46 41.56 0.93 
AP135 3.98 189.6 41.25 48 47.75 42.36 0.89 
AP137 3.99 204.4 41.3 48 42.9 48.6 1.13 
AP144 6.75 26.6 41.3 48 35.36 31.31 0.89 
AP149 6.36 50.5 41.35 48 30.86 42.5 1.38 
 
 
7.9.2 Qualitative and Quantitative Analyses after amplification of cDNA 
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Nanodrop readings indicated the amount of amplified cDNA and the bioanalyzer trace 
depicted the efficacy of the amplification process, as is shown below. Bioanalyzer traces are 
shown below. Nanodrop traces are included in supplementary data.  
 
Figure 7.21 –Bioanalyzer traces of amplified cDNA (Batch 1) 
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Figure 7.22 –Bioanalyzer traces of amplified cDNA (Batch 2) 
 
Figure 7.23 –Bioanalyzer traces of amplified cDNA (Batch 3) 
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Figure 7.24 –Bioanalyzer traces of amplified cDNA (Batch 4) 
 
Figure 7.25 –Bioanalyzer traces of amplified cDNA (Batch 5) 
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7.9.3 Qualitative and Quantitative Analyses after fragmentation of cDNA 
 
cDNA was later fragmented to achieve fragments of ~ 90-120 nt. This would ensure 
appropriate size that would facilitate hybridization. All fragmented cDNA revealed adequate 
size. This is shown in figures 7.26, 7.27, 7.28, 7.29 and 7.30. 
 
Figure 7.26 – Bioanalyzer traces of fragmented cDNA (Batch 1) 
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Figure 7.27 – Bioanalyzer traces of fragmented cDNA (Batch 2) 
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Figure 7.28 – Bioanalyzer traces of fragmented cDNA (Batch 3) 
 
 
Figure 7.29 – Bioanalyzer traces of fragmented cDNA (Batch 4) 
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Figure 7.30 – Bioanalyzer traces of fragmented cDNA (Batch 5) 
 
7.10 Quality Control metrics for Hybridization 
 
High 3’5’ ratios for house-keeping genes were noticed. Typically, a normal value for 3’/5’ 
ratio for the GAPDH is up to 3 and up to 20 for beta actin, since this gene is 2.2 kb long. This 
can be explained by the fact that the 5’ probes for the human actin gene are approximately 1.7 
kb from the 3’ polyA tail of the message. QPCR analysis has revealed that the Ovation 
amplified cDNA material is long enough to provide good transcript representation out to 1 kb 
from the polyA tail (Figures 7.31 and 7.32). This is completely adequate for use on the 
current generation of Affx arrays as the probes for the arrays are designed to be within 600 
bases of the polyA tail. 
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Table 7.10 – Quality control metrics for batch 1 hybridizations 
Sample Name AP029 AP034 AP046 AP047 AP048 AP051 
       
       
Scale Factor (SF): 0.2942 0.31752 0.3356 0.2865 0.3668 0.3385 
Background: 27.1639 29.7466 27.684 29.506 28.704 28.947 
Total Probe Sets: 54675 54675 54675 54675 54675 54675 
Number Present: 56.3457 60.2451 61.652 62.219 59.076 55.02 
       
Housekeeping Controls:       
AFFX-
HUMGAPDH/M33197 11.7952 11.6848 11.679 11.429 11.81 11.876 
AFFX-HSAC07/X00351 11.9694 12.0084 12.246 11.903 12.34 12.138 
Spike Controls:       
Probe Set Sig(3') Sig(3') Sig(3') Sig(3') Sig(3') Sig(3') 
AFFX-r2-Ec-bioB 9.11221 9.29811 9.4174 9.0247 9.3237 9.2846 
AFFX-r2-Ec-bioC 10.2282 10.3554 10.469 10.198 10.448 10.371 
AFFX-r2-Ec-bioD 11.7378 11.8621 11.958 11.708 12.019 11.944 
AFFX-r2-P1-cre 12.5358 12.6011 12.758 12.436 12.821 12.708 
 
Sample Name AP052 AP055 AP059 AP065 AP079 AP091 
       
Scale Factor (SF): 0.3278 0.3678 0.2841 0.3864 0.3276 0.28361 
Background: 28.576 28.3763 30.198 28.351 29.332 28.7078 
Total Probe Sets: 54675 54675 54675 54675 54675 54675 
Number Present: 58.345 58.9886 59.546 56.913 59.497 60.225 
Housekeeping Controls:       
AFFX-
HUMGAPDH/M33197 11.792 11.7199 11.557 12.126 11.641 11.3354 
AFFX-HSAC07/X00351 12.162 12.2479 11.95 12.343 11.914 11.8933 
Spike Controls:       
Probe Set Sig(3') Sig(3') Sig(3') Sig(3') Sig(3') Sig(3') 
AFFX-r2-Ec-bioB 9.2079 9.25516 8.9654 9.3981 9.1323 9.16866 
AFFX-r2-Ec-bioC 10.369 10.3948 10.162 10.468 10.326 10.2459 
AFFX-r2-Ec-bioD 11.869 11.9666 11.754 12.062 11.739 11.7761 
AFFX-r2-P1-cre 12.655 12.7418 12.511 12.836 12.536 12.4713 
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 Figure 7.31 – Actin and GAPDH probe sets 
  
  
Figure 7.32 – Distribution of probes on U133A genechip 
  
Having said that, it has to be kept in mind that the QC metrics by Affymetrix have been 
optimized for aRNA probes, not cDNA, so their recommended values may not be applicable 
on the selected ovation protocol treated hybridizations. Besides, the percentage of present 
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calls was found to be quite high in the samples, along with improved scaling factor and low 
background. 
 
Keeping all this in the context, these QC metrics were considered adequate and reliable. 
Diagrammatic representation is presented below in figures, including RNA degradation plot 
(Figures 7.33 and 7.34)  
 
 
Figure 7.33 – Quality control metrics of the house keeping genes 
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Figure 7.34 – RNA degradation plot 
7.11 Qualitative Analyses 
 
Quality control metrics (QC) were performed to ensure efficient hybridizations. These can be 
broadly classified into within arrays, between arrays and between batches. It is of paramount 
importance to perform quality checks at all these points so as to minimise any systematic bias. 
For ‘within array’ QCs, assessment of 'housekeeping genes' is undertaken (approximately 100 
on standard affymetrix chips). These act as controls and there are several probe sets 
corresponding to controls. These are easily identified by the letters ‘AFFX’ at the beginning of 
the probe identifier. Some of them are spiked-in control genes. The matching targets are added 
in precise quantities and at different steps in the labelling and hybridization process. These 
transcripts have predictable expression levels and so the probe sets play an important quality 
control role in the MAS algorithm. Controlled input results in predictable outcomes, enabling 
discovery and correction of sources of error, if any. The chips are re-scaled so the average 
values of these housekeeping genes are equal across all chips. This is much better than using a 
single housekeeping gene, and probably adequate for about 80% of chips in practice. Figure 
(7.35) below depict the QCs for labelling, hybridization, 3’-5’ and pm/mm respectively. These 
demonstrate that the intensity of the house keeping genes was predominantly consistent 
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through all the samples. There was some variability but it was not significant enough for the 
sample to be labelled as an outlier and therefore, all samples were included in the final analysis.  
 
Labelling 
                       
 
Hybridization 
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3’/5’ ratio 
 
Perfect match/mismatch repair 
 
 
 
Figure 7.35 – Quality Control Metrics for labelling, hybridisation, 3’-5’ and pm/mm 
 
Quality control for ‘between arrays’ was performed by looking at probe level, expression level 
and relative expression level (REL) data. 
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Box plots show a picture of the overall distribution of probe intensities found on each array. 
As it can be seen in the figures below (7.36), that the probe level, expression level and REL 
intensities overlap and have similar distribution. 
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Figure 7.36 – Quality control metrics for probe level, expression level and REL intensities 
 
Data obtained from the probes (probe level data) was transformed to expression estimates using 
MAS5. This is a standard affymetrix algorithm which performs background correction and 
normalisation algorithm. It converts the values to log10 and then averages across genes and 
samples. It helps to equalise the contribution of different probes as well. 
 
7.12 Principle Component Analysis 
 
Batch effects are technical sources of variation that have been added to the samples during 
handling. The importance of removing these cannot be over-emphasised.  Their presence 
decreases statistical power, since it adds variation to the data, may act as a confounder and 
induce differences between the study groups.  It is absolutely critical that this type of 
technical variation does not confound with the biology, ensuring that biological treatment 
groups do not overlap with technical groups. This is often evaluated using explorative 
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approaches, involving distance measures, clustering and spatial methods. Principle 
Component Analysis (PCA) was used in this study to illustrate this and Analysis of Variance 
(ANOVA) to assess and correct for batch effects.  
Figure 7.37 shows differences between the two study groups on the basis of their disease 
(mild vs. severe) with and without the batch effects, respectively. 
With batch effects 
Without batch effects
 
Figure 7.37 – Principle Component Analysis demonstrating difference between MAP and SAP, with and 
without batch effects 
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Another difference to assess for was between the different batches. Since all the samples were 
processed in five batches, these were classified according to that and batch effects removed. Figure 
7.38 depicts the different batches before and after removal of batch effects, respectively. 
With batch effects 
Without Batch Effects 
 
Figure 7.38 – Principle Component Analysis demonstrating difference between different batches 
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7.13 Hierarchical Clustering 
 
As the next step, gene expression analysis was performed by using two way ANOVA (with 
CV <30%, IQR >0.5 and fold change of 2.0). ANOVA not only improves the estimate of 
disease effects but also quantitates both batch and disease effects per gene, using only the 
disease specific effects for inference. Based on that, 98 genes were identified that are 
differentially expressed between mild and severe pancreatitis. Based on those 98, the groups 
separate out quite well as can be seen in hierarchical clustering plot below. Both the gene and 
sample distances were Euclidean and average linkage was used for clustering; the images are 
scaled so that mean is 0 and standard deviation is 1.  
 
Figure 7.39 - Hierarchical Cluster Analysis of differential gene expression data from mild and severe 
acute pancreatitis patients. Heat map depicting the gene expression patterns in 58 patients (35 mild and 
23 severe acute pancreatitis). Columns represent individual samples and rows represent each gene. Each 
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cell in the matrix represents the expression level of a gene feature in an individual sample. Blue 
represents mild and red illustrates severe patients. Upregulated (high expression level) genes are coloured 
red whereas downregulated (low expression level) genes are shown as green, as indicated in the scale bar 
(log2-transformed scale). 
The above figure shows the genes clustering to specific disease groups. While there are a few 
samples that are intermediate in their expression, the fact that clustering is clearly appreciated 
translates into a clear distinction between the groups – mild and severe. This provides 
evidence that based on gene expression, these are two different disease groups where 
different mechanisms are at play, leading to different clinical pictures and hence the 
outcomes.  
It also raises an extremely pertinent point of the intermediate patients – where the expression 
lies somewhere between the two, eluding to presence of a different entity which may have 
different clinical presentation and may represent a different category altogether. 
 
7.14 Overall gene expression differences between severe and 
mild acute pancreatitis 
 
 98 genes were differentially expressed (FC 1.5, FDR < 0.05) in severe acute pancreatitis 
(SAP) in comparison to mild acute pancreatitis (MAP). Table 7.11 lists the most significantly 
differentially expressed (upregulated) genes between all SAP and the corresponding FC and 
p-values obtained from comparisons with MAP. Details are provided in appendix 2. The 
single most up-regulated gene was MMP8 (Matrix Metallopeptidase 8) (FC=4.49), which 
codes for MMP 8 protein - a neutrophil collagenase, actively involved in breaking down of 
the extracellular matrix. Its role in cancer is very well established where it is involved in 
proliferation, invasion, epithelial-to mesenchymal transformation, metastasis and 
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angiogenesis. OLAH and ADAMST genes code for enzymes that are heavily involved in the 
extracellular matrix remodelling and development. Another important upregulated gene was 
found to be HPGD (Hydroxy prostaglandin dehydrogenase 15). This enzyme converts 
proinflammatory PGE2 to anti-inflammatory PGE2. In a recent study, HPGD is found to be 
protective against Lipopolysaccharide induced liver injury by activating PPAR-γ in Kupffer 
cells and concurrently, inhibiting their ability to produce inflammatory cytokines [340]. It is 
safe to assume a similar role is played by HPGD upregulation in the setting of acute 
pancreatitis as well.  Cysteine- rich secretory protein 3 (CRISP3) gene was found to be 
upregulated in our dataset as well. It is defence-associated molecule (due to its expression in 
B lymphocytes) with predominant expression in the salivary gland, pancreas and prostate. It 
has been shown to be involved in pathophysiology of chronic pancreatitis [341]. CRISP-3 
seems to play an important role in acinar cell degeneration and ductal cell proliferation in the 
course of the tissue destruction and remodelling in chronic pancreatitis and has also been 
found to be expressed in specific granules of neutrophils in response to pathogen infections 
[342, 343]. This would explain its source and potential role in the context of AP where 
neutrophils are the hallmark cellular component.  
 
Table 7.11. Top 50 differentially expressed genes (upregulated) in severe and mild acute 
pancreatitis  
Gene Symbol ID P value Fold Change     
MMP8 231688_at 0.000108 4.49 
OLAH 222945_x_at 0.0005 3.419 
ADAMTS2 226311_at 0.0000419 3.095 
RETN 220570_at 0.000028 3.085 
HPGD 211548_s_at 0.00263 3.077 
SLC1A3 202800_at 0.000335 3.072 
OLAH 233126_s_at 0.00108 2.918 
HPGD 203914_x_at 0.00316 2.915 
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OLAH 219975_x_at 0.0028 2.87 
GPR84 223767_at 0.000604 2.847 
SLC51A 229230_at 0.000368 2.739 
CRISP3 207802_at 0.000132 2.701 
HPGD 211549_s_at 0.000838 2.624 
DAAM2 212793_at 0.0018 2.551 
CD163 216233_at 0.0000173 2.538 
FGF13 205110_s_at 0.00332 2.537 
ANKRD22 239196_at 0.000477 2.534 
VSIG4 204787_at 0.000163 2.452 
BPI 205557_at 0.0000131 2.445 
PFKFB2 226733_at 0.000208 2.398 
TIMP4 206243_at 0.0000661 2.391 
ARG1 231663_s_at 0.000666 2.335 
SH3PXD2B 231823_s_at 0.00036 2.315 
HGF 210997_at 0.000874 2.31 
HGF 209960_at 0.000334 2.302 
PTGES 210367_s_at 0.000518 2.252 
SAMSN1 1555638_a_at 0.000349 2.238 
TMEM45A 219410_at 0.0000832 2.227 
CEACAM1 210610_at 0.000094 2.221 
DLC1 224822_at 0.00183 2.21 
TCN1 205513_at 0.0000795 2.196 
DHRS9 224009_x_at 0.000477 2.195 
SEMA6B 223567_at 0.000799 2.182 
LCN2 212531_at 0.00161 2.165 
CYP1B1-AS1 1553829_at 0.00273 2.157 
ADAMTS2 214535_s_at 0.0000261 2.151 
DHRS9 223952_x_at 0.000497 2.149 
LTF 202018_s_at 0.00292 2.134 
CEACAM1 206576_s_at 0.00104 2.124 
CRISP2 210262_at 0.000751 2.111 
HGF 210998_s_at 0.000224 2.103 
C1QC 225353_s_at 0.00269 2.1 
THBS1 235086_at 0.000875 2.094 
CEACAM1 211889_x_at 0.00129 2.09 
SIRT5 219185_at 0.0000365 2.073 
DHRS9 219799_s_at 0.000357 2.06 
FGF13-AS1 1560537_at 0.000345 2.053 
ERLIN1 202444_s_at 0.0000247 2.048 
PDE4D 1554717_a_at 0.000131 2.027 
KL 205978_at 0.000595 2.012 
 
The most differentially expressed genes (upregulated) in severe and mild acute pancreatitis, (FC 1.5 and FDR < 
0.05) and the corresponding FC and p-values. Abbreviations: FC =  fold changes (FC); FDR =  False discovery 
rate. 
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Table 7.12 lists the most differentially expressed (downregulated) genes between all SAP and 
the corresponding FC and p-values obtained from comparisons with MAP. 
Table 7.12 - Top 50 differentially expressed genes (down regulated) in severe and mild 
acute pancreatitis 
Gene Symbol ID P value Fold Change 
    
NELL2 203413_at 0.000450 -2.594 
NOV 214321_at 0.000285 -2.519 
YME1L1 234849_at 0.000218 -2.407 
YME1L1 234013_at 0.00125 -2.405 
TRDV3 216191_s_at 0.0000328 -2.398 
YME1L1 217143_s_at 0.0000358 -2.386 
RORA 226682_at 0.0000236 -2.364 
P2RY10 236280_at 0.0000354 -2.321 
THEMIS 1558972_s_at 0.00018 -2.299 
INPP4B 235046_at 0.000166 -2.292 
TRAT1 217147_s_at 0.00037 -2.283 
KIAA1671 225525_at 0.000529 -2.254 
GZMK 206666_at 0.0000878 -2.235 
YME1L1 213830_at 0.0000298 -2.214 
BCL11B 219528_s_at 0.000125 -2.208 
RPS6KA5 1557113_at 5.51E-06 -2.201 
GBP4 235175_at 0.000101 -2.178 
TRAV9-2 217412_at 0.000319 -2.165 
GATA3 209602_s_at 0.0000954 -2.159 
CD28 206545_at 0.000194 -2.139 
CAMK4 229029_at 0.00103 -2.113 
TBC1D4 203387_s_at 0.0000443 -2.104 
CD160 207840_at 0.000213 -2.091 
TRAV24 234398_at 0.000694 -2.09 
BEX2 224367_at 0.00321 -2.082 
PRKCQ-AS1 1561004_at 0.000382 -2.075 
IFNLR1 244261_at 0.000122 -2.068 
TRAC 210972_x_at 0.00035 -2.03 
DPP4 211478_s_at 0.000147 -2.026 
RPS6KA5 204635_at 0.0000249 -2.022 
GRAMD1C 219313_at 0.000717 -2.02 
ATP8B2 226771_at 0.0000993 -2.016 
ETV7 224225_s_at 0.00165 -2.012 
ISM1 235182_at 0.00174 -2.007 
LOC105369609 244798_at 0.00274 -2.003 
CAMK4 241871_at 0.000522 -2 
THEMIS 1558971_at 0.000189 -1.984 
CD3D 213539_at 0.000425 -1.982 
PYHIN1 240413_at 0.000401 -1.977 
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RORA 236266_at 0.000103 -1.975 
LCK 204891_s_at 0.000231 -1.972 
BCL11B 222895_s_at 0.000208 -1.97 
YME1L1 211902_x_at 0.000521 -1.968 
CXCR3 207681_at 0.0000454 -1.966 
CD40LG 207892_at 0.000941 -1.954 
MYBL1 213906_at 0.000183 -1.954 
NR3C2 205259_at 0.000664 -1.939 
GBP5 238581_at 0.000391 -1.936 
TRAC 209671_x_at 0.000479 -1.935 
RPS6KA5 204633_s_at 0.000152 -1.931 
 
The most differentially expressed genes (downregulated) in severe and mild acute pancreatitis, (FC 1.5 and FDR 
< 0.05) and the corresponding FC and p-values. Abbreviations: FC =  fold changes (FC); FDR =  False 
discovery rate. 
 
NOV (Neuroblastoma overexpressed) was found to be one of the most downregulated genes 
in our dataset. NOV is involved in regulating multiple cellular activities, including migration, 
proliferation, differentiation and survival. It has also been found to be involved in causing 
Ca2+ influx. Recently, regulatory T cells were identified to mediate oligodendrocyte 
differentiation in regeneration of myelin following damage. NOV was thought to be a key 
player in facilitating this process.  
YME1L1 encodes for ATPases and is involved in mitochondrial organisation and protein 
metabolism. Pancreas is known to be one of the only organs in the body to have high 
concentrations of its protein due to high concentration of mitochondria. YME1L1 controls the 
accumulation of respiratory chain subunits and is required for apoptotic resistance, cristae 
morphogenesis, and cell proliferation.  
T cell Receptor Associated Transmembrane Adaptor 1(TRAT1), T cell Receptor Delta 
Variable 3(TRDV3), T cell Receptor Alpha Variable 9-2 and 24(TRAV 9-2 and TRAV24), T 
cell Receptor Alpha constant (TRAC) are all responsible for stabilising the T cell receptor 
(TCR) and are particularly involved in NFAT pathway. These were found to be most 
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significantly downregulated in SAP, indicating their dysregulation to be a key event in the 
disease process. This was further confirmed and is highlighted in the description of canonical 
pathways.
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Figure 7.40 - Top canonical pathways differentially expressed in SAP and MAP 
The above figure (7.40) lists top 34 pathways differentially expressed in severe acute 
pancreatitis when compared with mild acute pancreatitis. The stacked bar chart displays the 
percentage of genes that were upregulated (red), downregulated (green), and genes not 
overlapping with our data set (white) in each canonical pathway. The numerical value at the 
top of each bar represents the total number of genes in the canonical pathway. The secondary 
x-axis shows the −log of P-value calculated by the Benjamini-Hochberg (B-H) method; the 
B-H method was used to adjust the right-tailed Fisher’s exact test P-value, which indicates 
the significance of each pathway.  
Adjusting the rate helps to control for the fact that sometimes small p-values (less than 5%) 
happen by chance, which could lead to incorrect rejection of the true null hypotheses. In other 
words, the B-H procedure helps to avoid type I errors (false positives). 
Details of the top canonical pathways identified are listed in table 14.3. 
 
Table 7.13 - Top canonical pathways differentially expressed in SAP and MAP 
Ingenuity Canonical pathways P 
value 
Downregulated Upregulated No overlap with the 
data set 
     
T Cell Receptor Signalling 10.6 18/109 (17%) 2/109 (2%) 89/109 (82%) 
iCOS-iCOSL Signalling in T Helper 
Cells 
9.31 19/123 (15%) 0/123 (0%) 104/123 (85%) 
CD28 Signalling in T Helper Cells 5.32 15/132 (11%) 0/132 (0%) 117/132 (89%) 
PKCθ Signalling in T Lymphocytes 5.32 15/143 (10%) 0/143 (0%) 128/143 (90%) 
CTLA4 Signalling in Cytotoxic T 
Lymphocytes 
5.24 12/98 (12%) 1/98 (1%) 85/98 (87%) 
Calcium-induced T Lymphocyte 
Apoptosis 
5.04 11/70 (16%) 0/70 (0%) 59/70 (84%) 
Role of NFAT in Regulation of the 
Immune Response 
4.91 16/197 (8%) 1/197 (1%) 180/197 (91%) 
Natural Killer Cell Signalling 4.4 12/116 (10%) 1/116 (1%) 103/116 (89%) 
Hematopoiesis from Pluripotent Stem 
Cells 
4.4 8/63 (13%) 1/63 (2%) 54/63 (86%) 
Primary Immunodeficiency Signalling 4.37 9/62 (15%) 0/62 (0%) 53/62 (85%) 
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Regulation of IL-2 Expression in 
Activated and Anergic T Lymphocytes 
4.31 11/89 (12%) 0/89 (0%) 78/89 (88%) 
Systemic Lupus Erythematosus 
Signalling 
4.21 15/247 (6%) 1/247 (0%) 231/247 (94%) 
Phospholipase C Signalling 3.37 14/260 (5%) 3/260 (1%) 243/260 (93%) 
T Helper Cell Differentiation 3.32 7/72 (10%) 2/72 (3%) 63/72 (88%) 
Nur77 Signalling in T Lymphocytes 3.24 8/63 (13%) 0/63 (0%) 55/63 (87%) 
Type I Diabetes Mellitus Signalling 2.51 8/121 (7%) 2/121 (2%) 111/121 (92%) 
Role of Macrophages, Fibroblasts and 
Endothelial Cells in Rheumatoid 
Arthritis 
2.51 10/333 (3%) 8/333 (2%) 315/333 (95%) 
Communication between Innate and 
Adaptive Immune Cells 
2.51 8/109 (7%) 1/109 (1%) 100/109 (92%) 
CCR5 Signalling in Macrophages 2.45 8/94 (9%) 0/94 (0%) 86/94 (91%) 
OX40 Signalling Pathway 2.34 7/94 (7%) 0/94 (0%) 87/94 (93%) 
NF-κB Signalling 2.26 9/175 (5%) 3/175 (2%) 163/175 (93%) 
Role of Osteoblasts, Osteoclasts and 
Chondrocytes in Rheumatoid Arthritis 
2.2 8/238 (3%) 6/238 (3%) 224/238 (94%) 
Glucocorticoid Receptor Signalling 1.94 10/294 (3%) 5/294 (2%) 279/294 (95%) 
p53 Signalling 1.85 4/96 (4%) 4/96 (4%) 88/96 (92%) 
Cytotoxic T Lymphocyte-mediated 
Apoptosis of Target Cells 
1.85 6/85 (7%) 0/85 (0%) 79/85 (93%) 
Thyroid Cancer Signalling 1.6 4/42 (10%) 1/42 (2%) 37/42 (88%) 
IL-15 Signalling 1.56 6/67 (9%) 0/67 (0%) 61/67 (91%) 
Altered T Cell and B Cell Signalling 
in Rheumatoid Arthritis 
1.49 5/92 (5%) 2/92 (2%) 85/92 (92%) 
Role of MAPK Signalling in the 
Pathogenesis of Influenza 
1.49 5/69 (7%) 1/69 (1%) 63/69 (91%) 
Bladder Cancer Signalling 1.48 2/91 (2%) 5/91 (5%) 84/91 (92%) 
Crosstalk between Dendritic Cells and 
Natural Killer Cells 
1.48 7/95 (7%) 0/95 (0%) 88/95 (93%) 
IL-12 Signalling and Production in 
Macrophages 
1.47 6/156 (4%) 3/156 (2%) 147/156 (94%) 
Hepatic Fibrosis / Hepatic Stellate Cell 
Activation 
1.42 4/146 (3%) 5/146 (3%) 137/146 (94%) 
IL-6 Signalling 1.39 3/124 (2%) 5/124 (4%) 116/124 (94%) 
 
Figure below (7.41) depicts the genes involved in TCR signalling in our dataset. The 
downregulated genes are highlighted in green. This demonstrates the process of TCR 
activation which promotes a number of signalling cascades, resulting in cytokine production 
and progression of inflammation. Lymphocyte protein tyrosine kinase (Lck) and Zeta-chain 
associated protein kinase (Zap-70) become activated and further lead to recruitment of 
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inducible T cell kinase (Itk). This phosphorylates phospholipase C γ1 (PLCγ1) which in turn 
hydrolyses phosphatidylinositol 4,5-bisphosphate (PIP2) to produce the second messengers 
diacylglycerol (DAG) and inositol trisphosphate (IP3). IP3 triggers the release of Ca2+ from 
endoplasmic reticulum, which promotes entry of extracellular Ca2+ into cells through calcium 
release-activated Ca2+ (CRAC) channels. Calcium-bound calmodulin (Ca2+/CaM) activates 
the phosphatase calcineurin, which promotes IL-2 gene transcription through the transcription 
factor NFAT. 
 
Figure 7.41 - T Cell Receptor Signalling from the canonical pathways 
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Interestingly, NFAT was found to be the most abundantly expressed molecule in the 
differentially expressed canonical pathways. Out of the top 25, at least 12 pathways had 
NFAT as a key component, making it a crucial player in the pathogenesis.  
As is evident from the figure below (7.42), on antigen engagement of lymphocyte receptors, 
phospholipase C-γ (PLC-γ) becomes activated and hydrolyses phosphatidylinositol-4,5-
bisphosphate into inositol-1,4,5trisphosphate (IP3) and diacylglycerol. IP3 then binds to 
speciﬁc receptors on the endoplasmic reticulum and drives calcium release from the 
endoplasmic reticulum into the cytoplasm, which triggers STIM1 and Orai1-mediated 
opening of calcium release activated calcium channels. As a result of increased intracellular 
calcium, the calcineurin enzyme becomes active and dephosphorylates NFAT, allowing 
NFAT translocation into the nucleus and subsequent regulation of gene expression. It should 
be noted, however, that NFAT must ultimately bind to additional transcription factors, such 
as AP1 to regulate gene expression [344, 345]. 
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Figure 7.42 – Role of NFAT in regulating immune response from the canonical pathways 
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CHAPTER 8: MICRO RNA PROFILING 
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8.1 Samples Used  
 
Plasma samples obtained from patients with acute pancreatitis were used for this part of the 
project. These were obtained from patients at the time of admission and retrieved from 
Liverpool NIHR Pancreas Biomedical Research Unit Acute Pancreatitis Biobank, where 
these were stored as 1 ml aliquots. 
Multiple experiments were designed to optimise the RNA extraction protocol to ensure 
maximum concentration of total RNA. Following is the final optimised protocol. 
 
8.2 Total RNA extraction from Plasma samples 
 
One aliquot of 1 ml plasma was used for each patient. Protocol used was Plasma/Serum 
Circulating RNA Purification Kit from Norgen Biotek Corporation. 
 
8.2.1 Prior to extraction 
 
All centrifugation steps were performed at room temperature. 
All solutions were at room temperature prior to use. 
Wash Solution I was prepared beforehand by adding 14.5 mL of 95% ethanol to the bottle 
containing the concentrated RNA Wash Solution.  
Wash Solution II was also prepared by adding 10 mL of 95% ethanol to the bottle 
containing the concentrated RNA Wash Solution.  
1 ml aliquots were speed vacuumed to 500 µl to concentrate the RNA and maximise the 
yield. 
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8.2.2 Procedure of RNA extraction 
 
One mL of Lysis Solution was added to 500 µl of concentrated plasma sample. This was 
vortexed for 15 seconds. 
 
The lysate was incubated for 10 minutes at 60oC. 
 
1.5 mls of 96 - 100% Ethanol was added to the plasma sample. This was mixed by vortexing 
for 10 seconds. 
 
Lysate was then transferred to the Maxi Column assembly and vortexed for 15 seconds.  
 
The Maxi Column assembly was centrifuged for 2 minutes at 3,000 RPM, after which, the 
collection tube was removed and flow-through discarded. The Maxi Column was 
reassembled with the collection tube and process repeated till all the lysate was applied. 
 
700 μL of Wash Solution I was then applied to the column and centrifuged for 2 minute at 
3,000 RPM, the flow-through discarded and Maxi Column with the collection tube 
reassembled. The process was repeated one more time. 
 
700 μL of Elution Solution I was applied to the column and centrifuged for 2 minutes at 500 
RPM, followed by 3 minutes at 3,000 RPM. Maxi Column was discarded from the conical 
tube. 
 
One mL of Binding Solution was added to the eluted RNA contained within the conical tube 
and vortexed for 15 seconds. 
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0.5 mL of 96 - 100% ethanol was added to the resultant mixture. This was then mixed by 
vortexing for 10 seconds. 
 
700 μL of this mixture was applied onto the Mini Spin Column and centrifuged for one 
minute at 14,000 RPM. 
 
 This was repeated to load the rest of the sample. 
 
400 μL of Wash Solution II was applied to the column and centrifuged for one minute at 
14,000 RPM. 
 
 This was repeated a second time to wash the column. 
 
The column was centrifuged for 2 minutes at 14,000 RPM in order to thoroughly dry the 
resin.  
 
The column was placed into a fresh 1.7 ml Elution tube and 100 μL of Elution Solution 
II was added to the column. It was centrifuged for 3 minutes at 2,000 RPM, followed by two 
minutes at 14,000 RPM. 
 
The resultant total RNA was then used for further assessment. 
 
 
 
160 | P a g e  
 
8.3 Quantification of extracted RNA 
 
Aliquots of total RNA for quality control assessments were taken at the time of extraction. 
Concentration of the samples was analysed using Thermo Scientific NanoDrop™ 1000 
Spectrophotometer.  
 
8.4 Poly A tailing and ligation 
 
Following figure provides diagrammatic representation of the process of Poly A tailing and 
ligation of the extracted RNA (Figure 8.1). 
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Figure 8.1 – Poly-A Tailing and ligation (Adapted with permission) 
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8.4.1 Poly (A) Tailing 
 
Protocol used was FlashTag® Biotin HSR RNA Labeling Kit for Affymetrix® GeneChip® 
miRNA Arrays. 
 
The total RNA was in a final volume of 80 µl. This was speed vacuumed to a volume of 8 µl.  
 
All samples were heat denatured at 80oC for 10 minutes. 
 
ATP mix was diluted in 1mM Tris in a ratio of 1:500. 
 
2μl RNA Spike Control Oligos was added to the RNA sample, taking the total volume to 10 
µl. 
 
Following components were added to the 10μl RNA/Spike Control Oligos, for a volume of 
15μl and microfuged:- 
 
1.5μl 10X Reaction Buffer  
1.5μl 25mM MnCl2  
1.0μl diluted ATP Mix  
1.0μl PAP Enzyme  
 
The mixture was incubated in a 37oC heat block for 15 minutes.  
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8.4.2 FlashTag Biotin HSR Ligation 
 
15μl of tailed RNA was briefly microfuged and placed on ice. 
 
4μl 5X FlashTag Biotin HSR Ligation Mix and 2 μl of T4 DNA Ligase was added. The 
resultant mixture was gently mixed and microfuged. 
 
This was incubated at 25°C (room temperature) for 30 minutes. 
 
The reaction was stopped by adding 2.5μl HSR Stop Solution. The 23.5μl of ligated 
sample was mixed and microfuged. 
 
8.5 Affymetrix GeneChip miRNA Array Procedure 
 
8.5.1 Hybridization 
 
The 20X Eukaryotic Hybridization Controls (bioB, bioC, bioD, cre from GeneChip 
Eukaryotic Hybridization Control Kit) were completely thawed and then heated for 5 minutes 
at 65°C. 
 
The following components were added to the biotin-labelled sample in order to prepare the 
array hybridization cocktail:- 
 
50μl 2X Hybridization Mix  
15μl 27.5% Formamide  
10μl DMSO  
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5μl 20X Eukaryotic Hybridization Controls  
1.7μl Control Oligonucleotide B2, 3nM  
 
 The resultant volume was 103.2μl. This was incubated at 99oC for 5 minutes, then 45oC for 5 
minutes. 
 
100μl was aspirated and injected into an array (miRNA_2.0 array from Affymetrix). 
 
The pipette tip was removed from the upper right septum of the array and both septa were 
covered with 1/2" Tough-Spots to minimize evaporation and/or prevent leaks. 
 
Affymetrix Hybridization Oven 640 was turned on and preheated at the temperature of 48°C 
and RPM of 60. 
 
The arrays were placed into hybridization oven trays and loaded into the hybridization oven. 
 
The arrays were then incubated at 48°C and 60 rpm for 16 hours. 
 
8.5.2 Washing and Staining 
 
After 16 hours of hybridization, the arrays were removed from the oven and the Tough-Spots 
taken off. 
 
The hybridization cocktail was extracted from each array and transferred to a new tube in 
order to save the hybridization cocktail and stored at –80°C for long-term storage.  
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Each array was completely filled with Array Holding Buffer. 
 
The arrays were allowed to equilibrate to room temperature before washing and staining. 
 
Vials were placed into sample holders on the fluidics station:- 
 
One (amber) vial containing 600μl Stain Cocktail 1 in sample holder 1. 
One (clear) vial containing 600μl Stain Cocktail 2 in sample holder 2. 
One (clear) vial containing 800μl Array Holding Buffer in sample holder 3. 
 
These were washed and stained with Fluidics Station 450 using fluidics script FS450_0003. 
 
Post Hyb Wash #1 - 10 cycles of 2 mixes/cycle with Wash Buffer A at 25°C. 
 
Post Hyb Wash #2 - 8 cycles of 15 mixes/cycle with Wash Buffer B at 50°C. 
 
1st Stain: The probe array was stained for 10 minutes with Stain Cocktail 1at 25°C. 
 
Post Stain Wash - 10 cycles of 4 mixes/cycle with Wash Buffer A at 30°C. 
 
2nd Stain: The probe array was stained for 10 minutes with Stain Cocktail 2 at 25°C. 
 
3rd Stain: The probe array was stained for 10 minutes with Stain Cocktail 1 at 25°C. 
 
Final Wash - 15 cycles of 4 mixes/cycle with Wash Buffer A at 35°C. 
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The probe array was completely filled with Array Holding Buffer. 
 
Once it was ensured that there were no air bubbles, both septa were covered with 3/8" Tough-
Spots. The array glass surfaces were inspected for dust and other particulates prior to 
scanning. 
 
8.5.3 Scanning 
 
Once the protocol was completed, the arrays were ready to scan on the GeneChip Scanner 
3000. Affymetrix Command Console software was used to scan the genechips.  
 
Genechips were inserted into the scanner. Once scanning was completed, Affymetrix 
Expression Console was used to generate the quality control metrics to ensure adequate and 
appropriate processing of the arrays.  
 
8.6 Analysis 
 
The miRNA QC Tool software was used for data summarisation, normalisation, and quality 
control.  
Analysis was performed using appropriate packages in R/Bioconductor and using Partek 
Genomics Suite software. Expression level data were invariant set normalised. Differential 
expression of miRNAs in severe versus mild acute pancreatitis was detected using ANOVA 
with batch hybridization effects removed. The Benjamini and Hochberg multiple testing 
correction was applied to the resulting p-values. 
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8.7 Quantitative Assessments 
 
There were 20 samples included, ten of each mild and severe patients. These were processed 
in 4 batches with equal mix of both the groups to avoid batch effects and to ensure 
homogeneity among the samples. 
 
Samples in each batch are as summarised below. 
 
Table 8.1 – Samples included 
 
Batch 1 
 
AP040 
AP041 
AP042 
AP043 
AP044 
AP045 
AP046 
 
Batch 2 
 
AP051 
AP063 
AP065 
AP066 
Batch 3 
 
AP077 
AP103 
AP117 
AP144 
AP192 
 
Batch 4 
 
AP048 
AP091 
AP168 
AP177 
AP187 
Red highlighted samples are severe acute pancreatitis 
 
Following table (8.2) provides concentrations of the total RNA extracted from plasma of each 
patient for microarray experiments.  
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Table 8.2 – Total RNA concentration of the samples included 
 
Sample Concentration (ng/µl) 
  
AP040 3.3 
AP041 2.7 
AP042 1.5 
AP043 2.3 
AP044 0.9 
AP045 2.3 
AP051 3.9 
AP063 1.5 
AP065 2.4 
AP066 2.3 
AP077 4.4 
AP103 3.0 
AP117 2.0 
AP144 3.2 
AP192 3.6 
AP048 4.7 
AP091 6.2 
AP168 6.4 
AP177 4.6 
AP187 6.1 
 
The first step post hybridization and scanning of the arrays is the generation of quality control 
(QC) metrics to ensure efficient hybridization. Following are the QC metrics for the included 
samples. 
 
Table 8.3 - Quality Control Metrics of the hybridizations 
 
Samples Mean Intensity Mean Background 
Intensity 
Detected 
Probes* 
 
Detected 
Probe 
sets¥ 
     
AP040 86.63517 
  
39.03065 19149 3273 
AP041 85.28208 
 
39.56137 12894 1823 
AP042 74.03575 
 
36.58618 13356 1792 
AP043 84.91063 
 
39.05802 12305 1906 
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AP044 90.64921 
 
39.60151 12422 1987 
AP045 87.27647 
 
40.36115 13691 2088 
AP051 90.4346   51.05437 13940 2193 
AP063   89.57281 52.92628 
 
12599 1954 
AP065 76.81561   38.08247 14702 2406 
AP066   85.99326 41.41285 14468 2391 
AP077 80.21484   42.16008 13756 2231 
AP103   71.31986 38.12845 13346 1994 
AP117 73.73982   38.61769 12687 1577 
AP144   139.3286 47.36808 21823 3313 
AP192 83.2539 
 
40.13697 12677 1867 
AP048 80.46622 
 
39.51514 12555 1992 
AP091 84.81396    40.57718 17584 3018 
AP168   76.28916 38.0399 12608 1949 
AP177   75.0023 39.34704 11931 1598 
AP187 83.39607 
 
45.20448 13611 2361 
*
Out of total 202752 probes 
¥
Out of total 20643 probe sets 
 
The above table indicates uniformity and homogeneity among the samples that hybridized to 
accepted standards, making the data retrieved from them reliable and of biological 
importance. 
 
This was then further investigated in the form of box plots. These are as follows:- 
 
 
Figure 8.2 – Quality Control Metrics of Probe intensities of the House keeping genes 
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This figure (8.2) shows the log 2 expression of the probe intensities of the house keeping 
genes. This appeared to be fairly evenly distributed across all the samples, but sample 20 
seemed to be an outlier. 
 
 
 
Figure 8.3 – Quality Control Metrics of Perfect match intensities 
 
This was further confirmed on ‘perfect match’ intensities as well. But the expression level 
boxplot (see below) didn’t demonstrate this as clearly. Therefore, it was decided to proceed to 
principle component analysis for batch effects with 20 samples.  
 
 
Figure 8.4 - QC metrics box plot on Log Expression Signal 
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8.8 Principle Component Analysis 
 
Principle Component Analysis (PCA) was then performed to look for and correct batch 
effects and also to analyse differential expression. This was done using Parteik. While it 
showed grouping of the samples into mild and severe rather elegantly, sample 20 was an 
obvious outlier. Therefore, it was decided to remove this from the group and performed the 
rest of analyses with 19 samples (10 MAP, 9 SAP). Also, it was noted on the PCA plots that 
when classified according to batch dates, reassuringly, no significant clustering was observed. 
 
 
 
Figure 8.5 – Principle component analysis according to disease severity 
 
 
 
With Batch Effects 
Batch Effects Removed 
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Figure 8.6 – Principle Component Analysis according to date of sample processing 
 
8.9 Hierarchical Clustering and differentially expressed 
miRNA 
 
Based on FDR <0.05, 45 probes were identified that were differentially expressed in the two 
groups. These were all human probes.  
 
 
 
 
 
 
 
 
With Batch Effects 
Batch Effects removed 
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Figure 8.7 - Hierarchical Cluster Analysis of differentially expressed miRNA in mild and severe acute 
pancreatitis patients. Heat map depicting the miRNA expression patterns in 19 patients (10 mild and 9 
severe acute pancreatitis). This was calculated keeping the FDR p < 0.05. 45 differentially expressed 
miRNA were identified, out of which only 23 were annotated in IPA/MetaCore. Columns represent 
individual samples and rows represent each gene. Each cell in the matrix represents the expression level 
of a gene feature in an individual sample. Blue represents mild and red illustrates severe patients. 
Upregulated (high expression level) genes are coloured red whereas downregulated (low expression level) 
genes are shown as green. 
 
Here is the list of top 20 differentially expressed miRNA between the two groups in order of 
their ranking based on p value and the fold change. Complete list is provided in appendix 3. 
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 Table 8.4 – List of top 20 differentially expressed miRNA between MAP and SAP. 
Affy ID Adjusted p Value Fold Change 
   
hp_hsa-mir-631_st 0.013909811 -1.86365 
hp_hsa-mir-3129_x_st 0.013909811 -1.58772 
ENSG00000238824_st 0.013909811 -1.29649 
hp_hsa-mir-1291_s_st 0.018768512 1.813645 
ACA50_st 0.018768512 -1.31933 
ENSG00000212611_x_st 0.019781918 -1.26774 
hsa-miR-592_st 0.021760076 1.7757 
ACA9_x_st 0.021760076 -1.55509 
ENSG00000239005_x_st 0.021760076 -1.45394 
ENSG00000238450_x_st 0.022441665 1.509782 
hp_hsa-mir-3157_st 0.022441665 -1.4312 
ENSG00000238615_st 0.022441665 1.341408 
hp_hsa-mir-548n_x_st 0.024523767 -1.77023 
hsa-miR-302e_st 0.026509154 -1.52089 
hsa-miR-513c_st 0.026509154 1.452108 
hsa-miR-548j_st 0.028097164 -1.45883 
ENSG00000206898_st 0.03542224 -1.24917 
hsa-miR-758_st 0.03572517 1.638581 
hsa-miR-3187_st 0.03572517 -1.58219 
v49_ENSG00000200237_st 0.037128192 -1.12136 
 
Role of miR-631 is well studied in prostate cancer. It is avowed to inhibit the migration and 
invasion of prostate cancer cells. Related canonical pathways are metabolism and 
glycosaminoglycan metabolism. 
miR-1291 (derived form SNORA34) has has been implicated in pathogenesis of various 
related and unrelated malignancies and disease processes. It was downregulated in clinical 
pancreatic ca samples and human pancreatic cancer cell lines and was also found to have 
significantly lower expression in oesophageal squamous cell carcinoma by acting as a tumour 
suppressor by targeting Mucin 1 (MUC1). High circulating levels have also been related to 
acute myocardial infarction. Loss of tumour repressive miR-1291 enhances renal cell 
carcinoma proliferation, migration and invasion through targeting SLC2A1/GLUT1. It is also 
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a biologically relevant regulator of GPC3 expression in hepatoma cells and acts through 
silencing of the endoplasmic reticulum stress sensor IRE1alpha. 
miR-758-5p is another miRNA that has been associated with varying disease processes but 
its role is mainly defined in cholesterol metabolism. It decreases lipid accumulation of foam 
cell by regulating CD36-mediated cholesterol uptake and its expression is significantly 
upregulated in hyper-cholesterolemic plaques, perhaps through regulating Cholesterol-Efflux 
Regulatory Protein (ABCA1).  It has also been suggested that it may serve as a potential 
diagnostic biomarker for lupus nephritis in patients with systemic lupus erythematosus (SLE). 
It also mediates Hepatitis C virus infection induced changes in Toll like Receptor 3 and 7.  
Small nucleolar RNA SNORA70 (U70) is a non-coding RNA (ncRNA) molecule which 
functions in the biogenesis (modification) of other small nuclear RNAs (snRNAs). 
miR-592 has been linked to progress of various malignant processes. It has been laid out to 
be a novel and a potential carcinogen-initiated and metastasis-related biomarker in colorectal 
cancer, and down-regulation of miR-592 has been given due consideration as a potentially 
significant molecular treatment strategy for these patients [346, 347]. Overexpression of miR-
592 has been shown to reduce cell proliferation, migration and invasion and induce cell arrest 
at G1/G0 phase in glioma tissues and cell lines. It was also demonstrated to yield smaller 
tumour volume and weight, specifying a promising application for its use in glioma treatment 
[348]. In addition to glioma, miR-592 is being considered as a promising therapeutic target 
for non-small cell lung cancer, due to its function as a tumour suppressor by suppressing 
SOX-9 [349].  
miR-513 is expressed in human cholangiocytes and is down-regulated upon IFN-γ exposure. 
It regulates B7-H1 (a molecule that plays a critical role in immunomodulation of the cell 
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mediated immune response) translation and is involved in IFN- γ induced B7-H1 expression 
in the cholangiocytes. This emphasises role for miRNA mediated gene silencing in the 
regulation of cholangiocyte response to IFN- γ [350]. 
Small Nucleolar RNA (SnoRNA) U13 (SnoU13) was first described in 1989 [351]. It has 
been well characterized in 35 species by both functional assay and prediction. It is involved 
in the nucleolytic cleavage at the 3′ end of 18S rRNA where it works as a trans-acting factor. 
SnoRNAs, in general, are poorly understood. While it is well known that they form the 
majority of non- coding RNAs, their functional value and role in cellular interactions is still 
largely unknown. Traditionally, snoRNAs have always been thought to be exclusively inside 
the nucleolus and Cajal bodies, involved in maturation of ribosomal RNA (rRNA) and small 
nuclear RNA (snRNA) locally [351, 352].  A recent study has however demonstrated that 
while more than 99% of the U13 snoRNAs are nuclear in their location in unstressed cells, 
cytoplasmic presence of snoRNA has been manifested by qPCR and RNA-seq, in response to 
stress, where their cytoplasmic abundance as a class is dynamically regulated by oxidative 
tone and is very rapid and significant. Because the nuclear snoRNAs are in vast excess to the 
cytoplasmic snoRNAs, even small changes in the nuclear pool would be expected to create 
large relative changes in the cytoplasmic pool. This study also suggests that cells have robust 
mechanisms for maintaining the cytoplasmic levels of snoRNAs and that detection of 
snoRNAs in the cytoplasm is not simply a “mass effect” in which some proportion of 
snoRNAs spill over into the cytoplasm [353]. It also entertains the possibility of anti-sense 
interactions of U13 snoRNA and the cytoplasmic mRNAs which could result in nucleotide 
modifications. It is safe to say that U13 snoRNA potentially could exert far reaching effects 
on cytoplasmic functions, a lot more than previously thought to be.  
Small Nucleolar RNA U30 thought to act as a 2'-O-ribose methylation guide for ribosomal 
RNA [354].  
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Small Nucleolar RNA ACA 9 (SnoRA9) guides the sites of modifications of uridines to 
pseudouridines [355]. 
Small nucleolar RNA SNORA50 (also known as ACA50) is a non-coding RNA which 
affects modification of other small nuclear RNAs (snRNAs). ACA50 was originally cloned 
from HeLa cells and belongs to the H/ACA box class of snoRNAs. SnoRNA ACA50 is 
predicted to guide the pseudouridylation of U34 and U105 of 18S ribosomal RNA (rRNA) 
[355]. 
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CHAPTER 9: DISCUSSION 
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In this observational, translational study, including 58 patients with acute pancreatitis, it has 
been identified and established that severe and mild acute pancreatitis are two different 
disease groups. While the underlying basic mechanisms of initiation of the disease may stand 
true for both of them, the progression is governed by different pathways altogether. It begins 
to explain why the outcomes and disease courses are so different for the same disease. The 
microarray experiments have identified various genes (98 genes with a fold change of 1.5) 
that are differentially expressed between mild and severe pancreatitis. Most of these 
differentially expressed genes are associated with various inflammatory processes and are 
involved in remodelling of extracellular matrix, recruitment of inflammatory cells, cellular 
proliferation and angiogenesis. These are all well-known early and key events in the initiation 
and progression of acute pancreatitis. Results confirm their significance in the disease 
process. By associating particular genes to these individual processes, it makes a lot of 
scientific sense to investigate these as potential biomarkers, especially early on in the disease 
course.  
Most interestingly, the functional analysis has shed light on the immune response in the 
disease and pathways involved. T cell signalling pathways have been found to be among the 
top most significant canonical pathways. This is a very important finding. This indicates a 
role of adaptive immunity in pathogenesis that has not been explored and emphasised on 
before.  
Another important canonical pathway that has been diagnosticated to be differentially 
expressed in SAP is ‘role of NFAT in immune response’. Its significance lies in the fact that 
NFAT has also been noted to be the most significantly implicated gene in our dataset, being a 
key molecule in at least 12 different pathways (out of the top 25 most differentially expressed 
pathways). This is of particular importance. 
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Based on a pilot study of 19 samples including mild and severe patients, a differential 
miRNA expression between the two disease states was successfully demonstrated. The 
groups separated out as two different entities, based on the miRNA expression. This was 
clearly demonstrated on hierarchical clustering. At least 45 miRNA were identified to be 
differentially expressed between the disease states. This was based on FDR of <0.05. These 
miRNA are the point of interest. Looking into their function, specification and interaction 
with mRNAs and targets will provide invaluable information on the pathogenesis of the 
disease but also an insight into potential biomarkers. Interpreting canonical pathways for 
miRNA implicated in this dataset would have to be considered with caution – not much is 
known about them and therefore, lack of evidence for links to a particular function does not 
translate to absence of it. In fact, most of the differentially expressed miRNA in this dataset 
have been found to be of prognostic/predictive value in various malignancies and their role in 
the setting of inflammation, infection or sepsis is largely unknown.  
Of particular note, was the abundance of sno RNAs in our dataset – in fact, almost 50% of 
our most differentially expressed miRNA were found to be sno RNAs. Small Nucleolar RNA 
(sno RNA) represent a class of regulatory RNAs responsible for post-transcriptional 
maturation of ribosomal RNAs (rRNAs). Since defects in ribosome maturation and function 
can cause disruption of vital processes and lead to diseases and transformation of normal cells 
into tumour cells [356-358], it is well reasoned to postulate that snoRNA level can affect 
physiological condition of cells, tissues, and organs, thereby leading to various diseases. 
9.1 Biomarker Research in Acute Pancreatitis 
 
Acute pancreatitis continues to be a clinical challenge. While management of the disease is 
uncertain and unpredictable at best, prognostication poses an even bigger problem. Severe 
acute pancreatitis, especially, is associated with high morbidity and mortality and therefore, 
181 | P a g e  
 
early identification is the key. The current scoring systems require at least 48 hours to be of 
full use and even then, suffer from low sensitivity. The crying need of the time is an efficient, 
robust clinical system, whereby a patient diagnosed to have AP can readily be stratified into a 
category with good confidence and outcomes predicted. This will help to allocate clinical 
care in the best suited manner. This will be particularly useful in clinical trials, where 
categorisation of patients into an appropriate group is of paramount importance. Accurate 
disease stratification ensures effective assessment of the impact of the treatment. Once a 
reliable method/molecules is/are identified, this can then be exploited to not only assess 
severity at the time of admission but also predict different outcomes, i.e., necrosis, organ 
failure, death etc. 
Biomarker discovery has taken an accelerated pace in recent times and is taking advantage of 
ever growing technologies. The approaches involved are multidisciplinary, from basic to 
translational and clinical research. As biological processes are complex, multi-technological 
approaches are crucial in understanding the basic pathophysiology. Prognostication in acute 
pancreatitis is still evolving. From implementation of Ranson’s Score in 1974 [359] to the 
new genomic markers in the form of miRNA, we have come a long way in unravelling the 
mysteries of pathophysiology that have led the path for discovering more reliable and 
clinically useable biomarkers. However, this unfortunately still hasn’t translated into ultimate 
success. We still do not have any biomarker/panel of biomarkers which is efficient enough. 
More and more clinical parameters and molecular entities are being tested every day.  
Many clinical and biochemical markers and scoring systems have been tried in the clinical 
and experimental arenas – Modified Glasgow scale, APACHE II, organ failure related 
scoring systems(SOFA, Marshall, MOF/Goris), radiologic scores (Balthazar, CTSI), CRP and 
procalcitonin are some examples. Cytokines are at the helm of prognostication – there is 
already sizeable, well established body of data, grounding its claim to be reliable in 
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predicting severity in AP [360-362]. However, because of their limitations, no cytokines are 
useful enough to indicate disease progression of AP with simplicity and accuracy for routine 
clinical use. Recently, Growth differentiation factor-15 (GDF-15) and pentraxin 3 (PTX3) 
have been shown to have higher discriminatory value than the traditional markers of CRP and 
APACHE II in AP [363]. Another study found quantitative assessment of raised histone 
levels in plasma (from early death of immune cells) to be accurate in predicting persistent 
organ failure and mortality in patients with AP [364].  
Results from Early Achievable Severity (EASY) index trial are awaited with great 
anticipation [365]. This is the first multi-centred, international trial that will endeavour to 
identify factors, predicting severity of AP by way of easily obtainable parameters which are 
not only quick to gather but are also representative of the disease course. Along the same 
lines, is the establishment of Acute Pancreatitis Patient Registry to Examine Novel Therapies 
in Clinical Experience (APPRENTICE) [366]. It is yet another international, multi-centre 
consortium that aims to better understand the natural history of AP worldwide and to develop 
a platform for future randomized clinical trials. This electronic prospective registry will be 
fed from high-volume international centres with expertise in pancreatic diseases and will 
describe the current trends of demographics, risk factors, clinical profile, treatment patterns, 
and outcomes of AP around the world. In addition, the establishment of this unique 
international collaboration will not only serve as a bank for proteomic and genomic data from 
the included patients it will also allow for it to be used as a platform for future randomized 
clinical trials that can translate new therapies in less time and with a diversified patient 
population.  
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9.2 T Cell Signalling and Role of Adaptive Immunity In Acute 
Pancreatitis 
T cell depletion (CD4+ and CD8+) in the peripheral blood in the setting of SAP is now a 
celebrated fact. Many studies have substantiated the claim [254, 367-371]. This begs the 
question – why? What mechanisms are at play here? It would be reasonable to assume, for 
starters, that SIRS forces lymphocyte influx into the site/s of inflammation, like pancreas, 
lungs or kidneys, thereby, depleting the peripheral blood of its presence [372]. It has to be 
borne in mind that peripheral lymphocytes constitute a very small proportion of the total 
population as most of it is constantly being redistributed between other lymphoid tissues and 
organs [373], and therefore, a fall in the peripheral count does not necessarily represent 
impaired immune response [368]. Be that as it may, recent studies have now implicated role 
of apoptosis in eliminating excessive T cells which have been found to be primed to 
apoptosis in AP [369, 374]. Indeed, thymic atrophy as a consequence of apoptosis occurs 
during SAP in rats [375]. Also backing this piece of evidence is TGF β and intracellular 
calcium mobilisation induced apoptosis of lymphocytes in rat models of pancreatitis [369, 
376]. During the course of the disease, CD4+ are depleted, both in MAP and SAP, whereas 
CD8+ cell population is relatively unscathed [374] but this does not necessarily translate into 
impaired host immunity as the CD4+:CD8+ ratio remains unchanged.  Among the CD4+ 
cells themselves, Th1 CD4+ cells have been found to be more suppressed than their Th2 
counterparts. This has been eloquently described in many studies and confirmed by a much 
sharper rise in the Th2 cytokine production as opposed to Th1 [369, 374, 377], prompting a 
Th1/Th2 cytokine imbalance and a resultant depression of host’s immune mechanisms. It is 
important to briefly mention the role of regulatory T cells (Tregs), whose expression seems to 
increase through varying stages of SAP. These cells regulate immunosuppression through 
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their anti-inflammatory and immunomodulatory roles and may provide a compensatory 
response to the systemic inflammation in SAP [378, 379]. 
Experimental models of pancreatitis have hailed T cell activation to be at the centre of 
systemic immune-inflammatory response that is hallmark of AP. T cell deficient and CD4+ 
depleted mice developed a less severe disease than their healthy counterparts [380], turning 
the spotlight to the role of the adaptive immune response in this cascade. The very same 
paper also presented a plausible notion that T cells remain immunocompetent and augment 
immune responses locally and systemically, much like a burn injury, where the insult primes 
the immune system for an augmented T cell effect that could potentially precipitate a fatal 
shock like syndrome [381].  
9.3 Nuclear Factor of Activated T Cells (NFAT) as the Key 
Player in Determining Severity in Acute Pancreatitis 
 
Nuclear Factor of Activated T cells or NFAT was first described as an inducible nuclear 
factor binding to the Antigen Receptor Response Element – 2 (ARRE-2) of IL-2 promoter in 
human T cells [382, 383]. At the time of inception, it was considered to be exclusively 
associated with and expressed by T cells. However, further works have made evident its 
intimate involvement with various immune and non-immune cells and authenticated its 
pivotal regulatory role in inflammation, embryonic development, organogenesis, cell 
development and differentiation, cell motility, angiogenesis, tumorigenesis and cell survival 
[384-387]. The NFAT family consists of five members, four of which are calcium responsive 
(NFAT1-4) [388-392] and are activated by Ca2+ influx in the cell. This is either mediated 
through the PLC-γ pathway or store operated Ca2+ entry, particularly in lymphoid T cells 
[393]. Once intracellular levels of calcium increases, Calcineurin (a unique 
calcium/calmodulin-activated serine/threonine protein phosphatase) dephosphorylates the 
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isoforms, thereby activating them and leading to nuclear translocation [394-396], where 
active transcription of downstream gene targets subsequently occurs. This in fact, establishes 
a direct link between calcium signalling and gene expression [387, 397, 398].    
Evidence for role of NFAT signalling in inflammation and sepsis is accumulating. Studies 
have identified it to be critically important in various inﬂammatory responses [399] where it 
increases the expression of proinﬂammatory cytokines including interleukins (IL 2,3,13), 
TNF α, GM-CSF and MIP [400, 401]. NFAT is now known to be activated during sepsis and 
regulates expression of macrophage specific inducible nitric oxide synthase which is crucial 
for bactericidal activity of macrophages [402]. In the further extension of the same line of 
work [403], authors demonstrated in a murine model of sepsis induced acute lung injury 
(ALI) that NFAT regulated inflammatory genes produced by macrophages which seemed to 
be restricted to macrophages only. They stimulated NFAT deficient macrophages with LPS 
and discovered resultant attenuated expression of several cytokines, chemokines, and their 
receptors, thus translating to a profound phenotypic effect of NFAT deletion in sepsis 
induced ALI. NFAT deletion also showed decreased pulmonary oedema, neutrophilic 
inflammation and improved arterial oxygenation and survival. 
In addition, NFAT activation has been hailed as a momentous step in regulating neutrophil 
recruitment, systemic inflammation and T-cell dysfunction during abdominal sepsis [404]. 
Role of NFAT members in different mouse disease models such as spontaneous pulmonary 
hypertension, diabetic retinopathy and regulation of innate immune responses to fungal 
pathogens is well documented [405-407]. 
A study by Awla et al in 2012 avowed for the first time the key role of NFAT in AP [408]. 
They showed AP was associated with increased NFAT transcriptional activity which was not 
limited to pancreas only and instead, featured in the lung, aorta and spleen too. This indicated 
186 | P a g e  
 
that AP is associated with local and systemic activation of NFAT signalling. NFAT deficient 
mice did not exhibit activation of trypsinogen, tissue damage and neutrophil infiltration in the 
lung or pancreas. They demonstrated and concluded that NFAT signalling is involved in the 
activation of trypsinogen in the pancreas, co-ordination of neutrophilic infiltration, regulation 
of systemic pulmonary recruitment of neutrophils and transcriptional regulation of CXCL2 in 
the pancreas, setting its activity at the heart of the initiation of the disease. Another far 
reaching notion from this study is the role of NFAT signalling in innate immunity, when it 
has traditionally been exclusively associated with adaptive immune response. The authors 
proved through experimental models that initiation of AP which was largely driven by innate 
immune responses was highly dependent on NFAT signalling, implicating it as a powerful 
component of the innate inflammatory response. Another study also  that Toll-like receptor 
signalling in bone marrow derived macrophages appears to be dependent on NFAT activity 
[409].  
 
A fascinating proposition was put forward by in 2010 by da Costa Martins et al. – they 
believed that a strong and perhaps vital interaction existed between NFAT and miRNA, 
where both affected and regulated function [410]. This was further authenticated by another 
study that demonstrated miRNA induced suppression of DYRK1A which reduced nuclear 
export of NFAT and hence activated it. This may translate into a genetic and an epigenetic 
role for NFAT, affecting various cellular signalling molecules [411]. It still remains to be 
seen as to how this works in the setting of inflammatory systemic diseases, such as acute 
pancreatitis, since most of the evidence is in setting of tumorigenesis. Nonetheless, it stands 
as a viable, potential area of study. 
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In addition to its seminal functions in immune surveillance, NFAT has secured a reputation 
for itself as a key player in diverse pathophysiological states, both inflammation and cancer 
included. The substratal principle underlying the two main pathologies remains the activation 
of NFAT proteins in the nucleus and binding to the DNA to cause transcription of its 
downstream targets. NFAT activity has been shown to be crucial for cell survival and 
proliferation, invasive migration, and angiogenesis. Up till now only few mediators of the 
NFAT signalling axis have been identified - several others remain to be discovered. But more 
important than that, we need to have a clearer idea of the processes that drive NFAT 
activation. Possible mutations and/or amplifications in NFAT binding partners and 
export/maintenance kinases may be responsible. – these are frequently seen in several disease 
processes that are associated with constitutive NFAT nuclear localization. It is perfectly 
reasonable to opine that there is a lot of cross talk between NFAT and other pro-
inflammatory signalling pathways, since NFAT is closely linked to inflammation. Role of 
calcium signalling in this setting, particularly with reference to Calcineurin/NFAT pathway, 
cannot be over-emphasised. However, it is still a long way before a case for the use of agents 
inhibiting release of intracellular calcium release to block NFAT mediated cellular activities 
can be made. Nonetheless, these findings are encouraging for development of better 
therapeutics with multi-modal mechanism of action in human diseases. 
 
Another important and extremely significant interaction to consider in our dataset is between 
calcium/calmodulin dependent phosphatase, Calcineurin and NFAT, both of which were 
found to be significantly downregulated in SAP. Canonical activation of NFAT family 
members depends on cytosolic rise in calcium levels, contributed either from the endoplasmic 
reticulum or from extracellular matrix. This activates calcineurin which leads to the nuclear 
import of NFAT by dephosphorylating residues and causing exposure of a nuclear 
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localization sequence [412]. After nuclear import, NFAT reaches out to its nuclear binding 
partners and activates the expression of NFAT dependent inflammatory and 
immunomodulatory cytokines [413, 414].  
What makes role of NFAT so important, yet complex in immunity? They are the ‘star’ 
molecules that bridge the innate and adaptive immune responses and also modulate 
inflammatory responses [399, 415]. We know from evidence that the expression of NFAT 
family members is cell specific and these have differential binding ability to coactivators. 
This may explain their distinct roles in the immune system [344]. The calcineurin NFAT axis 
plays an extremely meaningful role in acquired immunity – in fact, it forms the basis of 
immunosuppressive treatment in transplant recipients [344, 416]. Per contra, its relevance and 
contribution in innate immunity is still poorly understood, although there has been a study 
implicating role of NFAT family members in neutrophil mediated innate immunity during 
fungal infection with Candida albicans [417]. 
NFAT regulation and NF-kB signalling were found to be among the most differentially 
expressed canonical pathways in the current study group. Crosstalk between these two has 
been identified in previous studies in the context of infection [418]. The two families share 
Rel homology domain structure, recognise similar DNA binding sequences and work hand in 
hand to regulate inflammatory cytokines and chemokines [419-421]. Indeed, studies have 
shown direct interaction between NFAT and NFκB that effectively integrates 2 disparate 
signalling pathways in promoting cardiac hypertrophy and ventricular remodelling [422]. 
While specific mechanisms of these interactions are yet to be determined with certainty, it 
has been thought to be through their synergistic promotion of gene expression or through a 
non-coding RNA, which serves as a scaffolding platform for the interaction to occur [423, 
424]. Moreover, Calcineurin has also been found to improve NFkB activity through 
dissociation and degradation of IkB (inhibitory molecule) [425]. 
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It is now well established that NFAT plays a crucial role not only in activation of T cells, but 
also in regulation of many aspects of T cell function. Therefore, it is no surprise that it has 
been considered as a potential target for immune regulatory therapeutics. Calcineurin 
inhibitors, such as cyclosporine A and FK506, renowned for their use as immunosuppressors 
to treat graft rejection and autoimmune diseases [426-429] , block calcineurin enzymatic 
activity and therefore, cannot be classified as true NFAT inhibitors [430]. These will block 
any other target that is dephosphorylated by calcineurin, possibly causing various toxicities 
associated with their use [431, 432]. The solution to this quandary was identified in the form 
of VIVIT peptide, a selective inhibitor of calcineurin mediated dephosphorylation of NFAT, 
which was found to prolong graft survival in experimental model of islet cell transplantation 
[433]. While far more promising than the earlier alternatives, these peptides still have the 
potential of blocking calcineurin interactions with other substrates like calcineurin inhibitors 
(CABIN1/AKAP79) [434]. Answer to this predicament appeared in the form of mutations in 
the two different regions of calcineurin that were pivotal to calcineurin and NFAT 
interactions [434, 435]. These newly identified mutations not only selectively impaired 
calcineurin binding to NFAT but also did not seem to affect any interactions between 
calcineurin and its other substrates [435]. This, unquestionably, constitutes a reasonably 
attractive target for design of even more precise inhibitors. As fascinating as the use of these 
peptide inhibitors appears, there are some plausible issues with their delivery, which could, in 
principle, be overcome by making use of smaller organic molecules by incorporating 
structural changes that consequently improves specificity, stability, delivery and distribution. 
Roehrl et al. [436] came up with a list of compounds in 2004, using Fluorescence 
Polarization Assay, which specifically inhibited calcineurin and NFAT interactions, 
culminating in impairment of NFAT dependent cytokine production by T cells. This was 
closely followed by Venkatesh et al  [437] who used a slightly different cell based method to 
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identify inhibitors of nuclear translocation of NFAT which acted by blocking store-operated 
calcium channels and hindering calcium mobilisation. These two approaches have provided 
immensely useful molecules that act upstream of calcineurin, aptly block NFAT dependent 
transcription and also consolidate cyclosporine effects [437]. These avenues can also be 
exploited to identify small molecules that will be selective and specific enough to modulate 
specific NFAT regulated functions. Also to ponder over is the matter of interactions between 
NFAT and its specific transcriptional partners which may be at the heart of complex 
signalling pathways that NFAT integrates into, to control various and numerous cellular 
programmes. The key would be to identify the protein-protein contact surfaces that are 
specific for these interactions. Molecules could then be designed and modified accordingly to 
regulate specific functions. These therapeutic molecules could revolutionise the treatment, 
improving the toxicity profile.  
9.4 MicroRNA and SnoRNA as potential Biomarkers in Acute 
Pancreatitis 
 
MiRNA have emerged as fantastic, novel biomarkers with many advantages to their 
credentials. Unlike mRNA, they are incredibly stable in circulation (blood, urine and tears) as 
they are protected from RNases and endure long-term storage well. A single miRNA 
regulates expression of multiple mRNA and therefore, offers complexity to the process and 
has rightly been implicated in the pathogenesis of many a disease processes. Recent studies 
have corroborated that miRNAs are not just the by-products of cell lysis. They possibly enter 
circulation by being packaged into endosomes or simply avoid degradation by associating 
with argonaute or nucleophosmin [299, 301, 302]. Another neoteric role for miRNA is as 
signalling molecules, for they affect functioning of distant cells once out in the circulation, 
perhaps by influencing the gene expression of the target cells [299]. Their ability to control 
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gene expression without affecting DNA sequence makes them one of the most powerful 
epigenetic regulators.  
Most of the published work on miRNA biomarkers to date has been for cancer diagnosis. 
Many serum/plasma studies have proﬁled the most abundant miRNAs in the tissue of interest 
and then assayed these in the circulation on the assumption that miRNAs that are high in the 
tissue will be secreted and readily detectable in blood. This is truly applicable in case of acute 
pancreatitis. It will not be clinically and technically feasible to sample pancreatic tissue in 
patients who are acutely unwell. If a peripheral blood sample, which is much easier to obtain, 
can provide the same information, such as miRNA profiling reflective of the pancreatic 
tissue, this could revolutionise the prognostication in this disease state.  
To the best of our knowledge, this is the first study that has demonstrated the involvement of 
snoRNA in acute pancreatitis. The specific role of snoRNA in many disease processes 
remains a bit of an enigma. While their functions largely remain unknown, there is emerging 
evidence of their involvement in malignant, neurodegenerative and viral diseases. In fact, 
they are slowly being recognised as fantastic biomarkers – a new study from China has 
implicated snoRNA in pathogenesis of colorectal cancer (CRC) and progression from 
ulcerative colitis to adenocarcinoma, linking it to the ‘inflammation to malignancy’ pathway 
[438]. They showed that snoRA15 and 41 were upregulated in CRC and as such, behaved as 
‘oncogenes’, due to their location at the genomic amplification regions that are 
characteristically associated with oncogenic function [439]. It was also noted that snoRD33 is 
downregulated in CRC and may well be a ‘tumour suppressor’, as it suppresses cancer cell 
growth and metastasis to distant organs by blocking antioxidant pathways [440]. Following 
the pattern, they identified the same snoRNA to be upregulated in UC patient samples as 
well. However, snoRD33 expression was found to be highest in CRC, lowest in controls and 
in between in UC, creating a place for this particular snoRNA as a mediator to promote colon 
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inflammation. This study very sensibly provides a link between inflammation and 
carcinogenesis. Expression of these snoRNAs was also found to be associated with disease 
severity, rendering them particularly useful as biomarkers for CRC prognosis and also for 
differentiating UC from CRC. This is extremely significant in terms of disease management.  
snoRNA are very stable in plasma and serum and lend themselves to be excellent biomarkers 
that can be easily employed in the clinical setting [441]. In fact, use of a snoRNA based 
biomarker panel in setting of non-small cell lung carcinoma has been very encouraging with 
81.1% sensitivity and 95.8% specificity [442].  
There is no direct evidence of involvement of snoRNAs in inflammation or sepsis and 
perhaps, this represents an area of unmet need. They categorically have proved themselves to 
be incredible biomarkers and their role in the setting of sepsis and acute pancreatitis, where 
there is a critical need for specific and sensitive biomarkers, is undoubtedly an area for future 
research. It is hoped that the next step would be quantitative assessment and then validation 
in an independent cohort.  
This study is not without its fair share of limitations, which must be acknowledged and taken 
into account while interpreting the results. Sample size, while representative of the 
population, is smaller than anticipated. This was partly due to the fact that the process of 
recruitment was prospective and severe patients were difficult to recruit as opposed to mild 
acute pancreatitis. Sometimes, these patients with SAP were too unwell to consent to 
participate in the study and therefore, couldn’t be included. Also, these patients were not as 
frequent to present as the mild acute pancreatitis, following the natural distribution of the 
disease severity. Being the tertiary referral centre for SAP, many patients were transferred 
from other hospitals later than 24 hours of presentation and hence were not eligible for 
inclusion.  
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While transcriptomic analysis is a very powerful tool for investigating molecular changes in 
different biological states, caution has to be exercised in interpreting the data. RNA profiling 
methods measure the concentration of RNA at a specific state and therefore, it is a plausible 
speculation that dynamically modulated processes and transcripts could be missed. 
Additionally, it does not inform of the regulatory changes associated with translation or of the 
effects of modulation by other proteins. Sample heterogeneity and preparation can introduce 
some serious bias in the results. While all care was taken to exclude batch effects, it is 
impossible to exclude it completely. Finally, both the RNA and miRNA profiling methods 
can only observe the average effect of multiple cell types and numbers of cells in different 
states in the sample which can add uncertainty to the data.   
Further works would almost certainly involve characterising the mRNA and miRNA better 
and understanding and identifying their targets. The list generated from this study of potential 
candidate genes and miRNA is not exhaustive but most definitively a step in the right 
direction. Next step should be quantification of these in AP patients and assess their value as 
prognostic markers. 
It is anticipated that the next five years will see a rapid expansion in the use of molecular 
diagnostic tests. This is likely to be particularly true for the introduction of mRNA and 
miRNA-based tests. Several companies are developing tests that utilize these for determining 
the diagnosis or prognosis of a variety of diseases. However, the increasing use of high 
content platforms, such as microarrays, is leading to identification of marker panels, therefore 
driving us towards the adoption of multiplex detection platforms and multiple marker tests. 
Given the fact that acute pancreatitis is a complex disease with multiple pathways involving 
intricately linked innate and acquired immune mechanisms, a panel of biomarkers is likely to 
be more suited than a single agent. This requires validations studies and testing in clinical 
trials settings.  
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CONCLUDING REMARKS 
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This observational, pilot study has successfully demonstrated that mild and severe acute 
pancreatitis are two distinct groups and exhibit different courses of disease, evident at the 
molecular and genomic levels. Microarray based experiments have clearly delineated the two 
groups and have also provided useful insights into the pathophysiology, highlighting the key 
pathways and molecules involved. This is of immense value, hinting at potential lines of 
enquiry for ascertaining prognostication and treatment in AP.  
NFAT emerged as the most significantly differentially expressed molecule, playing a pivotal 
role in many dynamic processes found to be associated with the disease.  The relevance of the 
calcium-regulated NFAT transcription factors to the regulation of many aspects of T-cell 
function is well stated in the more recent literature. In fact, during T-cell activation, most 
cytokine genes are regulated by NFAT proteins. As in line with the recent studies, our study 
has also identified role of NFAT in targeting many other genes that influence the activated T 
cells. The answer perhaps lies, in part, with the molecular structure of NFAT DNA-binding 
domain – this has various surfaces, allowing for interactions with different transcriptional 
factors that result in integration of NFAT into many signalling pathways. 
Future studies should focus on better characterisation of regulatory mechanisms surrounding 
NFAT activation, in the hope that newly identified transcriptional factors and target genes 
will give a better overview of the involvement of NFAT in various processes, not only 
including T cells but also other cells of the immune systems and spot the mechanisms that 
regulate them too. 
Another area of future endeavours, which already has attracted a lot of interest, is that of 
NFAT inhibitors and their development. While these have been tried in various trials, results 
have been far from encouraging. Derivatives of cyclosporine, although having been evaluated 
in phase III clinical trials, have not resulted in any commercial products, likely due to their 
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potential toxicity. Natural compounds possessing NFAT inhibition activities are 
unfortunately less potent. Peptide inhibitors of NFAT appear more lucrative as these are less 
toxic and have appeared to hold good potential as drug candidates in recent experimental 
models.  
Micro RNA hold a great deal of promise as biomarkers. The last ten years have seen a rapid 
rise in recognition of their ability to serve as potential biomarkers in diagnostic, prognostic 
and predictive arenas. This study has identified miRNA that are differentially expressed 
between MAP and SAP and their use and development in the field of severity stratification is 
within realm of possibility.  
In short, Genomics has presented us with, in the recent times, an extremely useful and 
powerful tool to investigate how molecular networks change between biological states. There 
are however, limitations to their application. It is possible to miss dynamically modulated 
processes and transcripts with most RNA experiments that measure the concentrations of 
RNA (for both mRNA and miRNA) at a specific state. Also, one can only contemplate the 
average effect of various cell types and numbers of cells in different states in the sample. It is 
also almost impossible to detect regulatory changes with the processes of translation. With 
regards to miRNA, their levels may not always correspond to their regulatory activities which 
in turn could have been modulated by other factors/molecules.  
One of the most confounding factors in RNA based experiments is the sample preparation 
and ensuring uniformity in sample handling and taking into account the heterogeneity of the 
disease within the sample, different cell types in the sample and genetic and environmental 
factors on individuals.  
At any rate, Genomic and transcriptomic analyses, as these stand, are the most powerful tool 
for interrogating molecular networks associated with disease and disease forms and are likely 
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to revolutionise the biomarker discovery, with particular emphasis on developing molecular 
signatures leading to molecular tests, in the coming times.  
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Appendix 1 
 
RNA Extractions – Nanodrops for qualitative and quantitative assessment 
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CDNA – Nanodrops for quantitative assessment  
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Appendix 2 
 
List of all differentially expressed upregulated genes in severe and mild 
acute pancreatitis 
 
Expr p-value 
Expr Fold 
Change Symbol Entrez Gene Name Location Type(s) 
      
0.000108 4.49 MMP8 matrix metallopeptidase 8 Extracellular Space peptidase 
0.0005 3.419 OLAH oleoyl-ACP hydrolase Cytoplasm enzyme 
0.0000419 3.095 ADAMTS2 ADAM metallopeptidase with thrombospondin type 1 motif 2 Extracellular Space peptidase 
0.000028 3.085 RETN resistin Extracellular Space other 
0.00263 3.077 HPGD hydroxyprostaglandin dehydrogenase 15-(NAD) Cytoplasm enzyme 
0.000335 3.072 SLC1A3 solute carrier family 1 member 3 Plasma Membrane transporter 
0.00108 2.918 OLAH oleoyl-ACP hydrolase Cytoplasm enzyme 
0.00316 2.915 HPGD hydroxyprostaglandin dehydrogenase 15-(NAD) Cytoplasm enzyme 
0.0028 2.87 OLAH oleoyl-ACP hydrolase Cytoplasm enzyme 
0.000604 2.847 GPR84 G protein-coupled receptor 84 Plasma Membrane G-protein receptor 
0.000368 2.739 SLC51A solute carrier family 51 alpha subunit Plasma Membrane transporter 
0.000132 2.701 CRISP3 cysteine rich secretory protein 3 Extracellular Space other 
0.000838 2.624 HPGD hydroxyprostaglandin dehydrogenase 15-(NAD) Cytoplasm enzyme 
0.0018 2.551 DAAM2 dishevelled associated activator of morphogenesis 2 Cytoplasm other 
0.0000173 2.538 CD163 CD163 molecule Plasma Membrane transmembrane receptor 
0.00332 2.537 FGF13 fibroblast growth factor 13 Extracellular Space growth factor 
0.000477 2.534 ANKRD22 ankyrin repeat domain 22 Nucleus transcription regulator 
0.000163 2.452 VSIG4 V-set and immunoglobulin domain containing 4 Plasma Membrane other 
0.0000131 2.445 BPI bactericidal/permeability-increasing protein Plasma Membrane transporter 
0.000208 2.398 PFKFB2 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 Cytoplasm kinase 
0.0000661 2.391 TIMP4 TIMP metallopeptidase inhibitor 4 Extracellular Space other 
0.000666 2.335 ARG1 arginase 1 Cytoplasm enzyme 
0.00036 2.315 SH3PXD2B SH3 and PX domains 2B Cytoplasm other 
0.000874 2.31 HGF hepatocyte growth factor Extracellular Space growth factor 
0.000334 2.302 HGF hepatocyte growth factor Extracellular Space growth factor 
0.000518 2.252 PTGES prostaglandin E synthase Cytoplasm enzyme 
0.000349 2.238 SAMSN1 SAM domain, SH3 domain and nuclear localization signals 1 Nucleus other 
0.0000832 2.227 TMEM45A transmembrane protein 45A Plasma Membrane other 
0.000094 2.221 CEACAM1 carcinoembryonic antigen related cell adhesion molecule 1 Plasma Membrane transporter 
0.00183 2.21 DLC1 DLC1 Rho GTPase activating protein Cytoplasm other 
0.0000795 2.196 TCN1 transcobalamin 1 Cytoplasm transporter 
0.000477 2.195 DHRS9 dehydrogenase/reductase 9 Cytoplasm enzyme 
0.000799 2.182 SEMA6B semaphorin 6B Plasma Membrane other 
0.00161 2.165 LCN2 lipocalin 2 Extracellular Space transporter 
0.00273 2.157 
CYP1B1-
AS1 CYP1B1 antisense RNA 1 Other other 
0.0000261 2.151 ADAMTS2 ADAM metallopeptidase with thrombospondin type 1 motif 2 Extracellular Space peptidase 
0.000497 2.149 DHRS9 dehydrogenase/reductase 9 Cytoplasm enzyme 
0.00292 2.134 LTF lactotransferrin Extracellular Space peptidase 
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0.00104 2.124 CEACAM1 carcinoembryonic antigen related cell adhesion molecule 1 Plasma Membrane transporter 
0.000751 2.111 CRISP2 cysteine rich secretory protein 2 Extracellular Space other 
0.000224 2.103 HGF hepatocyte growth factor Extracellular Space growth factor 
0.00269 2.1 C1QC complement C1q C chain Extracellular Space peptidase 
0.000875 2.094 THBS1 thrombospondin 1 Extracellular Space other 
0.00129 2.09 CEACAM1 carcinoembryonic antigen related cell adhesion molecule 1 Plasma Membrane transporter 
0.0000365 2.073 SIRT5 sirtuin 5 Cytoplasm enzyme 
0.000357 2.06 DHRS9 dehydrogenase/reductase 9 Cytoplasm enzyme 
0.000345 2.053 FGF13-AS1 FGF13 antisense RNA 1 Other other 
0.0000247 2.048 ERLIN1 ER lipid raft associated 1 Plasma Membrane other 
0.000131 2.027 PDE4D phosphodiesterase 4D Cytoplasm enzyme 
0.000595 2.012 KL klotho Extracellular Space enzyme 
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List of all differentially expressed downregulated genes in severe and mild 
acute pancreatitis 
 
 
Expr p-
value 
Expr Fold 
Change Symbol Entrez Gene Name Location Type(s) 
      
0.000152 -1.931 RPS6KA5 ribosomal protein S6 kinase A5 Nucleus kinase 
0.000479 -1.935 TRAC T-cell receptor alpha constant Plasma Membrane other 
0.000391 -1.936 GBP5 guanylate binding protein 5 Plasma Membrane enzyme 
0.000664 -1.939 NR3C2 nuclear receptor subfamily 3 group C member 2 Nucleus ligand-dependent nuclear receptor 
0.000941 -1.954 CD40LG CD40 ligand Extracellular Space cytokine 
0.000183 -1.954 MYBL1 MYB proto-oncogene like 1 Nucleus transcription regulator 
0.0000454 -1.966 CXCR3 C-X-C motif chemokine receptor 3 Plasma Membrane G-protein coupled receptor 
0.000521 -1.968 YME1L1 YME1 like 1 ATPase Cytoplasm peptidase 
0.000208 -1.97 BCL11B B-cell CLL/lymphoma 11B Nucleus transcription regulator 
0.000231 -1.972 LCK LCK proto-oncogene, Src family tyrosine kinase Cytoplasm kinase 
0.000103 -1.975 RORA RAR related orphan receptor A Nucleus ligand-dependent nuclear receptor 
0.000401 -1.977 PYHIN1 pyrin and HIN domain family member 1 Nucleus other 
0.000425 -1.982 CD3D CD3d molecule Plasma Membrane transmembrane receptor 
0.000189 -1.984 THEMIS thymocyte selection associated Cytoplasm other 
0.000522 -2 CAMK4 calcium/calmodulin dependent protein kinase IV Nucleus kinase 
0.00274 -2.003 LOC105369609 uncharacterized LOC105369609 Other other 
0.00174 -2.007 ISM1 isthmin 1 Other other 
0.00165 -2.012 ETV7 ETS variant 7 Nucleus transcription regulator 
0.0000993 -2.016 ATP8B2 ATPase phospholipid transporting 8B2 Plasma Membrane transporter 
0.000717 -2.02 GRAMD1C GRAM domain containing 1C Other other 
0.0000249 -2.022 RPS6KA5 ribosomal protein S6 kinase A5 Nucleus kinase 
0.000147 -2.026 DPP4 dipeptidyl peptidase 4 Plasma Membrane peptidase 
0.00035 -2.03 TRAC T-cell receptor alpha constant Plasma Membrane other 
0.000122 -2.068 IFNLR1 interferon lambda receptor 1 Plasma Membrane transmembrane receptor 
0.000382 -2.075 PRKCQ-AS1 PRKCQ antisense RNA 1 Other other 
0.00321 -2.082 BEX2 brain expressed X-linked 2 Nucleus other 
0.000694 -2.09 TRAV24 T cell receptor alpha variable 24 Other other 
0.000213 -2.091 CD160 CD160 molecule Plasma Membrane transmembrane receptor 
0.0000443 -2.104 TBC1D4 TBC1 domain family member 4 Cytoplasm other 
0.00103 -2.113 CAMK4 calcium/calmodulin dependent protein kinase IV Nucleus kinase 
0.000194 -2.139 CD28 CD28 molecule Plasma Membrane transmembrane receptor 
0.0000954 -2.159 GATA3 GATA binding protein 3 Nucleus transcription regulator 
0.000319 -2.165 TRAV9-2 T cell receptor alpha variable 9-2 Other other 
0.000101 -2.178 GBP4 guanylate binding protein 4 Cytoplasm enzyme 
5.51E-06 -2.201 RPS6KA5 ribosomal protein S6 kinase A5 Nucleus kinase 
0.000125 -2.208 BCL11B B-cell CLL/lymphoma 11B Nucleus transcription regulator 
0.0000298 -2.214 YME1L1 YME1 like 1 ATPase Cytoplasm peptidase 
0.0000878 -2.235 GZMK granzyme K Cytoplasm peptidase 
0.000529 -2.254 KIAA1671 KIAA1671 Other other 
0.00037 -2.283 TRAT1 
T cell receptor associated transmembrane 
adaptor 1 Plasma Membrane kinase 
0.000166 -2.292 INPP4B inositol polyphosphate-4-phosphatase type II B Cytoplasm phosphatase 
0.00018 -2.299 THEMIS thymocyte selection associated Cytoplasm other 
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0.0000354 -2.321 P2RY10 purinergic receptor P2Y10 Plasma Membrane G-protein coupled receptor 
0.0000236 -2.364 RORA RAR related orphan receptor A Nucleus ligand-dependent nuclear receptor 
0.0000358 -2.386 YME1L1 YME1 like 1 ATPase Cytoplasm peptidase 
0.0000328 -2.398 TRDV3 T cell receptor delta variable 3 Other other 
0.00125 -2.405 YME1L1 YME1 like 1 ATPase Cytoplasm peptidase 
0.000218 -2.407 YME1L1 YME1 like 1 ATPase Cytoplasm peptidase 
0.000285 -2.519 NOV nephroblastoma overexpressed Extracellular Space growth factor 
0.00045 -2.594 NELL2 neural EGFL like 2 Extracellular Space other 
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Appendix 3 
 
List of all differentially expressed miRNA in severe and mild acute 
pancreatitis 
 
Rank ID F p-value 
Adjusted p-
value 
Log Fold 
Change 
Fold 
Change 
Absolute 
Fold 
Change 
1 MIR631 3.69E-06 0.013909811 -0.89813 -1.86365 1.863649 
2 MIR3129 7.20E-06 0.013909811 -0.66696 -1.58772 1.587725 
3 snoU13 9.09E-06 0.013909811 -0.37461 -1.29649 1.296491 
4 MIR1291 2.04E-05 0.018768512 0.858892 1.813645 1.813645 
5 ACA50 1.82E-05 0.018768512 -0.39981 -1.31933 1.319331 
6 SNORD30 2.58E-05 0.019781918 -0.34226 -1.26774 1.267737 
7 MIR758 4.26E-05 0.021760076 0.828388 1.7757 1.7757 
8 ACA9 3.73E-05 0.021760076 -0.637 -1.55509 1.555091 
9 snoU13 3.91E-05 0.021760076 -0.53997 -1.45394 1.453938 
10 snoU13 4.91E-05 0.022441665 0.59434 1.509782 1.509782 
11 MIR3157 5.83E-05 0.022441665 -0.51723 -1.4312 1.431205 
12 snoU13 5.86E-05 0.022441665 0.423748 1.341408 1.341408 
13 MIR548n 6.94E-05 0.024523767 -0.82394 -1.77023 1.770233 
14 MIR302e 8.66E-05 0.026509154 -0.60491 -1.52089 1.520889 
15 MIR513c 8.34E-05 0.026509154 0.538149 1.452108 1.452108 
16 MIR548j 9.79E-05 0.028097164 -0.54481 -1.45883 1.458825 
17 SNORA51 0.000131 0.03542224 -0.32097 -1.24917 1.249168 
18 MIR758 0.000148 0.03572517 0.712447 1.638581 1.638581 
19 MIR3187 0.000141 0.03572517 -0.66193 -1.58219 1.582195 
20 SNORA70 0.000162 0.037128192 -0.16524 -1.12136 1.121356 
21 MIR184 0.00019 0.03787902 0.666223 1.586912 1.586912 
22 MIR199b 0.000186 0.03787902 -0.62895 -1.54644 1.546441 
23 SNORD109A 0.000188 0.03787902 -0.51885 -1.43281 1.432809 
24 MIR636 0.000248 0.039727972 0.792679 1.732288 1.732288 
25 MIR1976 0.000237 0.039727972 -0.7054 -1.6306 1.630598 
26 snoU13 0.000265 0.039727972 -0.65159 -1.5709 1.570901 
27 snosnR60_Z15 0.000229 0.039727972 0.624232 1.54139 1.54139 
28 14qII-17 0.000268 0.039727972 0.562621 1.47695 1.47695 
29 SNORA25 0.000241 0.039727972 -0.54568 -1.4597 1.459705 
30 MIR23a 0.000224 0.039727972 -0.52215 -1.43609 1.436094 
31 MIR192 0.000253 0.039727972 -0.28773 -1.22071 1.220714 
32 SNORA8 0.000312 0.042511604 0.600929 1.516693 1.516693 
33 snoU13 0.000298 0.042511604 -0.43351 -1.35051 1.350514 
34 SNORA3 0.000315 0.042511604 0.368014 1.290575 1.290575 
35 SNORA27 0.000327 0.042862865 0.612952 1.529385 1.529385 
36 MIR432* 0.000353 0.044994617 -0.65758 -1.57743 1.57743 
255 | P a g e  
 
37 SNORA8 0.000373 0.045138987 0.768009 1.702918 1.702918 
38 snoU13 0.000374 0.045138987 0.447187 1.36338 1.36338 
39 U8 0.000406 0.047838964 0.404085 1.32325 1.32325 
40 SNORA22 0.000421 0.04784593 0.757156 1.690155 1.690155 
41 MIR373 0.000458 0.04784593 0.703811 1.628801 1.628801 
42 SNORD56 0.000456 0.04784593 0.441721 1.358223 1.358223 
43 MIR589 0.00044 0.04784593 -0.39282 -1.31295 1.312953 
44 MIR135b 0.000428 0.04784593 -0.33667 -1.26284 1.262841 
45 MIR487b 0.000479 0.048927839 0.349223 1.273875 1.273875 
 
